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Abstract  
During lytic cycle replication EBV expresses at least three genes; BNLF2a, BILF1 and 
BGLF5, which individually act to inhibit efficient processing and presentation of CD8
+
 T cell 
epitopes. This thesis sets out to assess the relative contribution of these potential immune-
modulating proteins to the evasion from CD8
+ 
T cells at different stages of EBV lytic cycle. 
Lentiviral vectors for shRNAs were used to silence expression of these individual viral genes 
in EBV-transformed B-cells, which were then probed with CD8
+
 T cell effector clones of 
specificities for epitopes derived from the three phases of the EBV lytic cycle; allowing us to 
determine the contribution each immune evasion gene makes towards the inhibition of antigen 
presentation during lytic cycle.  
Cells replicating viruses lacking BNLF2a were more efficiently recognised by CD8
+
 T cells 
specific for immediate early and early expressed antigens relative to those lacking BGLF5 and 
BILF1. Conversely, cells lacking the expression of BILF1 were better recognised by CD8
+
 T 
cells specific for early and late lytic antigens. These data suggest that whilst the role BNLF2a 
plays in interfering with antigen presentation diminishes as lytic cycle progresses (IE>E>>L), 
BILF1 plays a more active role with the progression of lytic cycle (IE<E<<L).  
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CHAPTER 1 
 
INTRODUCTION 
 
 
1.1. The host response to viral infection 
 
Viruses are obligate intracellular infectious agents that hijack the cellular machinery of their 
hosts in order translate viral proteins and replicate their genome. As a consequence of this, 
they are exposed to a plethora of host immune controls; a pressure under which they need to 
survive. The course of infection differs greatly between viruses; some viruses infect a host, 
rapidly replicate and then transmit, so that the pressure to survive long term in the harsh 
immune environment is less important. Other viruses, such as those in the herpesviridae 
family, establish a persistent infection which is often asymptomatic, although occasional 
reactivation can occur. The requirement of a functional immune system is essential in order to 
control viral infections and maintain a healthy host. However, since viruses have been co-
evolving with their hosts for many years, some have adopted strategies to modulate the host 
immune responses. This interplay between the immune response of the host and immune 
modulation by the virus is essential for the maintenance of a lifelong viral infection of a 
healthy host.    
There are two arms to the human immune system, both of which play important roles in 
responding to viral infection. These are the innate and adaptive immune system and will be 
discussed in more detail below. 
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1.2. The innate immune response to viral infection 
 
In the first stages of viral infection, it is the innate immune system which is most important in 
order to detect incoming viruses, and is necessary to activate the adaptive immune response. 
The innate immune response is activated via detection of viral components through pattern-
recognition receptors (PRRs) (Akira et al., 2006). PRRs detect components including DNA, 
single and double stranded RNA and viral proteins. There are three classes of PRRs which are 
known to detect these components in innate immune cells, toll-like receptors (TLR), retinoic 
acid-inducible (RIG-I)- like receptors (RLRs) and nucleotide oligomerisation domain (NOD)-
like receptors (NLRs). Following the detection of viral components, these receptors activate 
intracellular signalling cascades, resulting in the secretion of type I interferons (IFN), 
proinflammatory cytokines and chemokines. Type I IFNs active intracellular signalling 
pathways involved in inducing the apoptosis of infected cells, and priming uninfected cells for 
resistance to incoming viral infection. Proinflammatory cytokines and chemokines are 
important for inducing inflammation and recruiting other immune cells to the site of infection 
(reviewed by (Takeuchi and Akira 2009). These responses are important for activating the 
adaptive arm of the immune system in the host. 
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1.3. The adaptive response to viral infection 
 
The adaptive immune system protects the host from viral infection through more specific 
responses and leads to the generation of immunological memory. It is comprised of two arms; 
the humoral, which is responsible for the production of antibody by B cells; and cell-mediated 
immunity in which T cells play a central role. Classically, B cells detect and bind their 
specific antigens, which tend to be located in the extracellular environment, via their cell 
surface B cell receptor (BCR). This engagement of BCR with antigen can lead to the 
formation of plasma cells which then secrete specific antibodies. By binding to epitope on 
antigens, antibodies can confer viral immunity in three ways: neutralise viral infection by 
binding to them; opsonise viral particles, leading to their elimination; activation of the 
complement system; and opsonisation of infected cells to mediate antibody dependent cell 
mediated cytotoxicity.  
Cell mediated immunity involves T cells, which are able to recognise specific peptide 
epitopes via their T cell receptors (TCR). These peptide epitopes are derived from the 
degradation of intracellular proteins, which may have originated from the extracellular or 
intracellular environment. The products of protein degradation are then presented on the cell 
surface by major histocompatibility complexes (MHC), also known as human leukocyte 
antigens (HLA), in humans. Upon recognition of these MHC:peptide complexes, T cells 
which have already experienced their antigen then elicit an effector function such as 
cytotoxicity of the target cell, whereas naïve T cells, that have not previously experienced 
their antigen, are primed to become effector cells.  
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T cells are further subdivided into two categories, depending upon their surface marker 
expression; those which express CD4 recognise peptides presented by MHC class II 
molecules, whereas those expressing CD8 recognise peptides presented by MHC class I 
molecules. This thesis is focussed on the interplay between EBV infection and CD8
+
 T cell 
responses. There follows, therefore, a review of the molecular and cellular components of 
CD8
+
 T cell responses, and of the relevant aspects of EBV biology.  
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1.4. The MHC class I antigen processing pathway 
 
MHC class I molecules are found on nearly every cell of the body. They are heterodimers 
composed of an MHC heavy chain (HC) associated with a beta-2-microglobulin (2m) and 
peptide. The extracellular region of the HC folds into three domains, with 2m forming the 
fourth. Two of the HC extracellular domains form a peptide binding groove, which bind 
specific peptide epitopes that are around 8-11 amino acids in length (Falk and Rotzschke 
1993). The heavy chain region of MHC class I molecules, encoded by the HLA-A, -B and –C 
genes on chromosome 6, are highly polymorphic, in that heterozygous individuals can express 
up to 6 different alleles. Since it is the sequence of the peptide binding groove which dictates 
the peptides that bind, this allows for a high diversity of epitopes which can be presented on 
MHC class I molecules. In addition, the peptide binding groove interacts strongly with only a 
few amino acid side chains of peptides, therefore further increasing the repertoire of peptides 
that can be presented.  
Assembled MHC class I molecules are loaded with peptide in the lumen of the endoplasmic 
reticulum (ER) and then exported to the cell surface via the Golgi apparatus. Once at the cell 
surface, MHC:peptide complexes are accessible for probing by circulating CD8
+
 T cells (Fig 
1.1). 
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Figure 1.1 MHC class I antigen processing pathway. MHC class I antigen presentation 
pathway.  
(Adapted from (Danchin et al., 2004)). (1) Proteins are degraded in the cytosol by proteasomes into 
short peptides. (2) Peptides are then translocated into the ER lumen by TAP. (3) Newly synthesised 
MHC class I HCs and β2m fold and assemble in the ER lumen with the aid of calnexin, calreticulin 
and ERp57. (4) MHC class I molecules associate with TAP and tapasin facilitates peptide binding. (5) 
Peptide loaded MHC class I molecules dissociate from TAP and are transported through the secretory 
pathway to the plasma membrane where they are displayed at the cell surface to circulating CD8
+
 T 
cells.    
  
2 Peptide translocation 
1 Antigen processing 
3 MHC class I folding 
4 TAP association 
and peptide binding 
5 Transport of peptide loaded 
MHC class I molecules to the 
cell surface 
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1.4.1. Degradation of proteins and generation of peptide epitopes 
 
Peptide epitopes in complex with MHC class I molecules originate from degraded 
intracellular proteins. The source of these peptides has been an area of conflicting opinions for 
many years. One school of thought, proposed by Rock et al. is that the major source of 
peptides is derived from the degradation of pre-existing functional proteins. This involves the 
ubiquitination of proteins, by ubiquitin (Ub) ligase enzymes, most commonly at lysine 
residues. Once one Ub has been tagged, this then signals other ligases to attach additional Ub 
molecules at the lysine residues within the previous Ub. The presence of at least four Ub 
molecules marks the protein for proteasomal degradation (discussed below).  
In 1996 it was proposed by Yewdell et al. that the majority of peptides are not derived from 
pre-existing protein degradation, but instead come from the rapid degradation of defective 
ribosomal products (DRiPs) (Yewdell et al., 1996). DRiPs are thought to occur when; mRNA 
translation is terminated early; there is a ribosomal frame shift during translation or; from the 
degradation of newly translated misfolded proteins. It since has been found that around 30% 
of mRNA translation products are rapidly degraded DRiPs and that the presence of peptides 
corresponds to the level of mRNA rather than the steady state level of full-length protein 
(Schubert et al., 2000; Khan et al., 2001; Qian et al., 2005). DRiPs are now widely believed 
to contribute a larger pool of peptide than the degradation of stable protein. A number of 
studies have been carried out that show that DRiPs likely are the major source of peptides 
presented on MHC class I. For example Mackay et al showed that upon inducing the 
expression of a viral protein encoded by Epstein Barr Virus (EBV), there is a rapid increase in 
peptide display and thus T cell recognition, before there is steady state of protein expression 
(Mackay et al., 2009). In contrast, when de novo expression of viral protein was suppressed, 
Chapter 1  Introduction 
8 
 
there was a rapid decline in peptide display and T cell recognition, despite the presence of 
mature protein (Mackay et al., 2009). In agreement with his finding, a more recent study has 
shown, using a different model, that the production of peptides occurs well before there are 
detectable levels of the corresponding protein, and moreover, the insertion of a premature stop 
codon in this mRNA still yielded high levels of antigenic peptide, despite the lack of protein 
production (Apcher et al., 2011). These findings support the idea that it is DRiPs which serve 
as the major source of peptides available for MHC class I loading. In terms of responses to 
viral epitopes this is perhaps more advantageous since viral protein translation occurs rapidly, 
before the accumulation of stable protein, and since there is a high error rate in the translation 
process, it is likely an ideal source for rapid peptide supply for presentation to CD8
+
 T cells 
and subsequent recognition of infected cells.  
These proteins, whether functional or defective, are then degraded by the cellular proteasome 
(Goldberg et al., 2002). In humans, the 26S proteasome is more commonly used. This is 
composed of a hollow 20S core and capped at each end by a 19S complex. The core is 
comprised of four symmetrical rings, which are themselves made up of - and -subunits; 
these rings form a hollow cylinder with ends that can be opened to allow entry of substrates. It 
is the 19S subunits which recognise Ub tagged proteins and unfold them to allow access to the 
core. The subunitswithin the inner two rings of the core contain peptidase sites, which act 
to cleave proteins at specific sites, creating a pool of diverse peptides (Kloetzel 2004). Cells 
are also capable of producing immunoproteasomes, in which there is the replacement of the 
constitutive subunits for the IFN- induced homologous -catalytic subunits (LMP-2, -7 and -
10) (reviewed, (Yewdell 2005)).  Immunoproteasomes carry different proteolytic sites and as 
a result generate a different diversity of peptides, thereby increasing the repertoire of peptides 
presented on MHC class I molecules. Immunoproteasomes are expressed constitutively in 
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immune tissues, however their production can be increased upon exposure to IFN-which is 
released upon detection of viral infection. It widely believed that the immunoproteasome does 
not completely replace the proteasome pool, and that it is the expression of both within the 
same cell that provides a greater repertoire of peptides for MHC class I presentation.  
Following proteasomal degradation of proteins, peptide products are released into the cytosol 
where they may be subject to further trimming by cytoplasmic peptidases. Products which are 
greater than 4-6 residues in length are trimmed predominantly by two peptidases, tripeptidyl 
peptidae II (TPPII) and thimet oligopeptidase (TOP). TPPII cleaves three residues at a time 
from the N-terminus of substrates and appears to prefer peptides that are more than 15 
residues in length (Reits et al., 2004), which will account for a small amount of the 
proteasomal degradation product (York et al., 2006). It has been found that silencing the 
expression of TPPII does not decrease the supply of peptides to the MHC class I pathway, due 
to only a small proportion of peptide products being more than 15 residues long (York et al., 
2006). TOP is considered to play the major role in the trimming of proteasomal products and 
it degrades peptides which are 9-15 residues in length (Kessler et al., 2011), accounting for a 
larger fraction of the proteasomal output (Saric et al., 2004). Indeed, silencing the expression 
of TOP results in increased presentation of peptides, while its over expression decreases 
peptide presentation  (York et al., 2003). This over expression of TOP limits the amount of 
peptides available for presentation by destroying them, thus limiting the supply of peptides to 
the ER. It should be noted that other peptidases have been identified such as an IFN- leucine 
aminopeptidase, that could trim an extended version of SIINFEKL, and was identified in the 
cytosol of HeLa cells (Beninga et al., 1998). However, these have been studied less 
extensively. Following trimming, peptides are then transported into the ER where they can be 
loaded onto MHC class I molecules. 
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1.4.2. Peptide transport into the ER 
  
Peptides are predominantly translocated into the ER via the transporter associated with 
antigen processing (TAP). TAP belongs to the adenosine triphosphate (ATP)-binding cassette 
(ABC) superfamily and is a heterodimer which spans the ER membrane. It is made up of 
TAP1 and TAP2 subunits, which each have an N-terminal hydrophobic transmembrane 
domain, containing an ER retention signal, and a C-terminal nucleotide binding domain 
(NBD) (Abele and Tampe 1999).  
Peptide translocation across TAP begins with the binding of peptides to the cytoplasmic loops 
of TAP1 and TAP2, in an ATP-independent manner. These loops are located close to a 
hydrophobic pore, made up of the transmembrane domains of TAP1 and TAP2, through 
which peptides are translocated. Following peptide binding, ATP binds to and is hydrolysed 
by the NBD of TAP1 and TAP2, providing the energy required to transport peptides from the 
cytosol to the lumen of the ER (van Endert et al., 1994). Interestingly, TAP2 mediated ATP 
hydrolysis is essential whereas TAP1 mediated hydrolysis has been found to be non- essential 
(Karttunen et al., 2001). The length of peptides that TAP can transport ranges from 7 to 20 
amino acids, although those which are 8-13 amino acids long are preferentially transported 
(Momburg et al., 1994). 
Although proteasome degradation and TAP transportation is considered the conventional 
route for peptide processing, other TAP-independent pathways may also contribute. Using 
TAP deficient T2 cells, it was noted that some EBV derived peptides are presented in the 
absence of TAP, indicating an alternative processing route (Lautscham et al., 2001). In TAP 
deficient individuals MHC class I peptide loaded molecules are still displayed, albeit to a 
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much lower extent. It has been found that some peptides, derived from signal sequences, are 
presented on TAP deficient T2 cells, and are also found on normal, TAP expressing cells 
(Henderson et al., 1992; Wei and Cresswell 1992), which would suggest that these alternative 
pathways may also be active in cells expressing TAP. More recently it was identified that in 
the absence of TAP, HLA-E molecules no longer present leader sequences and instead present 
a novel repertoire of peptides which are much like those peptides presented by HLA-A2 
molecules (Oliveira et al., 2010; Lampen et al., 2013). However, cells which expressed TAP 
were not able to present this novel pool, indicating that perhaps there is competition between 
the two pathways, where the alternative pathway is only present in the absence of TAP. 
Although the evidence points towards an alternative antigen processing pathway, the 
mechanism has yet to be identified. It has been proposed that there may be novel transport 
mechanisms via access to the vesicular pathways, which allow peptides into the ER, or that 
the ER may not be required and peptides may gain access on the secretory route, where they 
may displace poorly bound peptides and finally there is the suggestion that autophagy may 
play a role. Indeed, recently it was shown that an epitope derived from the HCMV encoded 
protein, pUL138 required autophagy for its presentation, via a TAP-independent class I 
processing pathway (Tey and Khanna 2012). The exact mechanisms involved here are yet to 
be elucidated and it is yet to be established how much of a role these alternative pathways 
play when TAP is present.   
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1.4.3. Assembly of MHC class I:peptide complexes and trafficking to the cell surface  
 
Following translocation into the lumen of the ER, peptides are loaded onto nascent MHC 
class I molecules. Prior to MHC class I loading, peptides often require further trimming by the 
ER-associated aminopeptidase (ERAAP) enzyme (Serwold et al., 2002). Interestingly the 
expression of ERAAP is increased in the presence of IFN-.  
The loading of peptides onto MHC class I molecules begins with the synthesis of the HC and 
2m subunits, which then enter the ER, via signal sequences. In the ER the HC rapidly 
associates with the ER-resident chaperone molecule calnexin (Germain and Margulies 1993). 
In the presence of 2m, HC subunits fold appropriately and calnexin dissociates. The loading 
of these MHC class I molecules relies on the peptide loading complex (PLC), which centres 
around TAP. Firstly, TAP recruits the HC-2m dimer complex via the adaptor tapasin. This 
transient interaction is stabilised by the thiol disulphide oxidoreductase protein, ERp57 and 
the ER chaperone calreticulin, allowing tapasin to serve as a bridge between TAP and the 
MHC class I molecule (Hulpke et al., 2012). In addition, tapasin functions to edit the peptides 
which are to be loaded, thereby ensuring optimal peptide binding (Williams et al., 2002). It 
has recently been discovered that two tapasin molecules are present in the PLC, one bound to 
each TAP subunit, this is thought to maximise effective loading (Hulpke et al., 2012). The 
blocking of tapasin interaction with TAP diminishes the level of MHC class I presentation, 
indicating an important role for tapasin in the PLC and antigen processing pathway (Hulpke et 
al., 2012). Furthermore, the cell line .220, which lacks the expression of tapasin, shows 
defective MHC class I association with TAP, peptide loading and decreased MHC class I 
surface levels (Sadasivan et al., 1996). 
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Once high affinity peptides have bound to the grove of MHC class I molecules the 
MHC:peptide complex dissociates from the PLC and is transported to the cell surface via the 
Golgi network. Some studies suggest that the MHC class I molecules may cycle out to the 
Golgi and be transported back for peptide loading, perhaps as a means of quality control 
(Garstka et al., 2007). Subsequent transport to the cell surface requires the presence of cargo 
receptors, such as Bap31 which facilitates the trafficking (Paquet et al., 2004), since MHC 
class I molecules lack trafficking signals in the cytoplasmic tail.   
Upon arrival at the cell surface, stable MHC class I peptide loaded complexes present the 
endogenously generated peptides to the TCR of CD8
+
 T cells. 
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1.4.4. Activation of naive CD8+ T cells   
 
During infection of the host, naive CD8
+
 T cells become primed when they encounter their 
MHC class I presented antigen in the secondary lymphoid organs, such as the lymph node 
and, perhaps more importantly the lymph node periphery (Hickman et al., 2008). Antigenic 
peptides are presented by antigen presenting cells (APCs) such as B cells, macrophages and 
dendritic cells (DCs). Although macrophages and B cells are efficient APCs, CD8
+
 T cells 
appear to prefer DC presentation of their cognate antigen. DCs can themselves be infected, 
resulting in antigen presentation to CD8
+
 T cells, or they may present the antigen via cross 
presentation by sampling antigens form the extracellular environment and processing and 
presenting these on MHC class I molecules, as described above. The antigen specific contact 
between naïve CD8
+
 T cells and other APCs, at specific anatomical sites, results in CD8
+
 T 
cell activation and expansion.  
The way in which naive T cells are able to home to lymphoid tissue is via the use of 
chemokine receptors and integrins. Chemokines such as CCL17, which are produced by DCs, 
have been shown to attract naive CD8
+
 T cells expressing the chemokine receptor CCR4  
during priming (Semmling et al., 2010). There is also an implied role of the chemokine 
receptor pair XCL1-XCR1. This receptor pair has recently been demonstrated to be important 
for the activation of CD8
+
 T cells. XCR1 expression is restricted to lymphoid tissue resident 
DCs and the XCL1 ligand, which is a chemoattractant for the DCs, is abundantly expressed 
by activated CD8
+
 T cells. The absence of XCL1 results in poor priming and expansion of 
CD8
+
 T cells thus, this interaction is required for maximal priming and expansion of CD8+ T 
cells (Parish and Kaech 2009). Therefore there is perhaps interplay between chemokines of 
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CD8
+
 T cells and DCs in order to achieve maximal recruitment of naïve CD8
+
 T cells and 
antigen presenting DCs, during priming. 
Following priming, naïve CD8+ T cells are induced to proliferate and differentiate into both 
effector and memory cells (Gerlach et al., 2010), although there is controversy surrounding 
the fate of naive T cells, and exactly what dictates this fate. The short lived effector cells, 
which account for the majority of CD8
+
 T cells in primary infection, mostly diminish once 
infection is cleared. However, a small proportion will remain and establish a memory pool 
(Parish and Kaech 2009). These memory cells can proliferate and expand rapidly in response 
to antigen re-encounter, which allows the immune system to respond to successive infections 
much faster and more efficiently.  
The fate of the effector cell is very different from that of the naive. Following the recognition 
of their cognate antigen, activated T cells upregulate cytokine receptors which allow them to 
enter the peripheral tissues and home to the site of infection. Here, effector CD8
+
 T cells will 
encounter and, via the TCR, will engage with cognate antigen presented by MHC class I 
molecules. This can result in cytolysis of infected cells and the release of cytokines, such as 
IFN-which essentially establishes an anti-viral state in neighbouring cells by inducing the 
upregulation of MHC class I molecules and more. CD8
+
 T cells also release the anti-
inflammatory cytokine IL-10, as a means of regulating the severity of tissue damage 
(Trandem et al., 2011).  
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1.4.5. CD8+ T cell killing of infected cells 
 
Activated CD8
+
 T cells are able to lyse infected cells in one of two ways; the granule 
exocytosis pathway or; via the upregulation of Fas-ligand (FasL). Both stimulate the caspase 
cascade, leading to apoptosis and cell death (Shresta et al., 1998). In order to minimise any 
destruction of neighbouring cells, CD8
+
 T cells establish an immunological synapse, upon 
interaction of their TCR with peptide loaded MHC class I molecules. This synapse encloses 
the TCR:MHC class I complex, so that the release of cytotoxic proteins is concentrated on the 
target cell only, thereby minimising bystander killing and maximising cytotoxic effects on 
infected cells. The granule exocytosis pathway relies upon the release of cytotoxic proteins 
which are stored in secretory lysosome-like granules within CD8
+
 T cells. Two types of 
cytotoxic proteins are stored in these granules; perforin and granzymes. Perforin exists in a 
monomeric form in the granules, rendering it inactive. Upon release into the immunological 
synapse, perforin polymerises to form transmembrane pores in membrane of the target cell. 
Granzymes are serine proteinases which induce the caspase dependant apoptotic pathway and 
it is the combined effect of perforin and granzyme which results in lysis of target cells 
(reviewed (Harty et al., 2000)).   
Although the granule exocytosis pathway is thought to account for the majority of target cell 
death, CD8
+
 T cells also have a second method of killing, via expression of FasL. Upon 
activation, CD8
+
 T cells upregulate FasL, which ligates to Fas on target cells and activates the 
caspase apoptotic pathway, resulting in target cell death. 
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1.4.6.  Immunodominance 
 
Although virally infected cells generate a vast number of viral peptides, only a small fraction 
of these actually induce a CD8
+
 T cell response (Yewdell and Bennink 1999). This results in a 
hierarchy of responses known as immunodominance. A number of factors contribute to 
immunodominance, such as the affinity of the peptides bound to MHC class I molecules, the 
number of complexes at the cell surface, suppression of some responses by more dominant 
populations and the interference with the antigen processing pathway by viruses. This viral 
interference may preferentially inhibit the presentation of a subset of potential peptide 
antigens.  
 
Chapter 1  Introduction 
18 
 
1.5. Viral immune evasion 
 
As a consequence of the immune pressure exerted on viruses during infection, it is 
unsurprising that many have co-evolved with their hosts in order to dampen down the immune 
responses mounted. The mechanisms used by different viruses vary, and they target multiple 
immune-response pathways. However, the MHC class I antigen presentation pathway is a 
particularly common target, with several stages targeted by different immune modulating viral 
proteins.  
 
1.5.1. Interfering with peptide production 
 
Many viruses have evolved to limit the generation of viral peptides by limiting protein 
expression and degradation, thus decreasing the availability of peptides for presentation to 
CD8
+
 T cells. 
One such viral protein, which is able to minimise its own proteasomal degradation and 
production of peptide is the EBV nuclear antigen I (EBNA1) protein (Blake et al., 1997; 
Levitskaya et al., 1997; Yin et al., 2003). EBNA1 encodes an extensive glycine-alanine (Gly-
Ala) repeat region which was first shown to minimise EBNA1 peptide presentation by 
preventing proteasomal degradation (Blake et al., 1997; Levitskaya et al., 1997). This was 
originally thought to be the reason that EBNA1 was able to prevent its own presentation to T 
cells, although this effect of the gly-ala repeat on proteasomal degradation is now thought to 
be an artefact of overexpression. More recently it was shown that the role of the gly-ala region 
is to inhibit the initiation of EBNA1 mRNA translation (Apcher et al., 2009; Apcher et al., 
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2010). EBNA1 mRNA is purine rich, as a result of the gly-ala region, which results in a lack 
of secondary structure, thereby inhibiting translation and reducing antigen presentation, thus 
avoiding DRiP formation (Yin et al., 2003; Tellam et al., 2008). Moreover, the expression 
level of EBNA1 has been found to be relatively low (personal communication, Dr Rose 
Tierney). Such a small level of transcript which is poorly translated probably results in low 
levels of DRiP formation and small amounts of peptide available for presentation. It is 
possible that the effect of the Gly-Ala repeat region may come in to play to protect residual 
DRiPs from proteasomal degradation. 
The -herpesvirus, Kaposi’s sarcoma (KSHV) has also evolved a similar mechanism in order 
to evade peptide presentation of its viral genome maintenance protein LANA1. LANA1, a 
homologue of EBNA1, has been shown to decrease its peptide presentation via the central 
repeat (CR) region. This CR region differs from that of EBNA1 as it is composed of repeats 
rich in glutamine, glutamate and aspartate. This can be further divided into three subdomains: 
CR1, CR1 and CR3. Although the CR2 and CR3 regions have been shown to retard protein 
synthesis (Kwun et al., 2007). The CR1 subdomain is now known to be primarily responsible 
for the prevention of peptide presentation by MHC class I, by a process which has yet to be 
identified, although it is known to be prior to translocation into the ER. This process is not 
dependent upon the inhibition of translation or on proteasomal processing (Kwun et al., 
2011), instead it has been suggested that this region may act to uncouple the proteasomal 
processing from the ER translocation machinery. Therefore, although LANA1 protein is a 
homologue of EBNA1, the mechanisms the two employ in order to inhibit their own peptide 
presentation appear to differ.  
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1.5.2. Inhibiting TAP-mediated peptide transport into the ER 
 
There are numerous examples known of viruses targeting the TAP transporter as a means of 
interfering with antigen processing and presentation. This is likely as a consequence of the 
vast majority of viral peptides requiring translocation by TAP, and since the sole function of 
TAP is in antigen processing, TAP inhibition will perhaps have little effect on the rest of the 
cell. 
The first discovered viral product seen to interfere with TAP was the herpes simplex virus 
(HSV) cytosolic protein ICP47. ICP47 was initially shown to block the transport of MHC 
class I molecules (York et al., 1994). This protein binds to the peptide binding site of TAP 
with a 10-fold higher affinity than the highest affinity peptides (Tomazin et al., 1996), thus 
acting as a competitive inhibitor of peptide binding (Ahn et al., 1996; Ahn et al., 1996; 
Tomazin et al., 1996). ICP47 binding to TAP it is thought to destabilise the structure of TAP 
(Lacaille and Androlewicz 1998), thereby altering the conformation and inhibiting peptide 
binding and ATP hydrolysis. As a result there is a decrease in peptide loaded MHC class I 
molecules at the surface of infected cells. Where normal peptides stabilise TAP and stimulate 
ATP hydrolysis, ICP47 does not, and is not translocated across the membrane, remaining 
associated with TAP (Lacaille and Androlewicz 1998).  
More recently, distinct molecular mechanisms of viral targeting of TAP was demonstrated by 
the UL49.5 protein encoded by the varicelloviruses; bovine herpersvirus-1 (BHV-1), 
pseudorabies virus (PRV) and equine herpesvirus 1 (EHV-1) and 4 (EHV-4). These three 
related UL49.5 genes all interfere with TAP function, leading to reduced expression of stable 
MHC class I complexes at the cell surface of virus infected cells, which can be restored 
following deletion of the UL49.5 gene (Koppers-Lalic et al., 2005; Koppers-Lalic et al., 
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2008). The way in which UL49.5 inhibits the function of TAP differs between these viruses. 
BHV-1 UL49.5 is able to target TAP for proteasomal degradation, a function which requires 
the C-terminal tail. BHV-1 UL49.5 is also able to block the conformational changes of TAP 
that are required for peptide transport, which interestingly requires only the core complex of 
TAP, and this function requires the ER luminal domain of UL49.5 (Koppers-Lalic et al., 
2005; Verweij et al., 2008; Verweij et al., 2011; Verweij et al., 2011). Both PRV and EHV-1 
are thought to induce conformational changes which prevent the translocation of peptides 
across TAP (Koppers-Lalic et al., 2008). In addition they are able to interfere with the energy 
supply that TAP requires for peptide translocation in different ways; PRV is able to block the 
conformational changes which follow ATP binding while EHV-1 blocks the binding of ATP 
to TAP (Koppers-Lalic et al., 2008)).     
Yet another molecular mechanism for interfering with TAP is displayed by the US6 gene 
product of Human cytomegalovirus (HCMV). This gene encodes an ER-localised integral 
membrane protein, which is able to interfere with the function of TAP (Hengel et al., 1997). 
US6 interacts with TAP and inhibits peptide translocation, preventing MHC class I assembly 
by binding to the ER lumen exposed loops of TAP at the ER luminal face (Ahn et al., 1997; 
Hengel et al., 1997). US6 binding to TAP induces a conformational change in TAP, which 
renders the NBD of TAP1 unable to bind ATP, thereby depriving TAP of the energy source 
required for peptide translocation, without affecting peptide binding (Hewitt et al., 2001). 
Since the ER luminal domain of US6 is required for ER retention and is sufficient to inhibit 
ATP binding, despite the NBDs being localised on the opposite side of the ER membrane, this 
is thought to be an indirect conformational effect exerted upon TAP1 NBD (Ahn et al., 1997; 
Hewitt et al., 2001). Like the above mentioned TAP inhibitors, this results in inhibition of 
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peptide transport by TAP and thus lower levels of cell surface MHC class I, thereby 
preventing CD8
+
 T cell recognition of infected cells.  
The most recent TAP inhibitor to be identified is the membrane protein CPXV12 encoded by 
cowpox virus, although the exact mechanism of action has yet to be identified (Wilkinson and 
Lehner 2009). 
The remarkably diverse molecular mechanisms employed by several different persistent 
viruses to target TAP is testimony to the key role of this transporter complex in regulating 
MHC class I antigen presentation to CD8
+
 immune effector cells.   
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1.5.3. Retention of MHC class I molecules in the ER 
 
Some viruses have also evolved to interfere with the export and trafficking of MHC class I 
molecules from the ER to the plasma membrane. The first example of such a mechanism was 
provided by the adenovirus gene product E3/19K (E19). Although subsequently shown to 
have dual immune evasion functions, E19 was originally shown to bind tightly to MHC class 
I -domains in the ER and prevent their transport to the plasma membrane, thereby 
reducing cell surface levels of MHC class I (Andersson et al., 1985). E19 is able to prevent 
MHC class I departure from the ER via two distinct mechanisms. Firstly, the cytosolic tail of 
E19 contains an ER retrieval motif, resulting in its transport from the Golgi apparatus back to 
the ER (Gabathuler and Kvist 1990). However, E19 mutants lacking this retrieval motif are 
still able to inhibit MHC class I transport from the ER, which is now known to be due to E19 
binding to TAP and preventing the tapasin-mediated binding of MHC class I molecules to 
TAP, thereby acting as a tapasin inhibitor (Bennett et al., 1999).  This dual function of E19 is 
thought to be a means of overcoming the lack of tight binding of E19 to some MHC class I 
molecules, therefore allowing it to interfere with the egress of those MHC class I molecules 
with which E19 shows weak association. 
A second paradigmatic example of virus mediated retention of MHC class I complexes in the 
ER is the HCMV US3 gene product. US3 encodes an ER-resident type I integral membrane 
protein which also promotes the retention of MHC class I peptide loaded molecules in the ER 
(Ahn et al., 1996). The association of US3 with MHC class I molecules is transient, after 
which it is degraded, thus there needs to be a constant supply of US3 (Gruhler et al., 2000). 
The exact mechanism by which this US3 functions is not fully understood. It is not thought to 
be via a retrieval signal since there is no known ER retrieval motif, in addition both the 
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transmembrane and luminal domain of US3 are required for to retain MHC class I molecules 
in the ER, although this may require an intermediate ER resident protein (Lee et al., 2000).  
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1.5.4. Diverting class I molecules to lysosomes 
 
Rather than preventing MHC class I complex trafficking by retaining them in the ER, some 
viral proteins have been shown to prevent transport by actively diverting the complexes to 
lysosomes for degradation. A prime example is the U21 protein of human herpesvirus 7 
(HHV7). U21 is an integral membrane protein which binds tightly to MHC class I molecules 
shortly after synthesis and rather than preventing their transport, targets them for lysosomal 
degradation (Hudson et al., 2001). Although the exact mechanism is yet unknown, it has been 
shown that there is no known lysosomal sorting sequence in the cytosolic tail of U21, and the 
luminal domain of this protein is known to be responsible for both associating with MHC 
class I molecules and the rerouting of these molecules to lysosomes, however, it does not 
localise to lysosomes along with MHC class I molecules. It is thought that there may be a 
cellular protein requited to mediate U21 redirecting of MHC class I molecules to the 
lysosomal compartment (Glosson et al., 2010). 
A second example of this immune evasion strategy is provided by the gp48 protein of murine 
cytomegalovirus (MCMV). gp48 also binds to MHC class I molecules via the 
luminal/transmembrane domain of the protein. These complexes are transported out of the ER 
and then redirected to the for lysosomal degraded (Reusch et al., 1999).  
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1.5.5.  Redirection of MHC class I molecules to the cytosol 
 
Under normal circumstances, the assembly of MHC class I molecules undergoes a quality 
control step in which misfolded MHC class I molecules are exported out of the ER to the 
cytosol, where they are subsequently degraded by the proteasome. This is another step in the 
MHC class I antigen processing pathway of which viruses have evolved to take advantage.  
HCMV encodes two such proteins, US2 and US11. These are ER resident integral membrane 
glycoproteins which induce degradation of newly synthesised MHC class I molecules. In cells 
expressing US11 it has been demonstrated that newly synthesised HCs are rapidly destroyed, 
displaying a much decreased half-life (Wiertz et al., 1996). Furthermore, this destruction can 
be blocked using proteasome inhibitors and those class I molecules which are not destroyed 
are found predominantly in the cytosol, which would suggest that US11 induces the 
retrograde transport of HC molecules to the cytosol, where they are deglycosylated and 
subsequently degraded by the proteasome (Wiertz et al., 1996). The transient interaction of 
US11 with MHC class I is thought to be what retains US11 in the ER, as it has no known ER 
retention signal. US2 also causes a translocation of class I molecules into the cytosol and 
subsequent proteasomal degradation, although this occurs more slowly than that seen for 
US11 (Wiertz et al., 1996), indicating that US2 is able to target HCs that are in complex with 
2m, sometime after their insertion into the ER. A major difference between US11 and US2 is 
that US2 is itself translocated into the cytosol, along with MHC class I molecules (Wiertz et 
al., 1996). Following translocation, HCs are deglycosylated and degraded, in the same way as 
is seen in the presence of US11. This translocation process has been shown to involve the ER 
translocon Sec61 (Wiertz et al., 1996), the translocon through which HC are initially inserted 
into the ER. Other cytosolic proteins are thought to be required, such as calnexin and 
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calreticulin, in the case of US2 (Oresic and Tortorella 2008)  and more recently US2 and 
US11 have been shown to associate with the translocating chain associated membrane protein 
1 (TRAM1) of the ER. Indeed, the knockdown of TRAM1 in cells expressing US2 and US11 
resulted in an impaired level of class I translocation  (Oresic et al., 2009). This study indicated 
that US11 may be more reliant upon TRAM1 than US2 (Oresic et al., 2009). Interestingly, a 
more recent study has suggested that US2 and US11 show differential targeting of HLA 
molecules, where they show less strong targeting of HLA-C molecules, possibly as a means 
of ensuring infected cells are not targeted by natural killer (NK) cell lysis (Ameres et al., 
2013). 
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1.5.6.  Internalisation and degradation of MHC class I molecules 
 
Those MHC class I molecules which make it to the cell surface are also targeted by some viral 
immune modulating proteins. KSHV encodes two such proteins, K3 and K5. These proteins 
are localised primarily near the plasma membrane and are able to increase the endocytosis of 
surface MHC class I molecules, in a clathrin-dependant manner (Coscoy and Ganem 2000). 
These proteins are E3 ubiquitin ligases, thus they are able to ubiquitinate the cytosolic tail of 
MHC class I molecules, which provides the signal for internalisation  (Hewitt et al., 2002). 
Once internalised, Ub tagged MHC class I molecules are sorted to acidic endolysosomal 
vesicles of the late endocytic pathway, where they are subsequently degraded. Surprisingly 
this ubiquitination occurs after MHC class I export from the ER and is thought to occur late in 
the secretory pathway or at the plasma membrane (Hewitt et al., 2002). These proteins have 
also been shown to differentially target HLA molecules. K5 dramatically down regulates 
HLA A and B, having a weak effect on HLA-C and no effect on HLA-E  whereas K3 is able 
to down regulate all HLA types (Ishido et al., 2000).  
The retrovirus HIV-1 also encodes a protein, nef, which is has been shown to modulate the 
cell surface expression of MHC class I molecules (Williams et al., 2002). Nef acts only on 
HLA-A and –B, so that HLA-C and –E remain present at the cell surface thus protecting 
infected cells from recognition and lysis by NK cells. Nef has been shown to directly bind to 
HLA-A2 molecules (Williams et al., 2002). This interaction is weak leading to the suggestion  
that nef acts more like an adaptor molecule, promoting an interaction between the MHC class 
I and the cellular adaptor protein AP-1 (Roeth et al., 2004). This interaction results in the 
rerouting of newly synthesised MHC class I molecules from the trans-Golgi network to 
lysosomal compartments for degradation.  
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1.5.7. Conclusion 
 
Clearly, the down regulation of cell surface display of MHC class I complexes is important 
for viral survival. Those mechanisms outlined above target almost every step in the antigen 
processing pathway, as a means of protecting cells from CD8
+
 T cell recognition and enabling 
the survival of the virus. Importantly for this research project, EBV is no exception to the 
immune evasion strategy. What follows is a detailed review of the relevant aspects of EBV 
biology, with particular focus on the different immune evasion strategies employed by EBV, 
and importantly for this work, the ability of this virus to evade detection by CD8
+
 T cells 
during lytic infection. 
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1.6.  Epstein Barr Virus 
 
EBV is a member of more than 130 known viruses that constitute the Herpesvirus family. 
Herpesviruses are further subdivided into three subgroups: the -, , and -herpesviruses. 
These are complex viruses which have linear double stranded DNA genomes and mostly 
infect vertebrate host animals. Of the 130 known Herpesviruses, eight are known to primarily 
infect humans and, in doing so, cause a variety of diseases which range in severity from self-
limiting skin lesions to cancer.  
The structure of all Herpesviruses consists of a double stranded DNA genome which, for EBV 
is 192 kbp but can be as big as 241 kbp. This DNA genome is contained within an icosahedral 
capsid which is further surrounded by a thick layer of virus encoded protein rich tegument. 
This is then surrounded by a membrane which is derived from the plasma membrane of the 
host cell during virus budding, and contains multiple virus-encoded glycoproteins which are 
involved in virus attachment and entry in to host cells, among other functions (Brown and 
Newcomb 2011).  
EBV is known to infect more than 90% of the human population. Infection normally occurs 
early in childhood and is often asymptomatic. However, if exposure is delayed until 
adolescence, it can be associated with the self-limiting disease, infection mononucleosis (IM). 
IM is characterised by a rapid expansion in CD8
+
 T cell responses directed towards EBV 
antigens. Following primary infection, EBV establishes a life-long infection of the host.  
Infection with EBV occurs via the oral route, through contact with infected saliva. The 
primary site of infection, within the oropharynx, was initially thought to be specialised 
epithelial cells, where it is thought to replicate and subsequently infect B cells trafficking 
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through the oropharynx. Some studies, however, have suggested that B cells in the 
oropharynx may be the primary site of infection (Karajannis et al., 1997; Niedobitek et al., 
1997). Irrespective of the primary infected cell, EBV establishes a latent infection of B cells 
in which the linear genome is circularised and maintained episomally.  
Following initial infection, B-cells are thought to express latency type III genes, as seen in 
lymohoblastoid cell lines (LCLs), these genes drive B-cell proliferation (as discussed below), 
or alternatively EBV may enter lytic cycle replication, producing virus which can 
subsequently re-infect epithelial cells (Fig 1.2). Upon entry into the blood, virus infected B-
cells are thought to differentiate into memory B-cells and express latency 0 pattern of gene 
expression, which is thought to be the latency pattern expressed by the majority of circulating 
memory B cells. In this latency pattern there are no viral genes expressed, unless the B-cells 
divide (entering latency I), whereby EBNA-1 is expressed (described in detail below) 
(Hochberg et al., 2004). Some of these circulating B-cells are thought to differentiate into 
plasma cells, entering lytic cycle replication, and release virus that can then infect other naïve 
B cells. Other circulating EBV infected B cells are thought to traffic back to the oropharynx, 
where they can undergo differentiation into plasma cells and shed virus into the saliva, or 
infect other epithelial cells, which then shed virus in to the saliva (Fig 1.1). Thus the need for 
lytic cycle in B-cells is paramount to maintain EBV infection and shed EBV into the saliva, 
enabling transmission to new hosts. The details of latency and lytic cycle are discussed in 
detail below. 
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Figure 1.2 Biology of EBV infection.  
(Adapted from (Cohen et al., 2000). (1) EBV initially either infects epithelial cells in the oropharynx 
where it replicates and then infects resting naïve B cells that traffic through the oropharynx, or it may 
infect resting, naïve B cells directly. (2) These B cells can undergo lytic infection and reinfect 
epithelial cells or B cells. Or EBV can establish a latent infection in these B cells, which eventually 
becomes latency 0. (3) Latency 0 infected memory B cells in the blood express no viral proteins, 
unless they divide. They can reactivate and undergo lytic cycle replication. These cells are subject to 
control by circulating CD8+ T cells. Released virus can infect other submissive cells. (4) Latency 0 
infected B cells can traffic to the oropharynx where they undergo lytic replication and release virus 
which can be detected in the saliva. This virus can further infect other cells. 
 
  
Lytic 
B 
Chapter 1  Introduction 
33 
 
1.6.1. Latent infection 
 
Following B cell infection, EBV is able to drive the proliferation of latently infected B cells 
by expressing a subset of latent growth transforming genes, establishing a form of latency 
known as latency III. These genes include; EBNA -1, -2, -3A, -3B, -3C and -LP; latent 
membrane proteins (LMP) 1, 2A and 2B; and two types of nontranslated RNA (Reviewed 
(Cohen 2000). The roles of these proteins have been studied using transfection of single genes 
into EBV negative cells and epithelial cell lines. They have also been studied in LCLs, which 
are established through in vitro EBV infection of B cells, using recombinant EBV to show 
which genes were dispensable or essential for transformation of B cells.  
EBNA-1 has been shown to be expressed in all known EBV-associated tumours, which 
reflects its essential role in maintaining the latent viral genome in proliferating cells. EBNA-1 
does this by binding to the plasmid origin of viral replication (OriP) site in the EBV episome 
and tethering it to the host genome, allowing the viral genome to be maintained during cell 
division (Yates et al., 1984).  
EBNA-2 plays an essential role in activating the expression of key cellular genes involved in  
EBV transformation of B cells (Cohen et al., 1989). This protein was the first EBV gene to be 
identified as being essential for EBV transformation of B cells, as isolates deleted for the 
EBNA-2 gene (e.g. Daudi cells) were shown to be transformation deficient. EBNA-2 interacts 
with the cellular protein RBPJThis interaction facilitates the transactivating role of EBNA-
2 by linking it to DNA response elements, resulting in activation and expression of cellular 
genes as well as LMP1 and 2 (Cohen et al., 1989; Johannsen et al., 1995).  EBNA2B is less 
efficient at transformation, which has been mapped to a single amino acid change (Cancian et 
al., 2011). The EBNA-3 proteins; -3A, -3B also bind to RBPJ, with a higher affinity than 
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EBNA2, therefore preventing EBNA2 from binding to DNA, thus inhibiting the ability of 
EBNA2 to disregulate gene expression (Robertson et al., 1996). EBNA3A and -3C are also 
required for B cell transformation (Tomkinson et al., 1993). EBNA-3B has been found as 
non-essential for transformation (Tomkinson and Kieff 1992). EBNA-3 proteins also 
upregulate the expression of other viral and cellular genes such as CD21 (Wang et al., 1990). 
EBNA-LP has been shown to regulate gene expression by inhibiting the EBNA2 induced 
activation of LMP1, LMP2 and cellular protein expression. EBNA-LP is also a classic 
example of the problems which have been encountered in defining genes as essential or non-
essential for transformation. In the first instance this protein was shown to be non-essential, 
because LCLs could still be generated with viruses knocked out for LP. However, more 
quantitative experiments suggest that the transformation more than 1000 times more efficient 
in the presence of EBNA-LP.    
LMP1 however, is essential for transformation of B-cells and also plays the role of an 
oncogenic gene, as evident in mouse studies, where the expression of LMP1 in transgenic 
mice leads to the formation of tumours  (Wang et al., 1985). LMP1 is also a functional 
analogue of a constitutively active form of the B cell surface molecule CD40 (Uchida et al., 
1999). In B-cells, the interaction of CD40 with its ligand results in binding to tumour necrosis 
factor receptor (TNFR)-associated factors and B cell activation and proliferation. LMP1 binds 
to several of these TNF-associated factors, which results in the activation of the nuclear 
factor-kB (NFkB) transcription factor, resulting in B-cell proliferation. In addition, LMP1 has 
been shown to upregulate the prosurvival, bcl-2 family members including, Bcl-2 and Mcl-2.  
      
EBV LMP2 proteins are not required for B-cell transformation by EBV and instead function 
to prevent the reactivation of EBV in latently infected B cells (Miller et al., 1994; Miller et 
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al., 1995), and allow B-cells to survive in the absence of normal B-cell receptor signalling 
(Caldwell et al., 1998). Thus both LMP1 and LMP2 are tapping into B cell signalling 
pathways that are known to affect differentiation and survival of B cells. The nontranslated 
RNAs of EBV do not encode proteins but are thought to be important for oncogenesis.  
EBV associated diseases tend to show one of three patterns of latency: latency 0/I, with the 
expression of no viral proteins or only EBNA1, upon cell division; Latency II, involving the 
expression of EBNA1, LMP1 and LMP2 and latency III, the expression of all latent genes.  
As described previously, the entry of EBV infected B-cells into lytic cycle is an essential 
component of EBV biology. Lytic cycle results in the production of viral progeny, resulting in 
infection of naïve B-cells and shedding of virus into the saliva in order to maintain and 
transmit the virus. Below is a detailed description on lytic cycle replication.  
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1.6.2. Lytic infection 
 
The study of EBV lytic cycle in vitro has proved difficult as there is currently no cell culture 
system which allows for primary lytic cycle infection to an efficiency necessary for in vitro 
study. As a consequence, in vitro models in which EBV is reactivated in latently infected cell 
lines have been used. This commonly involves the use of broad acting chemical inducers such 
as butyrates or the phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA); among other 
things, these agents activate transcription of the immediate early viral gene, BZLF1. The 
broad range of effects of chemical inducers include increased expression of components of the 
antigen processing pathway, such as MHC class I, which compromises their use in studying 
immune responses to EBV lytic cycle. A more physiological model is available in which 
surface immunoglobulin crosslinking on an EBV infected cell line, AKATA, induces the 
initiation of lytic cycle, allowing for the examination of the expression kinetics of lytic cycle 
(Takada and Ono 1989).  
During lytic cycle, EBV has been found to express more than 90 viral proteins, which are 
temporally regulated (Fig 1.3) and thus, like other herpesviruses, can be divided into three 
classes according to the timing of their expression: immediate early, early and late. The 
immediate early genes are transcribed even in the presence of protein synthesis inhibitors, and 
they function as transactivators of other lytic cycle viral and cellular genes. Direct and indirect 
targets of the immediate early genes include the early viral genes which are transcribed before 
viral DNA replication and their transcription is inhibited in the presence of protein synthesis 
inhibitors but is not inhibited by viral replication inhibitors. Finally, the late genes are those 
expressed following viral DNA replication, and their expression is blocked by inhibitors of 
viral DNA replication. 
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EBV expresses two immediate early proteins encoded by the BZLF1 and BRLF1 genes, both 
of which are required to activate the transcription of early viral genes (Feederle et al., 2000; 
El-Guindy et al., 2013). BZLF1 is a DNA binding protein with homology to cellular c-jun and 
c-fos proteins. BZLF1 binds to activator protein-1 (AP-1) like Z-responsive elements (ZREs) 
in promoter sequences (Farrell et al., 1989; Chang et al., 1990). Interestingly, BZLF1is able 
to activate its own expression, which also requires other cellular transcription factors, and this 
in turn transcriptionally activates the promoter of BRLF1, through direct binding to ZREs 
within the BRLF1 promoter (Urier et al., 1989). BRLF1 can then upregulate the expression of 
BZLF1 (Ragoczy et al., 1998). Combined, this results in rapid expression of BZLF1 and 
BRLF1 following reactivation of lytic cycle, which subsequently activates the expression of 
early and late genes by binding to response elements in the promoters of these genes. Whilst 
BZLF1 and BRLF1 are necessary for efficient induction of the lytic cycle cascade, there are 
also cellular factors involved. This is exemplified by the fact that BZLF1 will efficiently 
induce lytic cycle in Akata cells, but not in LCLs. This has not been extensively studied, but 
there is a suggestion that in addition to cellular factors, the expression of LMP1 in latency III 
may block the B cell differentiation required for lytic cycle (Vrzalikova et al., 2011), which 
may explain the effects of BZLF1 in Akata compared to LCLs. 
Proteins expressed during the early phase of lytic cycle play numerous roles such as 
protecting cells from apoptosis via the expression of the cellular bcl-2 homologue, BHRF1 
(Henderson et al., 1993), while some early genes function to activate the expression of other 
early genes. Collectively, two major roles played by the genes expressed in the early phase of 
lytic cycle are to mediate viral DNA replication, and to modulate the immune response 
directed towards EBV (discussed below). Using an in vitro assay to amplify plasmids 
containing the OriLyt, six early proteins have been identified which are essential for viral 
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DNA replication. These include the viral DNA polymerase, BALF5; BALF2, which functions 
as a single stranded DNA binding protein; BMRF1, which is a DNA polymerase accessory 
factor; the primase homologue BSLF1; a helicase homologue BBLF4 and BBLF2/3 a 
helicase-primase homologue (Fixman et al., 1992).In addition, the immediate early gene 
BZLF1, which interacts with the replication proteins, is also required for binding to the 
OriLyt.  
Those genes expressed during late phase lytic cycle predominantly encode the structural 
proteins of EBV. These include numerous glycoproteins, such as gp350, the major viral 
envelope protein encoded by BLLF1, which binds to its receptors CD21 on B cells, thereby 
enabling EBV attachment to submissive cells (Fingeroth et al., 1984). The capsid proteins, 
such as the major nucleocapsid protein encoded by BcLF1, and tegument proteins such as 
BNRF1 are also expressed at the late stages of lytic cycle.  
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Figure 1.3 Lytic cycle infection. 
Following entry of lytic cycle, proteins are expressed in a synchronous manner. This begins with the 
expression of immediate early genes i.e. BZLF1, followed by the expression of early gene products 
such as BMRF1 and some immune evasion proteins i.e. BILF1 and finally late genes such as BALF4. 
This sequence of events results in the production of viral progeny and can last up to 4 days.  
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1.6.3. The host immune response to EBV infection 
 
Infection by EBV elicits both an innate and adaptive immune response, however the cell 
mediated response is considered more important for control of the virus. This is most evident 
in the EBV-associated diseases which arise in immunocompromised individuals, including the 
onset of post-transplant lymphoproliferative disorder (PTLD) which is seen in transplant 
recipients, following immune suppression and is the result of uncontrolled proliferation of 
EBV transformed B cells, in the absence of functional T cells. 
Given that EBV encodes such a vast number of proteins expressed during latent and lytic 
phases of its biological cycle are they all equally potential targets for T cell responses, or is 
there immunodominance of a particular subset? The investigation of T cell responses in 
individuals suffering from IM, as well as healthy EBV infected carriers, has allowed for the 
detailed study of T cell responses mounted towards EBV during infection. During IM there is 
a dramatic expansion of CD8
+
, but not CD4
+
, T cell responses to both lytic and latent EBV 
antigens, although CD8
+
 T cells specific for lytic epitopes have been shown to be the more 
dominant population, while later in infection this population is dominated by CD8
+
 T cells 
directed towards latent antigens (Callan et al., 1998; Maini et al., 2000; Hislop et al., 2002). 
Within this population of lytic epitope specific CD8
+
 T cells, it has been shown that a pattern 
of immunodominance exists, where there is a higher proportion of CD8
+
 T cells directed 
towards the immediate early antigens, BZLF1 and BRLF1, with up to 44% of all CD8
+
 T cells 
directed toward one BZLF1 derived epitope, in one example (Callan et al., 1998; Hislop et 
al., 2002).  Reactivity towards early epitopes such as BMLF1 and BMRF1 are less frequent, 
accounting for up to 12% of the total CD8
+
 population (Callan et al., 1998; Annels et al., 
2000; Hislop et al., 2002), and T cells specific for late epitopes are rarely seen (Pudney et al., 
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2005).  Following control of IM, there is a rapid contraction in these EBV-specific CD8
+
 T 
cell responses (Hislop et al., 2002).   
This pattern remains similar in healthy carriers, where the frequencies of EBV specific CD8
+
 
T cells are lower than seen in IM, with around 0.2-2% of CD8
+
 T cells directed towards lytic 
epitopes while only 0.05-1% are directed toward the latent (Hislop et al., 2007). In a similar 
pattern as seen in IM patients, healthy donor lytic epitope specific CD8
+
 T cell populations 
are dominated by those directed towards the early and especially immediate early epitopes. 
This pattern of CD8
+
 T cell immunodominance can be correlated with the efficiency with 
which the different epitope peptides are presented during infection (Pudney et al., 2005), 
where immediate early epitopes and early epitopes are better presented than late epitopes. 
This is thought to be due, in part, to EBVs immune evasion mechanisms which enable this 
virus to evade CD8
+
 T cell recognition by interfering with the antigen presentation during 
lytic cycle (discussed below).  
Studies into the CD4
+
 T cell response to EBV targets has been less well studied, although it 
has been shown that during IM, CD4
+
 T cells predominantly recognise EBNA-3C to a greater 
extent than EBNA-1 or EBNA-2, while later in infection EBNA-1 appears to be the dominant 
target (Woodberry et al., 2005). Interestingly, while there is a hierarchy of CD8
+
 T cell 
responses to lytic antigens, as described above, CD4
+
 T cell responses directed towards latent 
antigens appears to be more evenly distributed (Long et al., 2011). The frequency of 
responses in healthy individuals is, as mentioned, dominated by CD8
+
 T cells. However, 
CD4
+
 T cell responses are still important as both helper cells, producing IFN- and some also 
exhibit cytotoxic effects, evident in the ability of these cells to inhibit outgrowth of virus 
transformed cells (Long et al., 2005).   
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1.6.4. Immune evasion by EBV 
 
Due to this strong immunological pressure, EBV has necessarily evolved a number of ways to 
avoid detection by T cells, particularly CD8
+
 T cells. As described above, circulating EBV 
infected B-cells are thought to show latency-0 pattern of expression. This minimal expression 
of viral proteins can be considered a means of avoiding elimination by T cells, by reducing 
the amount of viral peptides available for presentation to T cells. In addition, some latently 
expressed proteins employ their own mechanism to prevent presentation to CD8
+
 T cells, such 
as EBNA1, as described in section 1.6.1. However, during lytic cycle, more than 90 viral 
proteins are expressed, creating an extensive pool of viral epitopes available for presentation 
to the immune system and thus cells undergoing lytic cycle are highly vulnerable to detection 
and elimination by the immune system.  
The study of CD8
+
 T cell evasion by EBV during lytic cycle was initially difficult due to the 
lack of an adequate in vitro model. As a consequence, the inducible EBV infected cell line, 
AKATA, was engineered to express a rat-CD2-GFP reporter plasmid, under the control of the 
early lytic cycle BMRF1 promoter, now known as AKBM cells. Upon induction, AKBM cells 
express both rat-CD2 and GFP, thus allowing for the isolation of lytic populations (Ressing et 
al., 2005). LCLs in culture can also spontaneously enter lytic cycle. Although, is normally a 
rather small subset of around 1-2% and rarely more than 5%. In addition, this is 
unpredictable, and the factors which dictate this are unknown. Nevertheless, using 
spontaneously lytic LCLs and the AKBM model described above, it has been shown that 
during lytic cycle there is a marked decrease in the expression of cell surface MHC class I 
molecules (Keating et al., 2002; Ressing et al., 2005). In addition to this, lytic cycle induction 
is also associated with impaired peptide transport by TAP (Ressing et al., 2005), this, together 
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with the finding that the efficiency of epitope presentation of EBV antigens diminishes as 
lytic cycle progresses (Pudney et al., 2005), suggests that EBV is able to interfere with the 
MHC class I antigen processing pathway.  
It is now known that there are multiple lytic cycle proteins capable of downregulating MHC 
class I surface levels, when ectopically expressed. The first such EBV protein to be implicated 
was the vIL-10 encoded by BCRF1, which was reported to inhibit transcription of TAP1 
(Zeidler et al., 1997). However, the first EBV gene to be shown to inhibit functional 
recognition by CD8
+
 T cells specific for lytic cycle gene epitopes, was BNLF2a (Hislop et al., 
2007). 
BNLF2a is a small tail-anchored protein which is able to insert into the ER membrane via its 
C-terminal hydrophobic domain, a process facilitated by the cellular protein AsnaI, while the 
N-terminal domain of BNLF2a is responsible for TAP inhibition (Horst et al., 2011). In 
contrast with other known viral TAP inhibitors which target either the ATP or peptide binding 
functions of TAP, the association of BNLF2a with TAP inhibits both the ATP and peptide 
functions of TAP (Hislop et al., 2007). As a result there is a very efficient reduction of 
peptide transport and subsequent peptide loading of MHC class I molecules, thereby reducing 
cell surface expression of MHC class I molecules in cells expressing BNLF2a (Hislop et al., 
2007). The interaction of BNLF2a with TAP requires TAP2 which is thought to stabilise 
BNLF2a, since in cells lacking TAP expression, there is decreased levels of BNLF2a protein 
expression (Horst et al., 2009). In this same study, ectopic expression of BNLF2a in EBV-
negative cells was demonstrated to impair their functional recognition by epitope specific 
CD8
+
 T cells. Importantly, recognition of EBV lytic cycle antigens was significantly 
enhanced in spontaneously lytic LCLs transformed with recombinant EBV lacking BNLF2a, 
compared to LCLs transformed with wild-type EBV. Interestingly, whilst there was a 
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dramatic increase in recognition of epitopes originating from immediate early and early 
antigens, there was little effect on recognition of late lytic epitopes  (Croft et al., 2009). This 
suggests that additional immune evasion mechanisms are in place during lytic cycle, which 
are also able to interfere with the processing and presentation of lytic peptides. 
Very recently, in addition to aiding in the evasion of CD8
+
 T cell detection in cells 
spontaneously reactivating into lytic cycle replication, BNLF2a has also been implicated in 
protecting EBV infected cells from CD8
+
 T cell recognition immediately after infection of B-
cells. This same study showed that BNLF2a mRNA is contained within the EBV virion, and 
is transcribed and active immediately after infection of B-cells, thus protecting newly infected 
B-cells from CD8
+
 T cell recognition in the initial stage of infection, before the virus enters 
full lytic cycle replication (Jochum et al., 2012; Jochum et al., 2012).  
More recently, the early lytic expressed protein BILF1 has been shown to reduce cell surface 
expression of MHC class I, and recognition by EBV lytic epitope specific CD8
+
 T cells, upon 
ectopic expression  (Zuo et al., 2009).  BILF1 is a G-protein coupled receptor which is able to 
bind to MHC class I molecules, requiring the C-terminal domain to do so, and subsequently 
increase their turnover from the cell surface and subsequent lysosomal degradation (Zuo et 
al., 2009; Griffin et al., 2013). The exact function which enables BILF1 to exert this effect on 
MHC class I molecules is currently unknown, however it is not dependent upon ubiquitination 
of MHC class I molecules, as it the case with KSHV immune modulating  proteins, K3 and 
K5 (Zuo et al., 2009). The function of G-protein signalling and MHC class I turnover by 
BILF1 are independent of one another, which was shown in a study using a BILF1 mutant 
which lacked in the signalling ability yet was still able to downregulate surface MHC class I 
levels (Zuo et al., 2009). In addition to increasing the degradation of cell surface MHC class I 
molecules, BILF1 is also able to target newly synthesised MHC class I molecules which are 
Chapter 1  Introduction 
45 
 
trafficking to the cell surface, by diverting them from the exocytic pathway. Indeed, this latter 
mechanism appears to be responsible for a greater reduction in cell surface MHC class I than 
is caused by internalisation of MHC class I (Zuo et al., 2011). Importantly, B cells infected 
with EBV in which BILF1 has been deleted revealed that in the absence of BILF1, EBV 
infected B cells were better recognised by CD8+ T cells specific for lytic epitopes (Zuo et al., 
2011), while the ectopic expression of BILF1, albeit in a different cell type, has been shown 
to decrease CD8
+
 T cell recognition (Zuo et al., 2009). Moreover, the ability of BILF1 to 
target MHC class I molecules appears to be selective, in that it has been shown to have 
minimal effect on levels of HLA-C molecules. By deleting a portion of the C-terminal domain 
of HLA B8 HC molecules, BILF1 was unable to reduce the cell surface expression of MHC 
class I molecules, indicating that some or all of these residues are required for BILF1 binding 
to MHC class I molecules, moreover it was shown that these required residues were not 
present in the cytoplasmic domain of HLA-C molecules (Griffin et al., 2013). 
The early lytic cycle expressed protein BGLF5 has also been implicated in CD8
+
 T cell 
evasion by EBV. BGLF5 was first identified as a viral exonuclease enzyme, which is required 
for successful viral replication and production of viral progeny (Feederle et al., 2009), is now 
known to have a host shut-off function that decreases the synthesis of new MHC class I 
molecules (Rowe et al., 2007; Zuo et al., 2008), which is genetically separable from its 
DNase enzyme function, and is responsible for impaired recognition of antigen presented to 
CD8
+
 T cells. The molecular mechanism of BGLF5 host shut-off was resolved by Buisson et 
al (2009) who demonstrated that in addition to DNase activity, BGLF5 had potent RNase 
activity that was dependent upon the presence of Mn++ ions (Buisson et al., 2009; van Gent 
et al., 2011). While the RNase activity of BGLF5 accounts for the host shut-off function of 
BGLF5, its consequences are not confined to MHC class I synthesis but extended to reduce 
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the levels of most host mRNA species, including MHC class II (Rowe et al., 2007). More 
recently it has been shown that during lytic cycle replication there is a strong decrease in the 
synthesis of the dsDNA sensor TLR9, which is itself activated by the EBV infection. In vitro 
studies have shown that in the presence of Mn
2+
 BGLF5 is able to reduce the transcription of 
TLR9 mRNA, suggesting that BGLF5 may contribute to the decreased expression of TLR9 
during lytic cycle (van Gent et al., 2011). This may suggest that BGLF5 adopts a less targeted 
approach to interfering with CD8
+
 T cell recognition of infected cells, and is also important in 
evading the innate immune responses which are initiated EBV upon infection.  
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Figure 1.4. The stages during MHC class I antigen presentation which are targeted EBV 
immune evasion proteins.  
BGLF5 increases the turnover of MHC class I mRNA. BNLF2a interferes with the function of TAP 
and BILF1 targets MHC class I molecules, which are en route to the cell surface and at the cell 
surface, for lysosomal degradation.  
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As mentioned previously, the BCRF1 gene of EBV encodes a vIL-10, which has a variety of 
effects on the immune system. These include reducing the mRNA levels of TAP1 and LMP2, 
a subunit of the immune proteasome, in  B cells (Zeidler et al., 1997). This results in  a 
decrease in peptide transport and subsequent peptide loading and presentation of MHC class I 
molecules at the cell surface (Zeidler et al., 1997). More recently it has been shown that vIL-
10 is expressed early after infection of primary B cells (Jochum et al., 2012). Although this 
did not result in a decrease in CD8
+
 T cell recognition, the deletion of this gene did resulted in 
an increase in NK cell lysis of B cells, compared to those infected with wild type virus 
(Jochum et al., 2012), suggesting it may impair NK cell mediated killing, thereby protecting 
newly infected cells from detection following infection. 
In addition to vIL-10, the BART2-5p EBV microRNA (miR), which has been shown to 
reduce expression of the MICB protein, a stress induced natural killer cell ligand which 
promotes the destruction of infected cells by natural killer cells. miR-BART2-5p achieves this 
by binding to the 3’UTR region of the mRNA which encodes MICB, this decrease in MICB 
leads to protection of infected cells from killing by NK cells (Nachmani et al., 2009).With the 
exception of these two examples there has been no other EBV encoded protein identified as 
being able to evade NK cell recognition, which is surprising considering the extent of proteins 
able to down regulate MHC class I levels. Indeed the down regulation of cell surface MHC 
class I expression means that cells undergoing lytic cycle replication are more vulnerable to 
NK lysis than latently infected cells (Pappworth et al., 2007). However, this is not to say that 
other NK cell evasion mechanisms that active during lytic cycle replication do not exist. Some 
of EBVs miRs have also been identified as having potential immune evasion mechanisms. 
This includes some that act to inhibit apoptosis of infected cells such as miR-BART5, -
BART4 and –BART15.  
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The evasion of CD4
+
 T cell responses by EBV has been less extensively studied. However, in 
addition to the turnover of MHC class II transcripts by BGLF5, BZLF1 has also been shown 
to interfere with MHC class II synthesis. Studies have revealed that BZLF1 inhibits the 
expression of MHC class II molecules by either binding to ZRE elements in the promoter of 
CIITA, the transactivator of MHC class II expression (Li et al., 2009), or by modulating the 
expression of the invariant chain, which plays a role in the loading of peptides on to MHC 
class II molecules and subsequent transport of these complexes (Zuo et al., 2011). This 
confers a decrease in cell surface expression of MHC class II molecules and reduced CD4
+
 T 
cell recognition (Zuo et al., 2011).  
The EBV encoded glycoprotein gp42 (BZLF2) has also been implicated in the evasion of 
CD4
+
 T cell recognition. Gp42 exists as a type II membrane protein and as a truncated soluble 
protein, both of which bind MHC class II molecules, at various stages of maturation (Ressing 
et al., 2005). This complex results in a block in the interaction of MHC class II:peptide 
complexes with TCRs and thus inhibits CD4
+
 T cell recognition (Ressing et al., 2003; 
Ressing et al., 2005). 
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1.7. Scope of thesis 
 
The ability of EBV to modulate the T cell response is clearly an important one, which allows 
for its lifelong persistence in a healthy host. Equally, the ability of the host to respond to 
infection is of paramount importance in order to control EBV infection and reactivation. 
Given the diverse range of mechanisms that EBV has evolved in order to interfere with the 
antigen presentation pathway, this research project aimed to assess the role that three of these 
proteins (BNLF2a, BILF1 and BGLF5) play, in the context of the whole virus, in evading 
CD8
+
 T cell recognition by interfering with the antigen presentation pathway at the different 
phases of lytic cycle (Fig 1.4), and to investigate the relative contribution each make towards 
this interference. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1. Tissue culture  
 
2.1.1. Tissue culture media and reagents 
 
RPMI-1640 supplemented with 2mM L-glutamine (sigma) was stored at 4°C. 
DMEM- Stored at 4°C (Sigma) 
Foetal calf serum (FCS) (PAA) was stored in 50ml aliquots at -20°C 
Human serum (HuS) (PAA) was free from virus and mycoplasma, and derived from a male 
type AB, and was stored in 50ml aliquots as -20C. 
Penicillin-streptomycin (Gibco) containing 500 IU/ml penicillin and 5000ug/ml 
streptomycin. Stored as 100x stock and stored at -4C. 
Trypsin-express (Gibco) was used as per manufacturer’s recommendations. 
Phosphate buffered saline (PBS) Made by dissolving 1x PBS tablet (Oxoid) per 100ml of 
water which had been filtered and ions removed. 500ml aliquots were then sterilised by 
autoclaving for 20 minutes at 121C. 
Recombinant interleukin-2 (IL-2) was supplied by PeproTech in lyophilised powder. This 
was reconstituted in PBS to give a concentration of 10
5 
IU/ml and stored as 200ul aliquots at -
20°C. 
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Monkey Leukocyte antigen-144 supernatant (MLA). Derived from the supernatant of 
cultured MLA-144 cells. Supernatant was filtered and stored in 60ml aliquots at -20°C. 
Lymphoprep was purchased in 500ml bottles (PAA) 
Dimethyl sulphoxide (DMSO)  
Opti-MEM- Purchased from Gibco 
 
2.1.2. Peptides 
Peptides were synthesised by either peptide 2.0 or Alta biosciences and dissolved in DMSO to 
obtain a concentration of 5mg/ml and stored at -20C. 
 
2.1.3. Isolation of peripheral blood mononuclear cells (PBMCs) 
Peripheral blood was collected from donors into a syringe with heparin and then diluted with 
1 part RPMI-1640. Lymphocytes were then separated by layering 35ml blood/RPMI onto 
15ml lymphoprep and centrifuged at 1800rpm with no break. Cells were then washed and 
either used immediately for experiments or cryopreserved. All experiments were approved by 
an ethics committee, and donors provided consent.  
 
2.1.4.  Isolation human of B cells 
B cells were selected from donor PBMCs using CD19 Pan B Dynabeads (Invitrogen), at a 
concentration of 4 beads per B cell (under the assumption that B cells account for 5% of total 
PBMCs). Cells were resuspended in 1ml of RPMI-1640 + 10% FCS per 1x10
7 
beads, and 
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incubated at 4ºC for 30mins on a roller. Cells were then washed 5 times in RPMI-1640 + 10% 
FCS on a magnetic rack, to retain the CD19 positive cells. Cells were then resuspended in 
500ul RPMI-1640 + 1% FCS with 20ul of anti-CD19 detachabeads (Invitrogen) and 
incubated for 45 minutes, on a roller, at room temperature. Detachabeads were then removed 
using a magnetic rack, resulting in the elution of purified B cells.  
 
2.1.5. Generation of LCLs 
Purified B cells (5x10
6
) were pelleted and resuspended in a high titre of recombinant EBV at 
a multiplicity of infection (M.O.I) of 50 using wild-type 2089-, BILF1-, NLF2a, 
BGLF5- or BZLF1-virus. Cells were incubated with virus for 30 minutes on ice and then 
excess virus was washed off with RPMI-1640. Cells were resuspended in RPMI-1640 + 10% 
FCS and incubated in one well of a 24-well tissue culture plate at 37C, 5% CO2 . 
Alternatively, to generate B95.8 virus transformed LCLs, 5x10
6 
purified B cells were 
incubated with 5ml of B95.8 cell line supernantant overnight at 37ºC in one well of a 6-well 
plate. B cell transformation could be seen within one week. Cells were expanded until they 
could be maintained in a 25cm
2
 tissue culture flask (Corning) in 10ml RPMI-1640 + 10% 
FCS. 
 
2.1.6. Limiting dilution T cell cloning 
T cell clones were established using either frozen PBMCs from either healthy donors or IM 
patients. These were thawed into T cell cloning media (RPMI-1640 + 10% FCS + 1% HuS + 
30% MLA + 50IU/ml penicillin + 50ug/ml streptomycin + 5-IU/ml IL-2). They were then 
seeded into 96 well round bottom plates (corning) at 0.3, 3 or 30 PBMCs per well in the 
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presence of irradiated (4000 rads) allogenic feeder PBMCs (10
6
/ml). These were generated 
from fresh ‘cones’ (Birmingham national blood service) and then activated with 
phytohaemagglutinin (PHA 10ug/ml) overnight in standard media. Alongside feeder cells, 
irradiated (4000 rads) autologous LCLs (10
5
/ml) were also used. 
Plates were incubated at 37ºC, 5% CO2 for one week, after which they were given fresh 
cloning media. One week after this, any clones which grew were expanded further in to 24-
well plates corning, in the presence of irradiated autologous LCLs (10
5
/ml) and allogenic 
feeder PBMCs (10
6
/ml). After this, clones were maintained by feeding twice per week with 
fresh T cell cloning media (see section 2.2.6) by removing 1ml of media and replacing with 
fresh media.  
 
2.1.7. Interferon gamma (IFN) capture T cell cloning 
To generate CD8
+
 T cell clones of known specificities, IFNcapture cloning was employed. 
PBMCs from healthy or IM patient donors were thawed and stimulated with the appropriate 
peptides, corresponding to the clone specificities required, for 4 hours at 37ºC, 5% CO2. 
Following this, cells were washed with cold MACs buffer (PBS with 0.5% (w/vol) BSA and 
2.5mM EDTA). Cells were then resuspended in 80l of cold standard media (RPMI-1640 + 
10% FCS) and 20l of CD45-conjugated IFN-catch reagent (Miltenyi Biotec). From here, 
the manufacturer’s protocol was followed. Collected cells were then plated out using limiting 
dilution (section 2.1.6). 
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2.1.8. Cryopreservation 
Cells to be preserved were pelleted and resuspended in freezing media (RPMI-1640 + 10% 
DMSO + 20% FCS) and transferred into sterile 1ml cryovials (Nunc). These were then stored 
in a ‘Mr Frosty’ at -80ºC overnight, allowing for a slow decrease in temperature (1ºC/minute). 
The next day, cryovials were transferred into liquid nitrogen freezers.  
 
2.1.9. Revival of cryopreserved cells 
To revive cells, 1ml cryrovials were placed into a 37ºC water bath for thawing. Following this 
cells were washed with standard media (RPMI-1640 + 10% FCS), resuspended in appropriate 
media and transferred into an appropriate plate or flask, for culturing in a 37ºC, 5% CO2 
incubator. 
 
2.1.10. Mycoplasma testing 
All cell cultures were routinely tested for the presence of mycoplasma by using a Mycoalert 
kit (Cambrex), as per manufacturer’s protocol. 
  
Chapter 2  Materials and methods 
 56  
 
2.2. Generation of shRNA lentiviruses and transduction of lytic LCLs 
 
Screening of candidate siRNAs 
Candidate siRNAs were generated by sigma aldrich, these are shown in Table 2.1. Candidate 
siRNAs were screened using 293 cells which had been transfected with a plasmid expressing 
the target knockdown gene. On day one 293 cells were plated into one 24cm
2
 flask, per panel 
of siRNAs, and incubated at 37ºC, 5% CO2 overnight. The next day, cells were transfected 
with plasmids expressing BNLF2a, BILF1-HA or BGLF5 using lipofectamine. To do this 
lipofectamine-2000 was incubated with OPTI-MEM for 5 minutes. Following this, 1ug of 
plasmid was added. This was incubated at room temperature for 20 minutes, after which, this 
mix was topped up with of OPTI-MEM and layered over 293 cells, these were left for 6 hours 
and then topped up with DMEM media, these are incubated over night at 37ºC, 5% CO2. The 
following morning, the transfected 293 cells are washed in PBS and resuspended using 1ml 
trypsin. Cells are then resuspended in 8ml of DMEM media and aliquoted into 8 wells of a 24 
well plate. This ensures that all wells have an equal proportion of cells expressing the target 
protein. Cells are then incubated at 37ºC, 5% FCS for 8 hours. Following this, cells are 
transfected with a panel of siRNAs (see Table 2.1) for each target gene, including a control 
siRNA for each screen.  
siRNAs were transfected using 1ul oliofectamine, which was incubated with 2ul of OPTI-
MEM per well, for 5 minutes at room temperature. Following this the required (50-250uM) 
concentration of siNRA diluted in OPTI-MEM was added and this mix was incubated at room 
temperature for 20 minutes. After this, 500ul OPTI-MEM was added and this was layered 
onto one well of transfected 293 cells. Each individual siRNA was screened in duplicate 
alongside a control. 24 hours later cells were harvested and lysed for use in western blot 
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analysis to measure the level of protein knockdown. Three different siRNAs were selected 
which showed successful knockdown of BNLF2a, BILF1 or BGLF5. 
These sequences were used to generate shRNA constructs for each individual knockdown 
(Table 2.1). These constructs also expressed a fluorescent tag a puromycin resistance gene, to 
allow for cell sorting and enrichment following transduction.  
 
Generation of shRNA lentiviruses 
shRNA lentiviruses were generated using FT293 cells. These cells were split on day one in 
30mls DMEM media and incubated in a 75cm
2
 flask, to achieve approximately 70-80% 
confluencey the following day. On day 2, DMEM media was removed and replaced with 5mls 
of DMEM media. Transfection mixes were then made, firstly 40ul of lipofectamine per one 
flask of FT293 cells, was incubated with 1.5ml of optimem for 5 minutes at room 
temperature. During this time an aliquot of 4ug of shRNA-vector plasmid, 2ug envelope 
plasmid-pMD2G (VSV-G envelope) and 6ug packaging plasmid-psPAx2 (gag-pol) in 1.5ml 
of OPTI-MEM per flask, was made up. This was then mixed with the lipofectamine and 
incubated at room temperature for 20 minutes. Following this, the 3ml mixture was added to 
the 5ml of fresh DMEM media in a 75cm
2 
flask and incubated in a 37ºC, 5% CO2 incubator 
overnight. On day 3, this media/transfection mix was removed and replaced with 10ml of 
fresh DMEM media. On day 5, virus was harvested. 
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Transduction of B95.8-LCLs 
Following the generation of virus using FT293 cells, cell supernatant containing virus was 
harvested and filtered. After filtration, supernatant was placed into a 15ml tube and 
concentrated using ultracentrifugation whereby supernatants are centrifuged in metal buckets, 
using a SW40-rotar at 19500rpm, 16ºC for 3 hours. Concentrated virus was then titrated to 
check the quality of the virus and one concentrated aliquot per flask was used to transduce 
2x10
6 
B95.8 LCLs. 
To transduce B95.8 LCLs lytic LCLs were selected on the basis of BZLF1 expression, which 
was assessed using intracellular BZLF1 staining and flow cytometry. These cells were then 
washed and aliquoted into 2x10
6 
per 15ml tube (Falcon) for each virus transduction, these 
were pelleted and the supernatant removed. Concentrated virus was then used to resuspend 
these cells, after which the virus/cell mix was centrifuged at 19000rpm for 30 minutes at 
32ºC. Cells were then resuspended directly into the supernatant and 1ml of standard media 
was added. This was then incubated in one well of a 24-well plate in a 37ºC, 5%CO2 
incubator. The next day, 1ml of standard media was added and 24 hours after this, the level of 
transduction was assessed using flow cytometry. If cells were not more than 90% transduced, 
firstly puromycin is used to enrich the transduced population (see 2.1.13). If this was not 
successful, transduced cells were sorted by selecting for successfully transduced LCLs which 
were expressing the appropriate fluorescent tag (fluorescence activated cell sorting). Cells 
were then maintained in RPMI-1640 + 10% FCS and used in T cell recognition assays. 
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2.3. Culturing cells 
 
EBV transformed LCLs 
Established LCLs were maintained in standard media (RPMI-1640 + 10% FCS + 50IU/ml 
penicillin + 50ug/ml streptomycin) and were split once or twice a week by removing half of 
the culture and replacing with fresh standard media.  
 
shRNA-lentivirus transduced LCLs 
Following transduction, LCLs were maintained in standard media. If transduced cells needed 
to be further enriched, puromycin was added to media (100ug/ml); this was removed once 
cells were efficiently enriched. 
 
B95.8 virus producing cell line 
B95.8 cells were maintained in 10ml of standard media. Cells were split two times per week. 
 
293 and FT293 cells 
293 and FT293 cells were maintained in 75cm
2 
flasks in 18ml of DMEM media (DMEM + 
10% FCS + 50IU/ml penicillin + 50ug/ml streptomycin), with the addition of geneticin for 
FT293 cells. Cells were split as required by removing media and washing with 10ml PBS. 
Following this 2ml of trypsin express was added and incubated with cells for 1 minute at 
room temperature. After, 10mls of DMEM media was added and cells were split as required. 
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MLA-144 
The gibbon cell line MLA-144 is an established line derived from a spontaneous 
lymphosarcoma of gibbon and is used to stimulate T cell growth. Cells were maintained in 
standard media in 150cm
2
 flasks for 2 weeks without feeding, after which supernatant was 
harvested and filtered, for use as T cell feeding media.  
 
CD8+ T cell clones 
Established clones were maintained in 24-well plates (2ml/well) with T cell cloning media 
(RPMI-1640 + 10% FCS + 1% HuS + 30% MLA + 50IU/ml penicillin + 50ug/ml 
streptomycin + 5-IU/ml IL-2). Cells were fed twice a week by removing 1ml of media and 
replacing this with fresh media. If clones needed to be restimulated 200ul of T cells were 
removed from cluture and mixed with allogenic feeder PBMCs (10
6
) and autologous LCLs 
(10
5
) in T cell cloning media. After one week these were fed with 1ml media and maintained 
as normal. 
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2.4. Immunological assays 
 
2.4.1. Chromium release assays 
Chromium release assays were used to assess the cytotoxic effects of potential CD8+ T cell 
clones on target cell lines which had been loaded with Cr
51
 and either infected with vaccinia 
constructs or sensitised with synthetic peptides. 
Target LCLs were infected with vaccinia at an MOI of 10 for one hour at 37ºC, 5%CO2, with 
continuous resuspension of cells. To this, 2ml of standard media was added and this was 
incubated overnight. Following this, cells were pelleted, the supernatant removed and 15ul of 
Cr-sodium-chromate (Cr
51
) (Perkin Lemer, 50uCi) was added. At this stage, peptide (5ug/ml) 
was added to those cells which required peptide sensitisation. Cells were incubated at 37ºC, 
5% CO2 for 1hour 30minutes and then washed twice with standard media. During the 
incubation of target cells, CD8+ T cells were plated into 96-well plates in 100ul standard 
media (250cells/100ul) to achieve a target to effector ratio of 1:10. Washed target cells were 
added to T cells at 2.5x10
3 
cells per well in 100ul standard media. This was carried out in 
triplicate for each combination. To control for background release of Cr
51
, the spontaneous 
release of Cr
51
 from target LCLs in the absence of T cells was measured, as a control for 
maximum release, target cells were incubated with standard 100ul of sodium dodecyl sulphate 
(SDS). Plates were then centrifuged at 900rpm for 5 minutes and then incubated for 5 hours at 
37ºC, 5%CO2. Plates were then centrifuged at 1000rpm for 5 minutes and 100ul of 
supernatant from each well was harvested in to LP2 tubes (Luckmann). Due to the use of 
vaccinia, these tubes were decontaminated overnight in the presence of paraformaldehyde 
fumes. Following this, the Cr
51
 release was then counted in a gamma-radiation counter (Cobra 
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II Auto-gamma, Packard). For all experiments the percentage of specific lysis was calculated 
using the following equation: 
(Release by target cells in the presence of T cell-spontaneous release)/ (Maximum release-
Spontaneous release) x 100    
 
2.4.2. IFN- enzyme linked immunosorbant assay (ELISA) 
To test the ability of CD8+ T cell clones to recognise targets, IFN-g ELISA was used. Firstly, 
target LCLs, either untreated or sensitised with appropriate peptide, were counted to give 
100x10
3
 cells per well (target to effector ratio of 10:1), washed twice in standard media and 
resuspended in 100ul of standard media per well of a v-bottom 96-well plate. Effector CD8
+
 T 
cells were then counted and washed in standard media to give 10x10
3
 cells per 100ul which 
was added to target cells. All target:effector combinations were carried out in triplicate. As 
controls, IFN-g release by T cells in the absence of target cells was measured (T cell alone), 
and as a positive control target LCLs were sensitised with peptide by incubating target LCLs 
with 5ug/ml of peptide for 2 hours and then washing three times in standard media, before 
adding to 96-well plate. Cells were then incubated overnight at 37ºC, 5% CO2, at the same 
time, MaxiSorp 96-well plates (Nunc) were coated with 50ul per well of anti-human IFN- 
antibody (0.75ng/ml) (Thermo Scientific) in coating buffer (0.1M Na2HPO4, pH 9) and 
incubated overnight at 4ºC.  
Following this, MaxiSorp plates were washed with wash buffer (PBS-0.05% tween-20) and 
then blocked with 200ul of blocking buffer (PBS-0.05% tween-20 + 10% BSA) for two hours 
at room temperature. Following this, plates were washed four times with wash buffer and then 
100ul of cell supernatant from the overnight assay was harvested and added to the MaxiSorp 
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plates. 100ul of an IFN-g standard was also added, in triplicate, this was done using doubling 
dilutions (2000pg/ml – 31.25pg/ml) of recombinant IFN (peprotech). Plates were then 
incubated at room temperature for 3-4 hours after which, plates were washed four times with 
wash buffer. 50ul of biotinylated anti-human IFN-ng/mlThermo Scientific), diluted 
in blocking buffer, was added to each well and plates were incubated for 1 hour at room 
temperature. Following this, plates were washed 4 times in wash buffer and then 50ul of 
streptavidin-peroxidase (ExtraAvidin-Peroxidase, Sigma), diluted 1/1000 in blocking buffer, 
was added to each well and plates were incubated at room temperature for 30 mins. Plates 
were then washed 8-times in wash buffer and 100ul of peroxidase substrate (3, 3’, 5, 5’-
tetramethylbenzidine (TMB) solution, Tebu-bio Laboratories) was added and the plates 
incubated for 30 minutes to allow for colour development. To stop the reaction, 100ul of 1M 
hydrochloric acid was added, resulting in a soluble yellow product. Plates were then read 
using dual wavelengths of 450nm and 695nm. Using the results from the IFN-g standard 
curve, the level of IFN-g release could be calculated as IFN-g release in pg/ml. 
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2.5. Detection of protein expression 
 
2.5.1. Intracellular flow cytometry 
In order to detect the presence of EBV lytic proteins, including, BZLF1, BRLF1, BHRF1 and 
BALF4 in transformed LCLs, we used intracellular flow cytometry. A 1ml aliquot of cells 
was taken and washed twice with PBS-5%HINGS and then fixed using 100ul of Intracellular 
Fixation Buffer (ebiosciences) for one hour, on ice. Cells were then permeablised by adding 
100ul of 0.02% Triton-X-100 (final concentration of 0.1%), on ice for 30 minutes. Cells were 
washed twice with PBS-5%HINGS. Following this, 100ul of appropriate primary antibody 
(see Table 2.1) diluted in PBS-5%HINGS+2% HuS, was added and incubated for one hour at 
37ºC. Cells were then washed twice with PBS-5%HINGS. After this, 50ul of secondary either 
FITC or R-phycoerythrin (RPE) conjugated goat anti-mouse IgG1-specific secondary antibody 
(Table 2.1) was added (diluted in PBS-5%HINGS), and incubated for one hour at 37ºC. Cells 
were then washed three times in PBS-5%HINGS and resuspended in 100ul of IC fixative 
before being analysed on a flow cytometer.  
 
2.5.2. Flow cytometry 
To detect the expression of GFP, CFP, YFP and FP635, transduced cells (100x10
3
) were 
washed three times in PBS-FCS and then ran on an using LSR-II or accuri (BD biosciences) 
and then analysed using Flow Jo (Tree Star).  
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2.5.3. Western blotting 
 
Cell lysate  
For each sample, 10
6
 cells were washed and pelleted in PBS by centrifugation and then 
resuspended in 100ul lysis buffer solution. Lysates were then sonicated for 30s at 30-40%. 
Samples were either used immediately or stored at -80ºC. 
 
SDS-PAGE 
Proteins were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE) using a 
mini gel tank. Pre-made resolving gels at 9-12% acrylamide were used. This was done by 
placing precast gels into a running-tank and submerging them in running buffer (0.192M 
glycine, 0.025M Tris, 0.1% SDS as pH 8.3). Following this, cell lysates were boiled at 90°C 
for 5 minutes And then 25ul (25x10
3
 cells) was loaded into each lane, alongside this, 6ul of 
SeeBlue Plus2 pre-stained marker (Invitrogen) was added to one well. The gels were then 
electrophoresed at 60v. 
Blotting of SDS-PAGE gels       
Resolved proteins were then transferred onto nitrocellulose membranes using transfer 
chambers as per manufacturer’s protocol. This was done by submerging the chamber in 
blotting buffer, inserting this into a gel tank and surrounding this with water, under a voltage 
of 95 for 3 hours.  
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Staining of nitrocellulose membranes 
Membranes were blocked for one hour at room temperature using 5% skimmed milk powder 
dissolved in PBS-Tween 20 (0.05% vol/vol). Specific proteins were then detected by 
incubation with primary antibodies for BZLF1 (murine monoclonal antibody (MAb) BZ.1, 
final concentration of 0.5ug/ml), BRLF1 (murine Mab clone 8C12, final concentration 
2.5ug/ml), BMLF1 (rabbit serum to EBV BSLF2/BMLF1-encoded SM, clone EB2, used 
1/6000), BMRF1 (murine MAb clone OT14-E, used at 1/2000), BALF2 (murine MAb clone 
OT13B, used at 1/5000), BNLF2a (rat hybridoma supernatant directed to the N-terminus of 
BNLF2a, clone 5B9, used at 1/1000), diluted in 5% skimmed milk powder dissolved in PBS-
Tween 20 (0.05% vol/vol), for two hours at room temperature. Following this, membranes 
were washed every 15 minutes for one hour, with PBS-Tween. 
Bound antibodies were detected by incubating membranes with appropriate secondary 
horseradish peroxidase (HRP)-conjugated antibodies for one hour at room temperature. 
Bound secondary antibodies were then detected using enhanced chemiluminescence.  
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2.6. Molecular techniques 
 
2.6.1. Media and buffers    
 
LB media  
LB (Luria Broth) was prepared by dissolving 20g/L of LB powder (Invitrogen) in sterile 
distilled water (SDW). This was then sterilised by autoclaving at 121ºC for 20 minutes at 
15psi. 
 
LB agar 
LB agar was prepared by dissolving 20g/L of LB agar powder (Invitrogen) in SDW and 
sterilising by autoclaving at 121ºC for 20 minutes at 15psi. 
 
Antibiotics 
Ampicillin was made up as a 1000x stock at 100mg/ml in distilled water and stored at -20ºC. 
 
Bacterial strains 
For the generation of the plasmids used for lentivirus production, stable 2 competent bacteria 
were used. For all other plasmids used in this work, DH5α competent bacteria were used. 
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2.6.2. Generation of plasmid DNA by bacterial transformation 
For generation of plasmids, competent bacteria (either stable-3, or DH5) were transformed 
using purified plasmid DNA (50-100ng). This was added to 200ul of competent bacteria in a 
1.5ml eppendorf and incubated on ice for 30 minutes. Following this, bacteria was heat 
shocked for 90 seconds at 42ºC and then placed briefly on ice. 800ul of LB broth was then 
added and samples were incubated in a shaker at 37ºC for one hour. For each transformation 
the bacteria were plated by spreading 200ul and 20ul onto two different agar plates 
(containing the appropriate antibiotic), and a final plate of concentrated bacteria. Plates were 
then incubated overnight at 37ºC.  
 
Purification of plasmid DNA 
Following plating of transformed bacteria, individual colonies were picked and inoculated 
into a 15ml falcon tube containing 3ml of LB broth, containing appropriate antibiotic. These 
were incubated in a 37ºC shaker overnight. The next day 1/1000 of this was inoculated into 
200ml of LB agar, containing antibiotic, in a 1L conical flask and this was incubated 
overnight in a 37ºC shaker. The following day 200ml of the bacterial culture was transferred 
into large containers and pelleted by centrifugation. Following this, plasmid DNA was 
extracted using a QIAgen Maxi Prep kit, as per manufacturers protocol (QIAgen). DNA was 
eluted in 200ul of nuclease free water. DNA concentration was quantified using a Nanodrop 
machine (Thermo Scientific). All DNA was diluted, in nuclease free water, to a concentration 
of 100ug/ul and stored at -20ºC. 
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2.6.3. Quantification of EBV transcripts 
 
RNA isolation 
Up to 5x10
6 
cells were washed in PBS by centrifuging at 1600rpm for 5 minutes, cells were 
then resuspended in 1ml PBS, transferred into a 1.5ml eppendorf and pelleted. Cellular RNA 
was then extracted and purified using RNAeasy Nugen kit, as per manufacturer’s protocol. 
RNA was quantified using a Nanodrop machine (Thermo Scientific), and stored at -80ºC until 
needed.   
 
DNase treatment of isolated RNA 
Since the majority of EBV lytic transcripts are unspliced, an extra step of DNase treatment 
was carried out, in order to remove any contaminating DNA. This was done using a Turbo 
DNA-free kit (Ambion), as per manufacture’s protocol. 1ug of isolated RNA was used, per 
reaction. RNA was then stored at -80ºC until needed. 
 
cDNA synthesis 
cDNA synthesis was carried out using on 10ul of RNA (0.05ug/ul) in a 0.5ml PCR tube. RNA 
was denatured at 90ºC for 3 minutes and then plunged into ice. Following this, 4ul of qScript 
mastermix was added with 6ul of water and incubated as per manufacturer’s protocol.    
qScript master mix, as per manufacturer’s protocol. cDNA was then diluted to 5ng/ul and 
stored at -20ºC until required.  
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qRT-PCR was performed using an Applied Biosystem 7500 machine. Reactions were carried 
out in 96-well plates and aliquoted in a sterile PCR room.  Each reaction was carried out in 
duplicate, alongside a non-template control and no reverse transcriptase reaction. Each well 
consisted of: 
5ul cDNA (5ng/ul) 
2.5ul forward primer 
2.5ul reverse primer  
1ul FAM labelled probe 
0.5ul VIC labelled GADPDH assay 
1ul water 
A standard control was included to allow relative levels of transcript to be calculate, this was 
either induced AKBM or lytic LCLs. cDNA from these cells was generated as above and then 
diluted to achieve 5000pg/ul, 1000pg/ul, 200pg/ul, 40pg/ml and 8pg/ul. 
Samples were run as follows: 
50ºC for 2 minutes 
95ºC for 10 minutes 
40 cycles of: 95 ºC for 15 seconds (denature) then 1minute at 60 ºC (primer anneal and 
extend). Data was then analysed using Applied Biosystems 7500 software. Transcript 
numbers were normalised using GAPDH and expressed as transcript level relative to control 
(or percentage of maximal expression), for each gene.      
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Table 2.1 siRNA sequences generated by Sigma Aldrich 
 
Gene Target siRNA name Sequence 5’-3’ 
BNLF2a -036 CACAGAGUACCACCAGGAG 
-123 CGGGCAGGCCGCAGGCAGA 
-140 GAGGACUGCUGCUCUAGCA 
BILF1 -251 GUGAAGGUGACGUUGCAUA 
-456 CCAUGGUAAUGAGGAGGAU 
-664 CGAGAACUCCUGAAUCAUU 
BGLF5 -363 GUGGAUUGAUGAAGAUGUU 
-541 GCGCUUACGGACAUCUUUA 
-881 CAGAUGAGCUUACAGACAA 
-096 CACGUACGAGCAGAGAACA 
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CHAPTER 3 
 
GENERATION AND CHARACTERISATION OF NOVEL CYTOTOXIC 
CD8
+
 T CELLS SPECIFIC FOR EBV LYTIC PROTEINS 
 
As reviewed in chapter 1, CD8
+
 T cells play a key role in controlling EBV infection. The 
ability of EBV to survive in the face of this CD8
+
 T cell response is thought to be due, in part, 
to the action of EBV’s immune evasion proteins BNLF2a, BILF1 and BGLF5, which interfere 
with the processing and presentation of viral epitopes during lytic cycle. The overall aim of 
this Research project was to determine the relative contribution that BNLF2a, BILF1 and 
BGLF5 make towards interfering with antigen presentation during immediate early (IE), early 
(E) and late (L) phases of lytic cycle.  
Briefly, this was done by assessing the ability of IE, E and L lytic epitope specific CD8
+
 T 
cells to recognise EBV infected cells which lacked the expression of BNLF2a, BILF1 or 
BGLF5. In order to carry out this work, it was important that the CD8
+
 T cell effectors used 
encompassed a wide range of specificities to epitopes originating from antigens expressed at 
all stages of lytic cycle (IE, E and L). For this reason, a selection of CD8
+
 T cell clones 
needed to be generated. Ideally these would include known and new specificities but, more 
importantly for the chosen experimental strategy, was a need to generate a set of CD8
+
 T cells 
restricted through the same HLA allele, with specificities directed towards lytic epitopes from 
all stages of lytic cycle (IE, E, and L).  
To date there have been a number of EBV lytic antigens to which CD8
+
 T cell responses have 
been identified  These span an extensive repertoire of specificities and are restricted through 
different HLA alleles. This results chapter documents the experiments which led to the 
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generation of CD8
+ 
T cell clones directed towards EBV lytic antigens. These clones included 
both known and novel specificities. Three different strategies were employed: i) IFN- 
capture, ii) Identification of novel peptides using mass spectrometry analysis of MHC class I 
complexes expressed by EBV infected B cells and, iii) limiting dilution using IM donor 
PBMCs. 
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3.1. Generation of known CD8+ T cell clones using IFN- capture  
 
The first experimental strategy used for generating EBV lytic epitope specific CD8
+
 T cell 
clones was IFN- capture, as described in chapter 2.1.7. A schematic description of this 
method is shown in Figure 3.1. Briefly, PBMCs from donors positive for common HLA-
alleles (Table 3.1) were stimulated with peptides of previously identified CD8
+
 T cell 
specificities, which would be presented by particular HLA alleles of each donor. Any T cells 
specific to the peptides used were stimulated and thus released IFN-. These reactive T cells 
were then selected on their IFN-production, and plated out to achieve one T cell clone per 
well of a 96 well plate. These were expanded and then tested for their specificity using 
autologous LCLs sensitised with the appropriate peptide. Any T cells which displayed 
specificity to only one peptide were further expanded and used as effectors in subsequent T 
cell recognition assays.  
This approach allowed us to generate CD8
+
 T cell clones of known specificity. Both lab and 
IM donor PBMCs were used as a source of CD8
+
 T cells (Table 3.1). IM donor PBMCs were 
preferentially used to generate CD8
+
 T cells specific to L lytic antigens, as these donors 
undergo an expansion of CD8
+
 T cell responses to EBV lytic antigens, thus are more likely to 
show L lytic antigen specific CD8
+
 T cell responses. This method of T cell cloning generated 
numerous clones, as shown in Table 3.2. For practical reasons a maximum of 100 clones were 
screened from each peptide stimulation.  
Those clones generated showed specificities representing each of the three stages of lytic 
cycle. These included more than 100 clones which recognise the IE antigens BRLF1 and 
BZLF1, restricted through HLA-A2 and B8 respectively. Numerous HLA-A2 restricted T 
cells specific to peptides from the E antigens BMRF1 and BMLF1, and a selection of CD8
+
 T 
Chapter 3  Results
   
 
 75  
 
cells which recognise L late antigens; BALF4 and BNRF1, restricted through HLA-A2. The 
generation of a complete panel of HLA-A2 restricted T cells is particularly important since 
this allows us to exclude the influence of HLA type when investigating the effects BNLF2a, 
BILF1 and BGLF5 have on antigen presentation at IE, E and L stages of lytic cycle.  
 
 
  
Chapter 3  Results
   
 
 76  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic demonstrating the method if IFN- capture.  
Donor PBMCs are simulated with a selection of known peptides for 4 hours. Cells which recognise 
peptide and release IFN-are selected using beads. These are then plated out and cultured with feeder 
cells for two weeks. Any T cells which expand are screened against peptides used in the first instance. 
Any reactive clones are further expanded and used in subsequent assays. 
 
 
  
Donor PBMCs 
Stimulate with selection 
of lytic antigen peptides 
(i.e. GLC, YVL, TLD, 
and FLD)  
Select T cells 
secreting IFN- 
Plate as single cell 
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for use in recognition 
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EBV specific T cells 
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Table 3.1. HLA types of donors used for cloning. 
Donor HLA A HLA B HLA C 
IM226 2 - 50 40 3 6 
IM225 2 3 7 27 2 7 
IM235 2 3 7 40 3 7 
LD13/18* 2 29 8 40 3 - 
* Donors used in IFN- capture T cell cloning only. All other donors were used in both IFN-capture 
and limiting dilution methods of T cell cloning. 
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Table 3.2. Restrictions and peptide specificities of T cell clones generated using IFN- capture 
 
Phase Protein Epitope 
sequence 
HLA 
restriction 
Number of clones 
generated 
IE BZLF1 RAKFKQLL 
 
B8 
 
>50 
 BRLF1 YVLDHLIVV A2 >50 
E BMRF1 TLDYKPLSV A2 
 
20 
 
 BMLF1 GLCTLVAML A2 >50 
L BALF4 FLDKGTYTL A2 
 
25 
 BNRF1 WQWEHIPPA A2 >50 
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3.2. Identification of novel epitopes using mass spectrometry 
 
Despite successfully generating more than 250 characterised clones with useful specificities 
and HLA restrictions, as shown in Table 3.2, isolation of T cell clones with some other 
expected specificity was unsuccessful. Notably, no HLA-B7 restricted T cells recognising the 
late BILF2 antigen were isolated; likewise no T cell clones of the same restriction which 
recognise the early antigen, BALF2, were obtained. In order to generate more CD8
+
 T cells 
with novel specificities, which would allow for a more extensive examination of the effects of 
BNLF2a, BILF1 and BGLF5 on antigen presentation during lytic cycle, a different approach 
was adopted. This involved using mass spectrometry to identify MHC class I presented 
peptides in EBV-infected cells. This element of work was done in a close collaboration with 
Dr Nathan Croft during a study visit that I made to the Bio21 institute in Melbourne, 
Australia. A schematic illustrating the experimental approach used is shown in Figure 3.2. 
Briefly, lytic EBV infected B-cells were lysed and incubated with an anti-MHC class I 
antibody (W6/32), in order to bind and isolate MHC class I:peptide complexes. The peptides 
in this complex were then eluted and purified using high performance liquid chromatography 
(HPLC). These peptides then analysed using mass spectrometry to identify the peptide 
sequences.  
The cells used for these experiments were from an LCL in which around 5% of the cells were 
spontaneously undergoing lytic cycle replication. The LCL used was established from a HLA-
A2 and HLA-B27 positive healthy donor by transformation of isolated B cells with EBV 
derived from the B95.8 producer line. Following elution and analysis of peptides using in-
house analysis software it was possible to identify potential EBV epitopes and their protein of 
origin (Table 3.3), as well as identifying modifications to these peptides. This software also 
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generates a confidence score, which reflects the how often the individual peptides were 
detected.  
Of the results generated, only those with a confidence score of more than 95% are normally 
used. These originated from proteins in the IE and E stages of lytic cycle. An example of 
novel peptides identified is shown in Table 3.3. It should be noted that some known HLA-A2 
restricted peptides were also identified; however these occurred with a lower frequency score 
than those peptides shown in Table 3.3. The majority of peptides identified originated from 
latent proteins and since for this work it is of particular importance to generate CD8
+
 T cells 
specific to late lytic proteins, this method was not ideal. In addition, the HLA restriction of 
these peptides would need to be predicted, in order to clone the T cells. Moreover, the 
presence of a peptide at the cell surface of infected cells does not guarantee the presence of 
reactive T cells. Therefore, this approach was deemed too time-consuming for this particular 
work and thus was not followed up. However, this method of identifying potential T cell 
targets could be used elsewhere, particularly as potential modifications are also identified. 
These peptides may be overlooked when using overlapping peptides, based on the B95.8 EBV 
sequence, to identify T cell specificities.  
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Figure 3.2 Schematic of peptide elution and mass spectrometry analysis of EBV infected 
cells. 
Adapted from Dr Nathan Croft. EBV infected cells were lysed and the MHC:peptide complexes 
purified using anti MHC class I antibody. Peptides were then eluted using HPLC and their sequence 
analysed using mass spectrometry. 
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Table 3.3 Peptides identified using mass spectrometry analysis of EBV infected LCLs. 
 
Peptide 
sequence 
EBV protein 
of origin 
Modifications Confidence score 
GQQLADIGVPQ BZLF1 (IE) Oxidation(P)@10 98 
APVSTIAPSV BPLF1 (L) Oxidation(P)@2; 
Thr->Ala@5 
97 
YLRQVATEGL BALF3 (E) - 97 
RLATVLPGLEV BALF2 (E) - 96 
Thr-Threonine 
Al- Alanine 
P- Proline 
@- amino acid position of modification  
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3.3. Generation of CD8+ T cells specific to EBV lytic antigens  
 
Although IFN- cloning was a successful method for generating CD8+ T cells of known 
specificities, the panel obtained (Table 3.2) lacked any HLA restrictions beyond HLA-A2. For 
this reason the method of limiting dilution was used, in the hope that it would allow for the 
generation of a more extensive panel of CD8
+
 T cell clones with different restrictions and 
ideally, a panel of T cells restricted through the same HLA allele, with relativities to IE, E and 
L lytic antigens.  
Three sets of IM donor PBMCs were used as a source of T cells. To set up a limiting dilution 
cloning, blood specimens were collected from each donor, from which PBMCs were isolated 
(as described in chapter 2). These were then used in limiting dilution assays as described in 
chapter 2.1.6. Briefly, PBMCs were plated out in 96 well plates in such a way to statistically 
allow for 0.3, 3 or 30 PBMCs per well. With the hypothesis that 0.3 cells per well will result 
in monoclonal T cell populations. These were incubated with feeder cells, autologous LCLs 
and cytokines required for CD8
+
 T cell growth. After two weeks, any wells in which there 
appeared to be T cell growth were selected and expanded from 96 to 24 well plates. Selected 
T cells were then screened against a panel of EBV lytic antigens. A schematic of this 
screening technique is shown in Figure 3.3. Briefly, recombinant vaccinia viruses expressing 
individual EBV lytic antigens were used to infect autologous donor LCLs. These were then 
loaded with Cr
51 
and used in a cytotoxicity assay, whereby they were incubated with the T 
cells to be screened. T cells which recognise the antigens being presented by LCLs lyse these 
Cr loaded LCLs, releasing the Cr
51 
into the supernatant. By measuring the levels of Cr
51
 
release, it is possible to identify the antigens which the T cells recognise.  
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In the first instance, T cells were screened in a cytotoxicity assay against autologous LCLs 
infected with pairs of vaccinia expressing EBV lytic antigens i.e. BRLF1 and BMLF1 (Fig 
3.4). This was done to minimise the number of targets and therefore, the number of T cells 
required. It should be noted that all antigens used in this assay were expressed from a 
recombinant vaccinia, with the exception of BZLF1. It was not possible to generate a vaccinia 
expressing BZLF1 due the toxicity associated with BZLF1 over-expression. Instead, synthetic 
overlapping peptides covering the amino acid sequence of BZLF1 were used. These were 15 
residues in length, overlapping each other by 10 residues. These were used to sensitise 
autologous LCLs, which were subsequently used as targets in a cytotoxicity assay. 
In total, more than 750 clones, form three different limiting dilution cloning experiments were 
screened using cytotoxicity assays, against 10 autologous targets which were infected with 
different pairs of vaccinia virus expressing lytic antigens. This allowed for the testing of T 
cell reactivity against a total of 21 EBV lytic antigens. An illustrative result for this screening 
strategy for three T cell clones from donor IM225 (c51, c97 and c155) are described below. 
Each of these clones recognised one target expressing a pair of lytic antigens or the pool of 
BZLF1 peptides (Fig 3.4). In all three cases there were low levels of background lysis of other 
autologous LCL targets. Thus, each CD8
+
 T cell clone recognised a peptide which originated 
from one of the antigen pairs, or in the case of c97 to a peptide from the BZLF1 antigen. 
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Figure 3.3 Schematic illustrating the cytotoxicity assays used for screening potential T 
cells clones.  
Following the plating of IM donor PBMCs into 1 cell per well, in a 96 well plate, and incubation of 
cells with feeder cells. Any T cells that grow are screened using a cytotoxicity assay. Autologous 
LCLs are infected with recombinant vaccinia expressing different EBV lytic antigens. These LCLs are 
then loaded with Cr
51
 and incubated with the selected T cell clones. T cells which recognise the 
antigen expressed by the LCLs lyse these cells, which releases the Cr
51
 into the supernatant. The level 
of Cr
51
 release is then measured, thus indicating the antigen which T cells recognise.  
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Figure 3.4 Specificity of EBV lytic antigen-specific clones derived from donor IM225. 
Three representative clones, c51 (A), c155 (B) and c97 (C) were used in cytotoxicity assays against 
autologous LCLs infected with pairs of recombinant vaccinia viruses expressing EBV lytic antigens. 
For BZLF1; overlapping 15-mer peptides for the protein were used. Results are shown as average % 
lysis. 
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Having identified T cell clones with significant reactivities, the next steps were to narrow 
down the lytic antigen specificity, determine the HLA restriction and identify the specific 
epitope. Where a T cell clone recognised targets infected with a pair of vaccinia viruses (c51 
and c 155) the next experiment involved screening these T cells against autologous LCLs 
infected with the component individual recombinant vaccinia viruses. As shown in Figure 
3.5a, c155 was shown to recognise only BNLF2b and c155 recognised only BNRF1 (Fig 
3.5b). Where a T cell clone recognised the pool of BZLF1 peptides, the specificity was 
narrowed down by screening against target LCLs stimulated with separate pools of peptides 
from the N-terminus or C-terminus of BZLF1; screening c97 in this way showed reactivity to 
the N-terminus peptide pool only (Fig 3.5c).  
Before proceeding to find the peptides to which these T cells were specific, experiments were 
carried out to determine the HLA restrictions of these clones. This allows for the prediction of 
possible peptides, since different HLA alleles have different anchor residue requirements. To 
identify the HLA molecules responsible for presenting peptide to these clones, a panel of 
partially HLA matched LCLs which express different combinations of HLA molecules were 
infected with vaccinia expressing antigen or sensitised with BZLF1 N-terminus peptide, and 
tested for their ability to stimulate responses from clones c51, c155 or c97, in cytotoxicity 
assays. Donor LCLs used to reveal the HLA-restriction element for each of the T cell clone 
are shown in Table 3.4, where the boxed alleles are those shared with donor IM225. 
Expression of the relevant target antigen for each T cell clone in this panel of partially 
matched allogeneic LCLs enables the use of this panel of LCLs as targets in cytotoxicity 
assays to reveal the HLA restriction.  
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Figure 3.5 Individual antigens recognised by c51, 97 and 155. 
Clones c51 (A), c155 (B) and c97 (C) were screened in a cytotoxicity assay against autologous LCLs 
infected with single recombinant vaccinia viruses expressing proteins BARF1, BNLF2b for c51, 
BNRF1 and BVRF2 for c155 and the N- or C- terminus of BZLF1 protein in the case of c97. Results 
are shown as average % lysis.  
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Table 3.4 Class I HLA types of LCLs used to determine the HLA restriction of CD8+ T cell 
clones c51, c155 and c97.  
 *Black squares represent HLA alleles expressed by both IM225 and those LCLs used in the panel. 
Not determines (ND) 
 
 
 
  
Donor           HLA A           HLA B          HLA C 
IM225 
(14,7) 
(22, 23) 
(19, 18) 
(18, 20) 
IM83 
(8, 12) 
2 
2 
1 
3 
2 
2 
1.01 
3 
32.01 
3 
31 
24.02 
ND 
2 
7 
44 
8 
 7 
27 
45.01 
44.02 
27 
ND 
35 
16 
35.01 
51 
57 
2 
5.01 
4 
W3 
2 
2 
5.01 
7 
ND 
7 
7 
4 
ND 
7 
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As shown in Figure 3.6a, after LCLs were infected with BNLF2b expressing vaccinia, c51 
lysed LCL LD19,18 and the autologous IM225 LCL. These LCLs both possess HLA-A3, -B7 
and -C7 alleles. The lack of lysis of LCLs from donor LD22,23 ruled out the possibility of 
these clones being restricted through HLA-A3 and no lysis of LD22,23 or LD8,12 LCLs ruled 
out the restriction being through HLA-C7. Thus c51 recognises an epitope presented by HLA-
B7. When the BNRF1-c155 effectors were similarly assayed on the same panel of LCLs but 
expressing BNRF1, the result was the identical; revealing that this clone was also restricted 
through HLA-B7. Likewise, when the same panel of LCLs were sensitised with the N-
terminus of BZLF1, and used in a cytotoxicity assay with c97, a similar result was seen. Thus 
c51, c155 and c97 are all restricted through HLA-B7. This is of importance for this work, 
since it represents a set of CD8
+
 T cells recognising antigens form each of the three phases of 
lytic cycle (IE, E and L) and restricted through the same common HLA allele. 
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Figure 3.6 HLA restriction of BNLF2b spcific c51, BNRF1 specific c155 and BZLF1 
specific c97 T cells. 
(A, B) c51 and c155 T cells were used in cytotoxicity assays against autologous LCLs and LCLs from 
donors LD14,7, LD22,23, LD19,18, LD18,20, IM83 and LD8,12  which were infected with vaccinia 
expressing BNLF2b or BNRF1 respectively. As a negative control an empty vaccinia (TK-) was used 
to infect the same panel of LCLs (C) The same panel of LCLs were loaded with synthetic peptides 
spanning the N-terminus of BZLF1. These were used to probe recognition by c97. Results are shown 
as average % lysis.  
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Following identification of the HLA restriction element and EBV-antigen specificity of these 
clones, their epitope specificity was then investigated. To determine the specificity of c97, 
BZLF1 N-terminus peptides were divided into five pools of peptides, and these were used to 
sensitise autologous LCLs. Using peptides as opposed to vaccinia viruses allowed for the use 
of IFN- ELISA as a read out of T cell recognition, which is considered more sensitive than 
cytotoxicity assays. As controls, IFN- release was measured from c97 alone and from c97 
co-cultured with LCLs sensitised with an equivalent dilution of DMSO, in which peptides are 
dissolved. As Figure 3.7a shows, IFN-release was highest when LCLs were sensitised with 
pool 1 peptides, a level comparable to that seen when LCLs were sensitised with the N-
terminus peptides of BZLF1. This demonstrates the specificity of c97 is for a peptide located 
in pool 1 of BZLF1 N-terminus. Target LCLs were then similarly sensitised with individual 
synthetic peptides from pool 1 and used as targets in an IFN- ELISA. As Figure 3.7b shows, 
c97 is specific for a 15-mer peptide DPYQVPFVQAFDQAT. HLA-B7 restricted peptides 
characteristically contain a proline at position two and are typically 9-11 residues in length. A 
series of peptides of 9-12 residues long, containing one of the two prolines at position 2, were 
therefore synthesised to more finely map the specific epitope within the 15-mer 
DPYQVPFVQAFDQAT. Autologous LCLs were sensitised with these peptides and used to 
probe the recognition by c97 in an IFNELISA (Fig 3.7c). The 11-mer peptide 
DPYQVPFVQAF showed the most effective sensitisation c97 T cells, with significant, but 
less efficient sensitisation achieved with longer and shorter peptides containing the DPY 
proline anchor sequence.  
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Figure 3.7 Peptide specificity of c97.  
(A) Peptides spanning the N-terminus of BZLF1 protein were divided into five peptide pools. These 
were used to sensitise autologous LCLs which were used to probe the recognition of c97. (B) Pool 1 of 
N-terminus BZLF1 was further divided into single 15-mer peptides. Which were used to sensitise 
autologous LCLs. These were then used to probe the recognition of c97. C) The 15-mer peptide was 
further minimised and used to sensitise autologous LCLs. All results are shown as pg/ml of IFN- 
release.  
A) 
B) 
C) 
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To determine the peptide specificity of clone c51, a similar approach was taken. Since 
BNLF2b is a relatively small protein of only 98 amino acids in length, synthetic peptides were 
generated (synthesised by peptide .0), which spanned the entire BNLF2b protein sequence. 
These peptides were 15-amino acids in length and overlapped by 10 amino acids. These were 
first divided into four pools and used to sensitise autologous LCLs for use as targets in a 
cytotoxicity assay. Clone c51 showed 50% specific lysis against LCLs sensitised with pool 1, 
which was comparable to the lysis of target LCLs infected with BNLF2b recombinant 
vaccinia virus, while targets incubated with peptide pools 2, 3, 4, or with DMSO solvent alone 
all showed less than 5% specific lysis (Fig3.8a). Autologous LCLs were then sensitised with 
the individual component peptides of pool 1. As Figure 3.8b shows, c51 specifically lysed 
only those LCLs sensitised with the MRPGRPLAGYATLR peptide. To more finely map the 
target epitope of c51, shorter synthetic peptides of MRPGRPLAGYATLR were synthesised 
based around a proline residue located at amino acid position two (Fig 3.8b). c51 specifically 
lysed LCLs sensitised with peptides RPGRPLAGFYA and RPGRPLAGFYATL to similar 
extents, suggesting that the minimal epitope for c51 is RPGRPLAGFYA (Fig 3.8c). To 
determine which of these two peptides c51 was specific for, peptides RPGRPLAGFYA and 
RPGRPLAGFYATL were diluted from 10
-6
M to 10
-10
M. These diluted peptides were then 
used to sensitise target LCLs in an IFN-ELISA. Clone 51 showed more specific recognition 
of RPGRPLAGFYA at the lower concentrations (Fig3.8d), suggesting RPGRPLAGFYA is 
the HLA-B7 restricted minimal epitope of c51. 
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Figure 3.8. Minimal epitope mapping of HLA B7 restricted BNLF2b-c51.  
(A) 15-mer BNLF2b peptides spanning the whole protein were divided into four pools. These were 
used to sensitise autologous LCLs, which were used to probe recognition by c51 in a cytotoxicity 
assay. Autologous LCLs were also infected with vaccinia expressing BNLF2b, as a positive control 
and an equivalent concentration of DMSO was used as a negative control. Results are shown as 
average % lysis. (B) Peptide pool 1 was further divided into individual peptides. These were used in a 
cytotoxicity assay to sensitise autologous LCLs, an equivalent concentration of DMSO was used as a 
negative control. Autologous LCLs were infected with vaccinia expressing BNLF2b, and original 
peptide pool 1 was included as positive controls. Results are shown as average % lysis. (C) Peptide 1 
was minimised from its original 15mer length. These shorter peptides were used to sensitise 
autologous LCLs. The full length 15-mer peptide 1 and LCL infected with vaccinia expressing 
BNLF2b were also used as positive controls. An equivalent concentration of DMSO was used as a 
negative control. (D) Lytic cycle defective HLA-B7 positive LCLs were sensitised with peptides 
RPGRPLAGFYATL and RPGRPLAGFYA in decreasing concentrations. These were used in an 
ELISA. Results are shown as IFN-γ release (pg/ml).   
  
B) A) 
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To determine the minimal epitope of BNRF1- c155, a different technique was used. Since the 
BNRF1 protein is a large protein of 1318 amino acids in length, it would have required the 
synthesis and screening of more than 200 15-mer peptides. Therefore, a more cost-effective 
screening strategy was devised. Four overlapping fragments of BNRF1 were amplified from 
the BNRF1 DNA sequence (Fig.3.9a) and inserted into a pCDNA3.1-TOPO vector. These 
were used to transfect HLA-B7 positive 293-cells, for use as targets for c155 in an IFN-
ELISA. As shown in Figure 3.9b, c155 recognised cells expressing fragment 4 of BNRF1, 
to a level comparable to that of BNRF1-vaccinia infected 293 cells. 20-mer overlapping 
peptides were then synthesised to span the length of fragment 4. These were divided in to six 
pools and used to sensitise 293 cells. C155 recognised a peptide contained in pool 4 of 
fragment 4 (Fig.3.9c). Pool 4 was then further divided into individual peptides and these were 
used to sensitise 293 cells, whereupon c155 was found to recognise 
AMNYPRNPTEQGNIAGLCSR to a similarly high level as pool 4 peptides, while other 
individual peptides were not recognised above background levels (Fig 3.9d). Smaller 
synthetic peptides were then generated by deleting one amino acid in the sequence, based 
around a proline residue at position 2. Titration of the 6 individual peptides and assaying IFN-
 release from co-incubated c155 T cells, revealed the 11-mer peptide YPRNPTEQGNI to be 
the most potent, with LCLs sensitised with as little as 10
-9
 M of peptide inducing IFN- 
release (Fig. 3.9e). A summary of the T cells generated using limiting dilution is shown it 
Table 3.4. 
Overall, the above T cell cloning strategies generated two panels of lytic antigen specific 
CD8
+
 T cell clones, one panel restricted through HLA-A2 and the other through HLA-B7.  
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Figure 3.9. Minimal epitope mapping of HLA B7 restricted BNRF1-c155.  
(A) Diagram shows the length (amino acids) and position of each fragment amplified from BNRF1 
DNA. (B) BNRF1 fragments were and transfected into 293 cells, which were subsequently used as 
targets for c155, recognition was measured as IFN-γ release using ELISA. Autologous LCLs infected 
with BNRF1 expressing vaccinia were used as a positive control. T cell alone and T cell with 293 cells 
transfected with empty vector were used as negative controls. Results are shown as IFN-γ release 
pg/ml. (C) 20-mer overlapping peptides designed to cover the region of BNRF1 fragment 4 were split 
into 6 pools. These were used to sensitise autologous LCLs which were used to probe the specificity of 
c155. (D) Peptide pool 4 was divided into single 20-mer peptides. Autologous LCLs were sensitised 
with these, pool 4 was included as a positive control and DMSO and T cell alone as a negative 
controls. Results are shown as IFN- γ release pg/ml. (E) Shorter derivatives of 
AMNYPRNPTEQGNIAGLCSR were designed and used to sensitise lytic negative HLA-B7 LCLs, at 
decreasing concentrations. Results are shown as pg/ml of IFN. 
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Table 3.5 CD8
+
 T cell clones generated using limiting dilution 
Phase Protein Epitope sequence HLA 
restriction 
Cloning technique and 
number of clones generated 
IE BZLF1 DPYQVPFVQAF* B7 1 
 BRLF1 YVLDHLIVV A2 >50 
E BMRF1 TLDYKPLSV 
LAY 
YRS 
A2 
C3 
C6 
>50 
1 
1 
 
 BMLF1 GLCTLVAML A2 >50 
 
 BNLF2b RPGRPLAGFYA* B7 1 
L BNRF1 YPRNPTWQGNI* B7 1 
* Novel CD8+ T cell specificities identified during this work 
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3.4. Identification of BNRF1 as a new latent antigen 
Although the specificity of those T cell clones generated above had been determined, this 
project required T cells that are potent enough to efficiently recognise endogenously 
processed lytic antigens that are presented in a minor subpopulation, often less than 2%, of 
LCLs undergoing lytic cycle replication. To assess their usefulness in this context, all clones 
were validated on wild-type (B95.8-EBV transformed) LCLs in which around 2% were 
undergoing lytic cycle, as determined by BZLF1 expression (Fig 3.10), and on LCLs 
generated with BZLF1 EBV, which are defective for lytic virus replication. As shown in 
Figure 3.11a and Figure 3.11b, BZLF1-c97 and BNLF2b-c51 showed relatively high levels of 
recognition of B95.8 LCLs, compared to peptide sensitised BZLF1-LCLs, thus they were 
deemed potent enough for use in this research project. In the course of these validation 
experiments, an interesting phenomenon was observed, where BNRF1-c155 showed good 
recognition of BZLF1 LCLs, as well as peptide sensitised and B95.8 lytic LCLs (Fig 3.11c). 
This was surprising since BNRF1 is reported as being expressed only in late stages of lytic 
cycle, thus this finding was further investigated.  
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Figure 3.10 BZLF1 expression levels in B95.8 transformed lab donor LCLs. 
Lab donor LCLs were fixed, permeablised and then stained with antibody for either BZLF1 or an 
isotype control (IgG1). Cells were analysed by flow cytometry. Dotplots show forward scatter (FS) 
versus BZLF1 or isotype control staining.    
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Figure 3.11 Recognition of endogenously expressed epitopes.  
C97 (A), c51 (B) and c155 (C) were used as effectors in an IFN- ELISA T cell recognition assay 
against B95.8 and BZLF1 transformed LCL targets. As a positive control BZLF1 LCLs were 
sensitised with peptide. All results are shown as IFN- release (pg/ml). 
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The first stage in proving or disproving this new finding was to determine if the above result 
was consistent using other lab donor LCLs. To do this, two sets of B95.8 and BZLF1 
transformed LCLs were used, from two different lab donors, which expressed both HLA-B7 
and HLA-A2 alleles. These were used as target cells in an IFN- ELISA T cell recognition 
assay against c155. As shown in Fig 3.12a the recognition of BZLF1 LCLs by c155 was 
comparable to the recognition of their B95.8-LCL counterparts. This was the same for both 
donors LD13,1 and LD7,19.  
Next, to confirm that BZLF1 LCLs were in fact devoid of lytic cycle expression, the same 
assay was performed, this time using a CD8
+
 T cell which recognised an epitope (YVL) 
which originates from the IE protein BRLF1. Using this T cell there was no recognition of the 
BZLF1 LCLs but good recognition of the B95.8 LCLs (Fig 3.12b). This confirms that the 
BZLF1 LCLs were not undergoing lytic cycle replication and that BNRF1 does appear to be 
expressed in latent LCLs. To further support these data, the levels of BNRF1 and BRLF1 
mRNA expression was measured using qRT-PCR analysis. (Fig 3.12d). As shown, there was 
no detectable transcript of BRLF1 in either LD13,1 or LD7,19 BZLF1 LCLs, confirming 
that these cells are not entering lytic cycle. The levels of other transcripts were also measured 
to confirm these cells were truly latent (data not shown). However, the level of BNRF1 
transcript in BZLF1 LCLs from both donors was higher than background, and comparable to 
that seen in LD7,19 B95.8 LCLs (Fig 3.12c). Taken together these data confirm the 
expression of BNRF1 in BZLF1 LCLs. These experiments were repeated using different 
donor LCLs and a HLA-A2 restricted, BNRF1 specific clone, which gave the same result 
(data not shown). 
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Figure 3.12 Recognition of BNRF1 in lytic incompetent cells.  
(A) Two pairs of B95.8 and BZLF1 LCLs from HLA-B7 positive donors LD13,1 and LD7,19 were 
used as targets c155 in and IFN-ELISA. Results shown as IFN- pg/ml (B) The level of BNRF1 
mRNA in LD13,1 and LD7,19 was measured using qRT-PCR analysis. Results are shown as mRNA 
relative to LD13,1 BNRF1 mRNA levels. (C) B95.8 and BZLF1 LCLs from donors LD13,1 and 
LD7,19 were used as targets in and IFN- ELISA to probe for recognition by a HLA-A2 restricted 
BRLF1-specific clone (c133). Results are shown as IFN- pg/ml. (D) The level of BRLF1 mRNA 
expression was measured in these cells using qRT-PCR analysis. Results are shown as levels relative 
to levels in LD13/1. 
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3.5. Discussion 
 
Since the overall aim of this research project was to determine the effect of EBVs immune 
evasion proteins BNLF2a, BILF1 and BGLF5 on antigen processing and presentation at the 
IE, E and L stages of EBV lytic cycle, it was important to have a variety of CD8
+
 T cell 
effectors which recognise antigens expressed in all of three phases of lytic cycle. The novel 
HLA-B7 and known HLA-A2 restricted CD8
+
 T cell clones which were generated were of 
particular importance as they represent two panels of T cells with specificities directed 
towards IE, E and L epitopes. This allowed for a more extensive investigation of the HLA 
specificity of the immune evasion proteins could be addressed.  
Although the use of mass spectrometry identification of epitopes presented by EBV infected 
cells was not useful for this Research project, it does raise some interesting points. The fact 
that no late epitopes were detected could indicate that, in support of previous findings, late 
epitopes are less well presented by B95.8-LCLs. It would be interesting to carry this work out 
using LCLs lacking in the expression of BNLF2a, BILF1 and BGLF5 to determine if these 
knockdown LCLs show better presentation of L epitopes. 
The novel finding of BNRF1 expression in lytic incompetent LCLs has important 
implications in the field of EBV biology. It has recently been found that CD8+ T cell 
responses directed towards BNRF1, in healthy individuals and IM patients, accounts for a 
dominant response (Abbott et al in review). To extend this work further, it would be an 
advantage to investigate the expression of this protein in tightly latent EBV infected cells, 
such as in NK/T cell lymphomas. This would confirm whether the expression of BNRF1 
protein in latency is a phenomenon of BZLF1 LCLs only. Since the majority of EBV 
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malignancies are typically latent, this could represent an important target for treatment or 
vaccine design. 
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CHAPTER 4  
 
USING RECOMBINANT EBV TO INVESTIGATE THE FUNCTIONAL 
IMPOTRANCE OF PUTATIVE IMMUNE EVASION GENES 
 
As described in chapter one, the detection and clearance of virally infected cells by the host 
immune system relies upon CD8
+
 T cell recognition of viral peptides presented by MHC class 
I molecules. EBV infected cells undergoing lytic cycle replication are particularly vulnerable 
to recognition by these T cells, since lytic cycle involves the expression of more than 90 viral 
genes, creating an extensive pool of viral antigens for presentation to the immune system. As 
a consequence of this, EBV, like other viruses, has evolved to express multiple immune 
evasion genes during lytic cycle, which are able to interfere with MHC class I processing and 
presentation. The importance of these immune evasion mechanisms during lytic cycle is 
implied by the potency and magnitude of the CD8
+
 T cell responses of healthy infected 
individuals, most of whom demonstrate continuous production of infectious EBV. A number 
of candidate immune evasion genes have been identified using gene-expression model 
systems. Amongst these genes are BNLF2a, BILF1 and BGLF5. It is presumed, but not 
formally shown that they are all operative and cooperate in during lytic cycle. This issue will 
be the main focus of this thesis.  
To demonstrate the functional significance of BNLF2a, BILF1 and BGLF5 in the context of 
EBV lytic cycle, it was decided first to take advantage of the available recombinant EBVs 
deleted for BNLF2a, BILF1 and BGLF5 expression. The panel of CD8
+
 T cell clones 
generated in chapter 3 allowed for the investigation of the sensitivity of recombinant infected 
cells, undergoing lytic cycle reactivation, to recognition by these T cells. To this end, 
∆BNLF2a-, ∆BILF1- and ∆BGLF5-transformed LCLs along with their wt-2089 and 
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∆BZLF1-counterparts were used as targets for CD8+ T cells specific for IE, E and L lytic 
epitopes. This allows for the assessment of the influence of BNLF2a, BILF1 and BGLF5 on 
presentation of lytic epitopes during the IE, E and L phases of lytic cycle. The proposed 
experiments presented technical difficulties that required carefully designed controls and 
optimisations, outlined below.  
4.1. Experimental strategy and methods 
LCLs were generated using wt2089, ∆BNLF2a-, ∆BILF1- ∆BGLF5- and ∆BZLF1-virus to 
transform donor B cells, as described in Chapter 2 1.5. LCLs were generated from numerous 
laboratory donors in order to span a variety of HLA class I alleles, these are summarised in 
Table 4.1. These LCLs were then used as target cells in CD8
+
 T cell recognition assays.  
A selection of CD8
+
 T cell clones generated from the work outlined in chapter 3 were used, 
these are summarised in Table 4.2. This Table shows their antigen and epitope specificity, the 
phase of lytic cycle in which the antigen is expressed and the HLA class I restriction of each 
clone, along with the number of clones used from each specificity.  
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Table 4.1 HLA alleles of donors used to generate wt2089, ∆BNLF2a-, ∆BILF1- ∆BGLF5- and 
∆BZLF1-LCLs. 
 
 
  
Donor number 
 
HLA A HLA B HLA C 
1 
 
2 24 27 35 2 4 
2 2 29 8 40 3 ND 
    
ND-Not 
determined  
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4.2. Quantification of spontaneous lytic antigen expression in knockout LCLs  
 
T cell recognition assays outlined in this chapter relied upon target LCLs (wt2089-, 
∆BNLF2a-, ∆BILF1- ∆BGLF5-virus transformed) spontaneously entering lytic cycle. The 
proportion of an LCL culture which will undergo spontaneous EBV-lytic cycle reactivation 
varies significantly between lines and even within the same line over time. Since this directly 
impacts the level of antigen available for presentation and therefore CD8
+
 T cell recognition, 
it is important to measure the level of lytic cycle in each cell line. Previously this has been 
assessed by measuring the level of BZLF1 protein, as an indicator of levels of lytic cycle 
(Croft et al., 2009). In this study, lines which showed the highest proportion of lytic cycle 
were diluted with a tightly latent ∆BZLF1-LCL from the same donor, until an equal 
proportion of BZLF1 positive cells was reached, this then allowed for direct comparison of T 
cell recognition between these LCL lines. However, this method assumes that the level of 
BZLF1 expression is directly related to the expression of other lytic cycle antigens, which is 
not always the case (discussed later in this chapter). Perhaps more importantly, it has been 
found that only a small proportion of cells expressing BZLF1 will progress the full way 
through lytic cycle, therefore, cells expressing late antigens may well be diluted out. 
Therefore, equalising different LCL lines on the level of BZLF1 expression may be 
misleading and lead to incorrect interpretation of T cell recognition data.  
As newly translated mRNAs supply the majority of peptides for MHC class I molecule 
presentation (DRiPs) (as discussed in chapter 1), it was reasoned that a more accurate measure 
of target antigen expression would be obtained by qRT-PCR analysis of the levels of the 
relevant mRNAs encoding the lytic antigen specifically recognised by each individual T cell 
clone. For example, for a CD8
+
 T cell which recognises the YVL epitope, derived from the 
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lytic antigen BRLF1, the mRNA level of BRLF1 would be measured and subsequently used 
to normalise the level of IFN- release (T cell recognition) by this T cell.  
To confirm that there is a direct correlation between the level of target antigen-mRNA and 
CD8
+
 T cell recognition, an initial experiment was performed. This involved diluting aliquots 
of spontaneously lytic LCL with tightly latent BZLF1-LCLs, to obtain a controlled range of 
decreasing levels of antigen, for a constant number of cells. These cell mixes were used as 
targets for a GLC (BRLF1)-specific CD8
+
 T cell, where the level of recognition was 
measured using IFN- release. Alongside this, the level of BRLF1 mRNA in each diluted mix 
was also measured. As shown in Fig 4.1 there was a direct correlation between the level of 
BRLF1 mRNA expression and recognition of the GLC epitope by CD8
+
 T cells. Thus, by 
measuring the mRNA-expression level of target antigens we can accurately account for 
differences in lytic cycle in LCL target cell lines and use this data to normalise CD8
+
 T cell 
recognition data (IFN- release levels). 
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Table 4.2 CD8
+
 T cell clones used in T cell recognition assays 
Phase of 
expression 
Protein Epitope 
sequence 
HLA 
restriction 
Number of clones used 
IE BRLF1 YVLDHLIVV A2 2 
E BMRF1 TLDYKPLSV A2 2 
 BMLF1 GLCTLVAML 
 
A2 2 
L BALF4 FLDKGTYTL 
 
A2 2 
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Figure 4.1 Correlation between mRNA antigen expression and CD8
+
 T cell recognition.  
A B95.8-LCL line in which 5% of the line was expressing BZLF1 protein (detected via intracellular 
staining) was selected. These lytic cells were then serially diluted with tightly latent BZLF1-LCLs, 
so that the proportion of lytic cell line ranged from 100% to 0%. These cell mixes were then used as 
targets for a GLC-specific CD8
+
 T cell clone in a T cell recognition assay. Recognition is shown as 
percentage IFN-release, where 100% release is that seen in undiluted lytic B95.8 LCLs. An aliquot 
of these cell mixes was also taken to extract RNA and carry out qRT-PCR analysis to detect the level 
of BMLF1 mRNA. This is shown as % of BMLF1, where 100% is taken as the level of BMLF1 in the 
lytic B95.8-LCLs before dilution with BZLF1-LCLs cells. 
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4.3. Recognition of WT2089-, ∆BNLF2a-, ∆BILF1- and ∆BGLF5-transformed LCLs 
by immediate early antigen-specific CD8
+
 T cells  
 
To determine the effects BNLF2a, BILF1 and BGLF5 have on antigen presentation during the 
IE phase of EBV lytic cycle, donor 1 (Table 4.2) LCLs were generated using wt-2089, 
∆BNLF2a-, ∆BILF1-, ∆BGLF5 or ∆BZLF1-virus. These were used as targets for HLA-A2 
restricted CD8
+
 T cell clones which recognise the YVL epitope of the IE protein BRLF1. This 
was done using two different T cell clones of the same specificity and each experiment was 
performed twice.  
Figure 4.2a shows the raw T cell recognition of HLA-A2 positive Donor 1 LCLs by a HLA-
A2 restricted, YVL specific, CD8
+
 T cell (clone 113). To confirm the specificity and 
sensitivity of this T cell clone, target ∆BZLF1-LCLs were sensitised with synthetic YVL 
peptide and as a negative control, the level of IFN- release by c113 in the absence of target 
cells was also measured. As shown, the lack of BNLF2a, BILF1 and BGLF5 expression 
resulted in increased levels of IFN- release by c113, where BNLF2a deletion resulted in the 
most dramatic increase in recognition. However, as discussed above, these LCL lines 
spontaneously enter lytic cycle to different frequencies. To account for the fact that a higher 
frequency of lytic cycle, and therefore more antigen expression may be the reason for this 
difference in recognition levels, the expression level of BRLF1 mRNA in each cell line was 
measured (Fig 4.2c), which was found to be similar for each target LCL. IFN- release was 
then normalised against the expression level of BRLF1 mRNA. This normalised data showed 
the extent of increase in YVL-epitope recognition differed between the different LCLs, where 
the knockout of BNLF2a shows the greatest increase in YVL-epitope recognition, resulting in 
an 11-fold increase above WT2089 recognition (Fig4.2e).  BILF1 deletion resulted in no 
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increase in recognition and the lack of BGLF5 expression increased the recognition of YVL-
epitope 4-fold above wt2089-LCL  
This assay was repeated using the same donor LCLs as targets for a different YVL-specific 
clone (c36) (Fig4.2b,d,f). In this example the level of IFN- release and BRLF1 mRNA 
expression levels are similar to that seen above (Fig4.2b,c). Thus, following normalisation, 
the effect of deleting BNLF2a, BILF1 and BGLF5 expression on recognition of an IE-epitope 
remains similar to that seen in Fig4.2e. Again, the most dramatic effect on increasing CD8
+
 T 
cell recognition was seen in cell lines lacking the expression of BNLF2a (Fig4.2f), while the 
deletion of BILF1and BGLF5 had little or no effect on recognition. These data show that 
BNLF2a-deletion has the most dramatic effect on recognition of an IE epitope and thus 
antigen presentation during the IE phase of lytic cycle. 
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Figure 4.2. Recognition of IE-YVL epitope presented by donor 1 ∆BNLF2a, ∆BILF1 and 
∆BGLF5-LCLs  
A,B) LCLs were incubated overnight with two different HLA-A2 restricted CD8
+
 T cell clones 
specific for the YVL epitope of BRLF1 (c113 and c36). IFN- release was measured using an ELISA. 
∆BZLF1-LCLs were sensitized with synthetic YVL peptide to confirm T cell activity and specificity. 
C,D) The mRNA expression of BRLF1 was measured using qRT-PCR. Levels are expressed as 
mRNA expression relative to wt2089-LCLs. E,F) IFN-release was normalized against mRNA 
expression level. Results expressed as T cell recognition relative to wt2089-LCLs. Representative of 
two repeats for each T cell. 
CD8+ T cell recognition of IE epitope YVL (BRLF1) 
BRLF1 mRNA transcript level 
Normalised recognition of target LCLs 
A) B) 
C) D) 
E) F)
) 
 A) 
YVL c113 YVL c36 
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4.4. Recognition of WT2089-, ∆BNLF2a-, ∆BILF1- and ∆BGLF5-transformed LCLs 
by early antigen-specific CD8
+
 T cells  
Having established that in donor 1 LCLs the deletion of BNLF2a appears to have the most 
dramatic effect of T cell recognition of an IE-epitope, the effect that these immune evasion 
genes have on recognition by E antigen-specific CD8
+
 T cells was then investigated. In the 
following representative examples, two different E-epitope specific T cells were used; one 
specific for the GLC epitope of BMLF1 (c112) and one for the epitope TLD, derived from 
BMRF1 (c2). Both of these T cells are restricted through HLA-A2 (Table 4.2).  
In a similar manner to the experiment in section 4.2, donor 1 wt-2089, ∆BNLF2a-, ∆BILF1- 
and ∆BGLF5-LCLs were incubated over night with CD8+ T cell clones described above. The 
level of IFN- release by these T cells is shown in Figure 4.3a,b. The increase in raw T cell 
recognition of LCLs lacking BNLF2a expression compared to wt-2089-LCLs shows 
BNFL2a-LCLs were more highly recognised. After normalisation of T cell IFN- release 
against the according expression of T cell antigen (Fig 4.3c,d), it is clear that BNLF2a 
deletion has the most dramatic effect on increasing E epitope recognition. Whereas the 
deletion of BILF1 increased recognition of these epitopes to a lesser extent and the lack of 
BGLF5 expression did not appear to increase recognition of these epitopes (Fig 4.3e,f). In this 
example, noting that this is derived from just one donor, it would appear that the results in 
Figure 4.3 e and f show essentially the same result as Figure 41.2 e and f, with the strongest 
effect shown by BNLF2a deletion, a small but measurable increase by BILF1 deletion and in 
this example no increase in the absence of BGLF5. 
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Figure 4.3. Recognition of E epitopes GLC and TLD presented by donor 1  ∆BNLF2a, 
∆BILF1 and ∆BGLF5-LCLs  
A) LCLs were incubated overnight with a HLA-A2 restricted CD8
+
 T cell specific for the GLC 
(BMLF1) epitope (c112) or (B) the TLD (BMRF1) epitope (c2), at a ratio of 10 to 1 target:effector. 
IFN- release was measured using an ELISA. ∆BZLF1-LCLs were sensitized with synthetic YVL 
peptide to confirm T cell activity and specificity. C) mRNA expression of BMLF1 or (D) BMRF1 was 
measured using qRT-PCR. Levels are expressed as mRNA expression relative to wt2089. E,F) IFN- 
release was normalized against mRNA expression levels. Results are expressed as T cell recognition 
relative to wt2089-LCLs. Representative of two repeats for each T cell.                                                                                                                                 
  
CD8+ T cell recognition of E epitopes GLC (BMLF1 and TLD (BMRF1)) 
mRNA transcript levels 
Normalised recognition of target LCLs 
A) B) 
C) D) 
E) F)
) 
 A) 
GLC c112 TLD c2 
BMLF1 BMRF1 
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4.5. Recognition of WT2089-, ∆BNLF2a-, ∆BILF1- and ∆BGLF5-transformed LCLs 
by late antigen-specific CD8
+
 T cells  
Again, using donor 1 LCLs, recognition of wt2089 Vs ∆BNLF2a-, ∆BILF1- and ∆BGLF5-
LCLs was measured using two different CD8
+
 T cell clones (clone 36 and 96) restricted 
through HLA-A2, both of which recognised the FLD-epitope derived from a L lytic protein 
BALF4. Recognition of donor 1 LCLs by clones 96 and 36 is shown in Figure 4.4a,b. The 
highest level of raw recognition in this example is of BILF1-LCLs, followed by BNLF2a 
and the lowest level of recognition is of BGLF5-LCLs. As shown in Fig4.4c and d, the 
different LCL lines show different patterns of expression of BALF4 mRNA. Despite this, the 
pattern of increasing recognition, following normalisation remains consistent between both 
examples (Fig e and f). In marked contrast to the recognition of IE and E epitopes (Fig 4.2 
and 4.3), the data in Figure 4.4e and f shows that T cell recognition of a L epitope is most 
enhanced by deletion of BILF1, less so by the deletion of BNLF2a and not at all or to a lesser 
extent by the deletion of BGLF5. 
Overall, the data in Figures 4.2-4.4 suggest that BNLF2a has the greatest immune suppressive 
effect upon recognition of IE and E epitopes, whilst BILF1 has the greatest effect upon 
recognition of L epitopes. Notably, the effect of BGLF5, if any, was consistently weaker than 
either BNLF2a or BILF1 for recognition of any target epitope. However, the above data relate 
to just one HLA restriction element, HLA-A2, and need to be confirmed with other restriction 
elements. Therefore, it was necessary to extend this work to cover a variety of donor LCLs 
and a more extensive panel of CD8
+
 T cells. However, upon repeating this with numerous 
different donors, a major experimental problem was encountered, whereby some of the target 
LCL panel were not always undergoing lytic cycle replication to a high enough proportion for 
T cell recognition. An example of this is shown in Figure 4.5. Here, donor 2 wt2089-, 
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BILF1-, BNLF2a- and BGLF5-LCLs were used in a similar assay to above, this time 
using a HLA-B8 restricted T cell specific for the IE-epitope RAK, derived from BZLF1. 
Firstly, the level of RAK epitope presented by all LCLs was very low, resulting in low 
recognition (Fig4.5a), despite good recognition of peptide sensitised BLZF1-LCLs. 
Moreover, ∆BNLF2a LCLs were not recognised due to low levels of lytic cycle and thus 
BZLF1mRNA expression (Fig4.5b). Since we rely on these cell lines spontaneously entering 
lytic cycle, such a low level of lytic cycle became a problem. Often, T cell recognition was 
only slightly above background, which was less than ideal, or more problematic was that 
some of the panel of LCLs were not lytic at all and thus there was no detectable T cell 
recognition, meaning that these experiments could not be carried out. To tackle this problem 
we first sought to design a way in which we could induce lytic cycle in LCLs.  
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Figure 4.4. Recognition of L FLD epitope presented by donor 1 ∆BNLF2a, ∆BILF1 and 
∆BGLF5-LCLs.  
A,B) LCLs were incubated overnight with two different HLA-A2 restricted CD8+ T cell specific for 
the FLD epitope of BALF4 (c36 and c96). IFN- release was measured using an ELISA. ∆BZLF1-
LCLs were sensitized with FLD peptide to confirm T cell activity and specificity. C,D) The mRNA 
expression of BALF4 was measured using qRT-PCR. Levels are expressed as mRNA expression 
relative to WT2089-LCLs. E,F) IFN- release was normalized against BALF4  mRNA expression. 
Results are expressed as the increase in CD8
+
T cell recognition relative to wt2089-LCLs. 
Representative of two repeats for each T cell.                                                                                                                                       
 
CD8+ T cell recognition of L epitope FLD (BALF4) 
BALF4 mRNA transcript levels 
Normalised recognition of target LCLs 
A) B) 
C) D) 
E) F)
) 
 A) 
FLD c36 FLD c96 
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Figure 4.5. Recognition of IE RAK epitope presented by donor 2 ∆BNLF2a, ∆BILF1 and 
∆BGLF5-LCLs  
A) LCLs were incubated overnight with a HLA-B8 restricted CD8
+
 T cell specific for the RAK 
epitope of BZLF1. IFN- release was measured using an ELISA. ∆BZLF1-LCLs were sensitized with 
synthetic RAK peptide to confirm T cell activity and specificity. B) mRNA expression of BZLF1 was 
measured using qRT-PCR. Gene expression levels are shown as levels of mRNA expression in all cell 
lines relative to wt2089-LCLs. These data are representative of two repeats.        
  
A) B) 
T cell recognition of IE-RAK (BZLF1) c3 BZLF1 mRNA expression 
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4.6. Inducing lytic cycle in LCLs  
Since it was determined during the course of the above work that we absolutely required at 
least 1% of target LCL lines to be undergoing lytic cycle, it was decided to attempt inducing 
lytic cycle in LCLs. Although there are methods which are known to induce lytic cycle in 
LCLs, such as exposure to sodium butyrate (Luka et al., 1979), antibody mediated cross-
linking of surface immunoglobulin (Tovey et al., 1978; Takada and Ono 1989) and exposure 
to 12-O-tetradecanoylphorbol-13-acetate (TPA) (zur Hausen et al., 1978), these were not 
suitable for this work, due to the induction of a plethora of side effects such as changes in 
MHC class I levels. Since the aim of this work is to investigate the roles of BNLF2a, BILF1 
and BGLF5 in the context of whole virus biology, with as little manipulation as possible, 
these were undesirable methods, as controlling for the side effects would be difficult.  
For this reason, inducing lytic cycle by overexpressing EBVs lytic switch protein, BZLF1, 
was investigated. To do this B95.8-transformed LCLs were electroporated with either BZLF1 
expressing plasmid (BZLF1 transfected cells) or a control plasmid (mock transfected cells), as 
shown in Figure 4.6. After 24 hours, cells were intracellularly stained for an IE expressed 
protein, BRLF1 (Fig4.6b), and a L expressed protein, BALF4 (Fig4.6c). In order to measure 
transfection efficiency, BZLF1 protein levels were also measured (Fig4.6a). As shown in 
Figure 4.6a, BZLF1 staining of mock transfected cells shows that less than 0.5% of cells were 
spontaneously undergoing lytic cycle replication. Following transfection with a BZLF1-
plasmid around, 6% of cells were expressing BZLF1 protein (Fig4.5a). Although this is 
considered a low transfection efficiency, it would be a high enough proportion of cells 
undergoing lytic cycle for use in T cell recognition assays involved in this research project. 
However, only 2% of cells were shown to be expressing the other IE protein BRLF1 
(Fig4.5b). Furthermore, only 0.5% were expressing the L lytic protein BALF4 (Fig4.5c). 
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From these data it would appear that not all cells which were successfully transfected actually 
progressed through lytic cycle to express BRLF1. In addition of those that did express 
BRLF1, not all then progressed to express the late lytic protein, BALF4. Therefore, this 
method of lytic cycle induction was not efficient, although there is clearly induction of 
BRLF1 expression in some cells. This is perhaps due to poor transfection efficiency of 
BZLF1-plasmid, which results in a low level of BZLF1 in the first instance and since not all 
cells that express BZLF1 will progress through lytic cycle, it may be that the transfection 
efficiency is the limiting factor, thus it was next decided to attempt to increase the transfection 
efficiency and/or enrich the transfected cell population. 
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Figure 4.6. Transfection of BZLF1 plasmid into target LCLs does not results in high 
levels of subsequent lytic cycle.  
A) Target LCLs were electroporated with the BZLF1-plasmid or a mock plasmid and 24hr later they 
were intracellularly stained for lytic proteins. The transfection efficiency was analysed by measuring 
the level of BZLF1 in transfected cells (A). The same cells were also stained for the expression of an 
IE protein BRLF1 (B) and a L-protein BALF4 (C). 
  
0.21% 
BZLF1 transfected cells 
Side 
Scatter 
Mock transfected cells 
0.49% 
L (BALF4)  
5.79% 
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Therefore, another system of lytic cycle induction was used whereby BZLF1 expression could 
be induced (Bornkamm et al., 2005). To do this, B95.8-transformed LCLs were transfected 
with either BZLF1-inducible vector (pRTS-CD2-BZLF1) or control vector (pRTS-CD2-
control), after which, successfully transfected cells were enriched.  These cells were then 
induced using doxycycline (dox) and 24 hours later, the expression of IE- (BRLF1), E- 
(BHRF1) and L- (BALF4) expressed lytic proteins were analysed using intracellular staining 
and flow cytometry (Fig 4.7). Upon treatment with dox, these cells co-induce both BZLF1 
and GFP, which means that the level of induction can be measured by using flow cytometry to 
detect the proportion of cells expressing GFP. As an additional control, the level of BZLF1 
expression was also measured. As shown in Figure 4.7a, 0.6% of control-induced cells were 
expressing GFP, while only 0.1% of BZLF1-induced cells expressed GFP. However, 1.3% of 
BZLF1-induced cells were expressing BZLF1. This was likely due to the process of 
intracellular staining which often quenches the fluorescence level of GFP. It should be noted 
that this is not due to the presence of dox, as the same effect was not seen in control-induced 
cells. Thus from here on the levels of GFP expression will be ignored, instead the expression 
of lytic proteins will be used as the measure of lytic cycle progression. To this end, the 
expression of BRLF1 in BZLF1-induced cells, was seen to be similar to the level of BZLF1 
expression (1.2%) (Fig. 4.7b). However, none of these cells showed detectable levels of the 
early EBV protein BHRF1 (Fig 4.7c) or the late protein BALF4 (Fig 4.7d). This would 
suggest that the expression of BZLF1 and BRLF1 is not suffice to induce full lytic cycle in 
LCLs, meaning this system of lytic induction is also not appropriate for CD8
+
 T cell 
recognition assays. Thus, whilst the Bornkamm vector has the potential to sort on the basis of 
rat-CD2 or GFP, this approach was not used as the above data were not promising with 
regards to E and L lytic cycle progression. 
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Figure 4.7. Lytic cycle does not progress to late lytic protein expression in LCLs after 
dox-induced expression of BZLF1 using a Bornkamm vector.   
Cells were transduced with a control- or BZLF1- vector followed by selection of positive cells. Cells 
were then dox-induced to express BZLF1 and 24hrs post-induction assayed for the expression of IE, E 
and L-lytic proteins alongside GFP, which is expressed by cells successfully induced, using 
intracellular protein staining and flow cytometry. A) Induced cells were stained for the expression of 
BZLF1 and GFP. Cells were also stained for the IE protein BRLF1 (B), the E protein BHRF1 (C) and 
L protein BALF4 (D). The reason not all cells which express lytic proteins also express GFP, as would 
be expected, is that the process of intracellular staining quenches the signal of GFP. 
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4.7. Discussion 
Overall, the data shown in Figures 4.2-4.4 suggest that BNLF2a plays the strongest role in 
interfering with the presentation of viral epitopes during the IE and E phases of lytic cycle, 
whereby the deletion of this gene results in enhanced recognition of 10-fold above wild type 
LCLs for IE-YVL, a 4-fold increase in E-GLC recognition and a 8-fold recognition of E-
TLD. BILF1, on the other hand, appears to have the greatest effect upon recognition of L 
epitopes, increasing recognition of L-FLD epitope 4- and 8-fold above wild type, for two 
different T cell clones. While at late stages BNLF2a appears to play a less dominant but still a 
notable role. In contrast, the deletion of BGLF5 showed little or no effect on increasing T cell 
recognition of IE- E- or L-epitopes, suggesting that BGLF5 may play a little or no role in 
interfering with antigen presentation at all stages of lytic cycle. The BNLF2a data generally 
confirm the previously published data of Croft et al. except that they observed no enhanced 
recognition of L epitope in BNLF2a-LCL targets, whereas the present data show clear 
enhanced of recognition, albeit less marked than shown by the deletion of BILF1. This 
discrepancy may be attributed to two factors: firstly, the T cell clones generated in this thesis 
are more potent than those used by Croft et al, and secondly, the method of normalisation of 
the T cell recognition has been improved in the present study.  
However, upon repeating the experiments presented in this chapter target LCLs were not 
always undergoing lytic cycle reactivation to a high enough proportion, or more importantly, 
some of the panel were not lytic at all. This made the confirmation of these findings using 
other donor LCLs and T cell specificities impossible. Since it was not feasible to wait for 
these target cells to become lytic, with no way of controlling this, it was attempted to induce 
lytic cycle. An obvious alternative would be to use the BAC-293 virus recombinant virus 
producer cell line. In these cells, the production of virus can be induced using BZLF1, thus 
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would make ideal targets. However, when this was attempted, although lytic cycle was 
induced and this progressed to late stages, there was no detectable T cell recognition (data not 
shown); therefore this of lytic induction was not pursued further. Likewise, chemical 
induction was not ideal, due to the pleptrophic effects these inducers have on cells. The failed 
attempts at inducing lytic cycle using induced expression of BZLF1 meant that an alternative 
strategy was required to confirm and extend the T cell recognition data shown in Figures 4.2-
4.4. During the course of this work it became clear that LCLs transformed using the B95.8 
strain of EBV showed consistently higher levels of spontaneous lytic cycle when compared to 
LCLs transformed with 2089-EBV strain (data not shown).  This led us to consider whether 
we could select from appropriate HLA-typed donor B95.8-transformed LCLs that showed 
consistently high subpopulations (more than 2%) of  LCLs in lytic cycle, and use a small 
hairpin RNA (shRNA) approach to selectively knockdown the expression of BNLF2a, BILF1 
or BGLF5. Such experiments are documented in the following chapter.  
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CHAPTER 5 
 
DEVELOPING ALTERNATIVE BNLF2A, BILF1 AND BGLF5 
KNOCKDOWN MODELS IN SPONTANEOUSLY LYTIC LCLS 
 
 
The method of gene knockdown, involving the expression of a shRNA, which binds to 
complementary mRNA and suppresses its translation, is widely used in other experimental 
models. However, there appears to be no reports in the literature of attempts to use shRNA-
mediated knockdown of EBV lytic gene expression in LCLs. This chapter outlines the results 
obtained from designing and generating shRNAs to knockdown the expression of BILF1, 
BNLF2a and BGLF5 in spontaneously lytic B95.8-LCLs.  
To order design successful shRNAs, standard practice is to identify a small interfering RNA 
(siRNA) which can transiently silence the expression a target gene, and use the sequence of 
this siRNA to design shRNAs. siRNAs are double stranded RNA molecules around 20-25 
base pairs in length, with a sequence complementary to the mRNA of the gene which is to be 
silenced. For this work, either two or three siRNAs were designed and generated using a 
service offered by sigma, to target the mRNA of either BILF1, BNLF2a or BGLF5 
(sequences shown in Table 5.1). To test these siRNAs, LCLs were not used, as siRNA 
transfection of LCLs is generally inefficient, therefore, would require high concentrations of 
siRNA in order to achieve knockdown. Instead, it was decided instead to use 293 cells to 
screen the panel of siRNAs. The advantage of using 293 cells are that they are readily 
transfectable with gene expression plasmids and siRNAs, thus they provide a level of 
sensitivity that permits replicate experiments requiring minimal amounts of siRNA.  
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Table 5.1 siRNA sequences generated and tested.  
Target gene and siRNA sequence (Sigma) 
 
Gene Target siRNA Sequence 5’-3’ 
BNLF2a -036 CACAGAGUACCACCAGGAG 
-123 CGGGCAGGCCGCAGGCAGA 
-140 GAGGACUGCUGCUCUAGCA 
BILF1 -251 GUGAAGGUGACGUUGCAUA 
-456 CCAUGGUAAUGAGGAGGAU 
-664 CGAGAACUCCUGAAUCAUU 
BGLF5 -363 GUGGAUUGAUGAAGAUGUU 
-541 GCGCUUACGGACAUCUUUA 
-881 CAGAUGAGCUUACAGACAA 
-096 CACGUACGAGCAGAGAACA 
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5.1. Screening BNLF2a-, BILF1- and BGLF5-siRNAs  
 
The experimental approach to screening the panel of candidate siRNAs listed in Table 5.1 is 
shown schematically in Figure 5.1. Briefly, aliquots of 293 cells were transfected with 
plasmids expressing BNLF2a, BILF1 or BGLF5. After 8 hours these transfected cells were 
divided into four wells of a 12-well plate. This avoided any differences in the transfection 
efficiency since each well would theoretically express the same level of target mRNA. The 
next day cells were transfected with individual siRNAs, or a control siRNA. After 24 hours, 
cells were harvested and the level of protein knockdown was examined using western blot 
analysis. Each candidate siRNA screen was repeated three times, using a range of siRNA 
concentrations.   
Figure 5.2a shows an example of the results for one such experiment, in which three candidate 
BNLF2a-siRNAs (-036, -123 and -140) were tested at a dose of 100nM. As shown, siRNA-
036 and siRNA-140 showed substantial BNLF2a protein knockdown, compared to control 
siRNA transfected cells (lane 1). This is representative of numerous repeats using siNRA 
concentrations ranging from 50nM to 500nM. In each case siRNA-036 showed the highest 
level of BNLF2a protein knockdown. Therefore, the siRNA sequence 5’ 
CACAGAGUACCACCAGGAG 3’ was selected for subsequent generation of shRNA-
lentivirus targeting BNLF2a. 
Screening of candidate BILF1 siRNAs (-664, -251, and -456) was carried out in a similar 
way, the only difference being that 293 cells were transfected with a HA tagged BILF1 
expression plasmid, since an antibody against BILF1 protein is not available. A representative 
example of the level of BILF1-HA protein knockdown in these cells is shown in Figure 5.2b. 
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siRNA-251 and siRNA-664 both caused an obvious reduction in BILF1-HA protein, whilst 
the siRNA-456 reproducibly upregulated BILF1-HA expression. Other experiments with 
lower concentrations of siRNA (data not shown) indicated that siRNA-664 gave more 
efficient knockdown than siRNA-251. Therefore, the siRNA-664 sequence 5’-
CGAGAACUCCUGAAUCAUU-3’ was taken forward to generate shRNA constructs. It 
should be noted, that the increase in BILF1-HA expression in the presence of siRNA-456 was 
unexpected, and is likely due to this particular siRNA activating the expression of BILF1.  
Finally, similar experiments were performed to screen four BGLF5 targeting siRNAs 
(siRNA-363, -541, -881, -096). A representative example of these results is shown in Figure 
5.2c which shows knockdown of BGLF5 protein by three of the candidate siRNAs (siRNA-
363, -541 and -881). siRNA-363 reproducibly resulted in the most efficient knockdown in all 
experiments performed, over a range of concentrations. Therefore, shRNA was subsequently 
designed around the sequence of the siRNA-363 (5’ GUGGAUUGAUGAAGAUGUU 3’). 
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Figure 5.1 Experimental method used to screen candidate siRNAs.  
293 cells were plated into a 25cm
2
 flask on day 0. The following day, cells were transfected with 
either BNLF2a, BILF1-HA or BGLF5 expressing plasmid. After 8 hours, these cells were transfered 
to a 12-well plate and left overnight. The following moring, cells were trasnfected with appropriate 
siRNAs and a control siRNA. After 24 hours cells were harvested and the level of protein knockdown 
was assessed using western blot analysis.  
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Figure 5.2 Knockdown of BNLF2a, BILF1 and BGLF5 using siRNAs 
293 cells were transiently transfected with BNLF2a (A), BILF1-HA (B) or BGLF5 (C) expressing 
plasmids. 8 hours later these cells were split into 4 wells. 16 hours later, each well was transfected 
with either specific siRNA or a control siRNA (100uM). 24 hours later these cells were harvested and 
screened for the level of BNLF2a (A), BILF1-HA (B) or BGLF5 (C) protein knockdown using 
western blot analysis. Each result is a representative example of numerous repeats using a range of 
different siRNA concentrations. 
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5.2. Generating shRNA-lentiviruses 
 
The selected siRNA sequences (Table 5.2) were then used to generate four shRNA-
lentiviruses (Fig 5.3a) (Service offered by sigma). The advantage of using shRNA-lentiviral 
delivery rather than transient transfection of siRNA is that shRNAs are integrated into the 
genome of cells so that the knockdown of target genes is constitutive and stable. In order to 
detect, and subsequently sort transduced cells, fluorescent tags were also expressed from the 
lentiviral vectors; different coloured tags were used for each shRNA vector, as shown in 
Table 5.2. These constructs also expressed a puromycin resistance gene, which allowed for 
the enrichment of transduced cells. Therefore, this overall approach allowed for the selection 
and maintenance of successfully transduced cells by sorting on the expression of a specific tag 
and by adding puromycin to cell culture, if necessary.  
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Table5.2 shRNA-lentivirus constructs used.  
Including information on the vector which encoded the shRNA, the gene targeted the fluorescent tag 
which was encoded for each shRNA and the DNA sequence of the shRNA. All vectors also encoded a 
puromycin resistance.  
 
 
 
 
 
 
Vector Gene 
targeted 
Fluorescent 
tag 
DNA sequence 5’-3’ 
pLKO.1-puro-
CMV-TagCFP 
 
BNLF2a CFP CACAGAGTACCACCAGGAG 
pLKO.1-puro-
CMV-TagFP635 
 
BGLF5 FP635 GTGGATTGATGAAGATGTT 
pLKO.1-puro-
CMV-TagYFP 
 
BILF1 YFP CGAGAACTCCTGAATCATT 
pLKO.1-puro-
CMV-tCFP 
None CFP TCCTAAGGTTAAGTCGCCCTC 
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5.3. shRNA-lentivirus transduction of lytic B95.8-LCLs   
 
Donor B95.8 LCLs for use in T cell assays were initially selected on the basis of their HLA 
type and subsequently, the proportion of cells undergoing lytic cycle was assessed using 
intracellular BZLF1 staining. While carrying out the work outlined in chapter 4, it became 
clear that if target LCLs were less than 1% BZLF1 positive, CD8
+
 T cell recognition was too 
low for accurate quantitation. For this reason, only B95.8 LCLs that were more than 1% 
BZLF1 positive were selected for transduction.  
As depicted in Figure 5.2b, selected lytic B95.8 LCLs were transduced with lentiviruses 
expressing shRNA-Non-target-CFP, shRNA-BNLF2a-CFP, shRNA-BGLF5-FP635 or 
shRNA-BILF1-YFP. Cultures were then expanded, and successfully transduced cells were 
selected on their expression of CFP, FP635 or YFP using a MoFlo fluorescence activated cell 
sorter. There cells were then re-cultured, with drug selection if required, until sufficient 
numbers were reached to validate the knockdown of the selected EBV lytic genes This 
allowed for the generation of populations of successfully transduced B95.8-LCLs, in which 
the lytic subpopulation were single knockdowns for either BNLF2a, BILF1 or BGLF5. These 
were then used as targets in CD8
+
 T cell recognition assays. 
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Figure 5.3 Schematic of shRNA-lentiviruses transduction of B95.8 LCLs. 
A) Diagram of shRNA vector plasmid used. B) The experimental approach used to generate shRNA 
transduced LCLS. B95.8-LCLs are selected on the basis of their HLA type and the frequency of cells 
undergoing lyric cycle. Cells are transduced with each different shRNA-lentivirus. Cell lines are then 
expanded and transduced cells are selected on the expression of the appropriate fluorescent tag.  
Knockdown is then confirmed and cells are used in downstream T cell assays. 
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5.4. shRNA knockdown of BNLF2a in lytic B95.8-LCLs  
 
Following transduction and expansion of parallel B95.8-LCL cultures with shRNA-BNLF2a 
lentivirus, transduced LCLs expressing high levels of CFP were observed (Fig 5.4a). 
Following selection by fluorescence activated cell sorting, and further expansion, expression 
of BNLF2a transcripts was assayed and found to be of similar levels in both shBNLF2a-LCLs 
and shNon-target-LCLs (Fig 5.4b), despite the fact that shBNLF2a-LCLs were around three 
times as lytic as control shNon-target-LCLs (Fig 5.4c). Therefore, when the expression of 
BNLF2a was normalised against the level of BZLF1 transcript (Fig 5.4d), the knockdown of 
BNLF2a mRNA was around 70%, compared to BNLF2a expression in shNon-target-LCLs. It 
should be noted, that although in this example the level of BZLF1 expression was used to 
measure lytic cycle and normalise BNLF2a expression, in other experiments, normalisation 
against BRLF1, BMLF1 or BZLF1 all confirmed the efficiency of BNLF2a knockdown in 
shBNLF2a-LCLs. 
The level of BNLF2a protein knockdown in these cells was also investigated using western 
blot analysis. This was complicated by the fact that shBNLF2a-LCLs in this example were 
more lytic than their shNon-target-LCLs counterparts. In order to address this difference in 
lytic cycle, the shBNLF2a-LCL sample was diluted 1 in 2 and 1 in 4, so that there was 
decreasing levels of BZLF1 protein in each lane. As shown in Figure 5.4e, the level of BZLF1 
expression was most comparable between shNon-target- (lane 1) and shBNLF2a-LCLs which 
have been diluted 1 in 4 (lane 3). When comparing these lanes, the expression of BNLF2a in 
shBNLF2a-LCLs is dramatically reduced compared to that in shNon-target LCLs. This effect 
can also be seen in undiluted shBNLF2a-LCLs, where when there is more BZLF1 protein, 
there are still lower levels of BNLF2a protein, compared to shNon-target-LCLs. Thus the 
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knockdown of BNLF2a in B95.8-LCLs using shBNLF2a-lentivirus was successful. It was 
also noted that there appeared to be unexpected expression of BNLF2a transcript and protein 
in BZLF1 LCLs (negative control). This will be addressed at the end of this chapter. 
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Figure 5.4 BNLF2a knockdown in B95.8-LCLs 
A) shBNLF2a-LCLs were expanded, and the CFP positive cells were selected. (B,C) qRT-PCR was 
used to measure the level of BNLF2a and BZLF1 mRNA. Data is shown as relative transcript level. 
D) BNLF2a mRNA expression was normalized against BZLF1. Data is shown as BNLF2a mRNA in 
shBNLF2a-LCLs relative to shNon-target. E) BNLF2a protein knockdown was assessed using western 
blot analysis. Protein levels of BNLF2a and BZLF1 was measured in shNon-target-, shBNLF2a- and 
BZLF1-LCLs. Since shBNLF2a-LCLs were more lytic, a 1 in 2 and 1 in 4 dilution of shBNLF2a-
LCLs was carried out, so that a similar level of BZLF1 expression was achieved (Red line). 
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5.5. Knockdown of BILF1 in lytic B95.8-LCLs using shRNA lentiviruses 
 
Similarly to the above, parallel cultures of B95.8 LCLs were transduced with shRNA-BILF1-
YFP lentivirus and expanded. Firstly, the level of YFP expression in transduced cultures was 
measured (Fig 5.5a), and those cells expressing high levels of YFP were selected using cell 
sorting and subsequently expanded. The level of BILF1 mRNA knockdown in these cells was 
then measured using qRT-PCR analysis. As was the case with shBNLF2a-LCLs, shBILF1 
LCLs expressed slightly more BZLF1 mRNA than their shNon-target-LCL counterparts (Fig 
5.5c). Despite this, the level of BILF1 mRNA in shBILF1-LCLs was lower than in shNon-
target-LCLs (Fig5.5b). Therefore, after normalisation of BILF1 expression against BZLF1 
(Fig 5.5d), the knockdown of BILF1 in shBILF1-LCLs amounted to around 75%. This was 
repeated using other lytic genes to normalise for lytic cycle, and the level of BILF1 
knockdown was always 70-90%. Unfortunately, since there is no available anti-BILF1 
antibody, protein knockdown could not be confirmed. 
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Figure 5.5 BILF1 knockdown in B95.8-LCLs 
A) shRNA-BILF1-LCLs expressing YFP were selected, using cell sorting. B,C) qRT-PCR analysis 
was performed to measure the level of BILF1 (B) and BZLF1 (C) transcripts in shNon-target and 
shBILF1-LCLs. As a negative control BZLF1-LCLs were included. Data is shown as transcript level 
relative to induced AKBM cells. D) BILF1 expression was normalized against the level of BZLF1 
transcript. Data is shown as BILF1 expression in shBILF1-LCLs relative to that in shNon-target cells.  
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5.6. Knockdown of BGLF5 in lytic B95.8-LCLs using shRNA lentiviruses 
 
Following sorting of shBGLF5-LCLs on the expression of FP635 (Fig5.6a) and subsequent 
expansion of these cells, the successful knockdown of BGLF5 was measured using qRT-PCR 
analysis to quantitative the levels of BGLF5 mRNA in shBGLF5-LCLs compared to shNon-
target LCLs. As shown in Figure 5.6b, the level of BGLF5 transcript in shBGLF5-LCLs was 
less than that in shNon-target LCLs. As shown in Figure 5.6c, shBGLF5-LCLs were in fact 
more lytic than the shNon-target LCLs. Therefore, when the expression of BGLF5 was 
normalised against the level of BZLF1 transcript, the knockdown of BGLF5 expression was 
seen to be 70%, compared to BGLF5 expression in shNon-target LCLs (Fig5.6d)  
Next, the level of BGLF5 protein knockdown was investigated. As shown in Figure 5.6e, the 
level of BZLF1 protein expression in shBGLF5 LCLs was slightly higher than in shNon-
target LCLs, which reflected the mRNA data in 5.6c. Despite these comparable levels of 
BZLF1 protein, there was a dramatic decrease in BGLF5 protein expression in shBGLF5-
LCLs compared to their shNon-target-LCL counterparts. Thus the knockdown of BGLF5, 
BNLF2a and BILF1 in lytic B95.8-LCLs using this method was successful. 
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Figure 5.6 BGLF5 knockdown in B95.8-LCLs 
A) shRNA-BGLF5-LCls were sorted on the expression of FP635 (B,C) qRT-PCR analysis was used to 
measure the level of BGLF5 (B) and BZLF1 (C) transcripts. Data is shown as transcript level relative 
to a standard of lytic EBV cells. D) BGLF5 expression was then normalized on the level of BZLF1 
transcript. Data is shown as BGLF5 expression in shBGLF5-LCLs relative to that in shNon-target 
cells. E) BGLF5 knockdown was then confirmed at the protein level using western blot analysis. The 
expression of BGLF5 and BZLF1 protein was measured in shNon-target-LCLs (no knockdown), 
shBGLF5-LCLs (knockdown) and as a negative control, BZLF1 ko-LCLs were included. 
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5.7. Expression of BNLF2a in latent EBV infected cells 
 
As shown in Figure 5.4, it was apparent that replication deficient BZLF1-LCLs expressed 
detectable levels of BNLF2a transcript and protein. This finding was unexpected and 
warranted further investigation. 
The ability of HLA-A2 restricted CD8
+
 T cells specific for the BNLF2a epitope, 
VLFGLLCLL, (Bell et al., 2009) to recognise BZLF1-LCLs was investigated. Firstly, the 
expression of BNLF2a in BZLF1-LCLs was confirmed using qRT-PCR (Fig5.7a). As a 
positive control, lytic 2089-EBV (wild-type) transformed LCLs and negative control of 
BNLF2a-LCLs were included. As shown in Figure 5.7a, in this particular example, both 
wild-type 2089-LCLs and BZLF1 LCLs expressed BNLF2a mRNA to similar levels, 
whereas there was no detectable BNLF2a expression in BNLF2a-LCLs. As shown in Figure 
5.7b BNLF2a specific CD8
+
 T cells were able to recognise 2089- and BZLF1-LCLs, whilst 
there was no recognition of their BNLF2a-LCL counterparts. This confirms that BNLF2a is 
indeed expressed in BZLF1-LCLs, that are considered to display only latent infection and, 
moreover, it is processed and presented.  
To confirm that BZLF1-LCLs were not expressing significant levels of other lytic 
transcripts, the level of the lytic antigen BRLF1, was assayed, and its recognition by a 
BRLF1-specific CD8
+
 T cell measured. As shown in Figure 5.7c, BRLF1 transcript was 
present in 2089- and BNLF2a -LCLs, while there was no detectable expression by BZLF1-
LCLs. Furthermore, there was no recognition of BZLF1 LCLs by BRLF1 specific T cells 
(Fig 5.7d), and 2089- and BNLF2a-LCLs were recognised by this T cell. Thus, BZLF1-
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LCLs are not undergoing lytic cycle replication, however they do express BNLF2a. Next, the 
expression of BNLF2a in other tightly latent EBV infected cells was investigated. 
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Figure 5.7 Recognition of BZLF1 ko LCLs by BNLF2a specific T cells. 
qRT-PCR analysis was used to measure the level of BNLF2a (A) and BRLF1 transcripts in 2089-, 
BNLF2a - and  BZLF1 -LCLs. Results are shown as expression relative to induced AKBM cells. 
(B,D,) CD8
+
 T cell recognition of BNLF2a and BRLF1 epitopes in 2089-, BNLF2a - and BZLF1 -
LCLs was measured using IFN- ELISA. Background IFN- release by T cell alone was measured and 
as a positive control, T cell recognition of peptide loaded cells was measured. Results are shown as 
IFN- release (pg/ml). 
  
T cell recognition of VLF (BNLF2a) BNLF2a transcript level 
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5.8. Expression of BNLF2a in latent EBV infected SNK/T cell lines 
 
In order to confirm that the expression of BNLF2a during latency was not exclusive to 
BZLF1-LCLs, the expression of BNLF2a in other latent EBV infected cell lines was 
investigated. To this end, the expression of BNLF2a in three NK/T cell lines derived from 
patients with EBV-associated NK/T cell lymphoma (ENKTL) or chronic active EBV 
(CAEBV): SBK6, SNK10 and SNT16, was assayed. As shown in Figure 5.8a, these cell lines 
do not express BZLF1 or other lytic transcripts (data not shown), thus they are considered 
tightly latent. However, they do express varying levels of BNLF2a (Fig 5.8b), whereby SNK6 
shows the highest level of transcript expression. This raises the question as to whether 
BNLF2a is functionally active in theses latent cells, and if it could be playing a functional role 
in latent CD8
+
 T cell evasion. However, due to time constraints, this work could not be 
pursued further during this research project. 
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Figure 5.8 Expression of BNLF2a in SNK and T cell lines. 
Using qRT-PCR analysis, the level of BZLF1 (A) and BNLF2a (B) transcripts in SNK-6,-10 and SNT 
16 cell lines was measured. As a control, B95.8 and BZLF1-LCLs were also included. Results are 
shown as transcription level relative to induced AKBM cells. 
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5.9. Discussion 
Although the experimental approach outlined in this chapter did enable the generation of 
single knockdown LCLs, there were some issues which complicated matters. Firstly, 
transduced LCLs did not survive for long periods of time. This was likely due to untransduced 
LCLs outgrowing transduced LCLs; however, it cannot be ruled out that transduced cells 
died-off faster, as a result of the transduction process. Moreover, sorted cells did not expand 
at the same rate as untransduced B95.8-LCLs and thus, the ability to use knockdown LCLs in 
T cell recognition assays was not always possible (discussed in chapter 6). This meant that all 
T cell assays, described in chapter 6, involved new transductions of B95.8-LCLs in parallel, 
for each experiment, which was not ideal and limited the amount of effector T cells which 
could be assayed. In addition, sorting of shBGLF5-LCLs was hampered by the fact that the 
sorting facility available did not possess a laser which could effectively excite the FP635 tag 
and thus cell sorting was less efficient. However, this method of gene knockdown was 
ultimately a success and allowed for the further investigation of the roles BNLF2a, BILF1 and 
BGLF5 play in interfering with antigen presentation at the three different stages of lytic cycle 
(IE, E and L). 
The novel finding of BNLF2a expression in latent EBV infected cells raises some interesting 
issues. It suggests that BNLF2a may play a role in interfering with antigen presentation in 
latent infections, implicating it as an important immune evasion mechanism in both latent and 
lytic forms of EBV infection. Interestingly, Jochum et al have recently shown that BNLF2a 
plays an important role in protecting newly infected B cells from T cell recognition (Jochum 
et al., 2012; Jochum et al., 2012). In this study (as discussed in chapter 1), the presence of 
BNLF2a transcript was detected in the EBV virion and it was found to be expressed and 
active early in infection, before the initiation of lytic cycle replication.  
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Regardless of whether BNLF2a expression in latency is sufficient to protect cells from CD8
+
 
T cell recognition, the data presented in this chapter (Fig 5.7) suggest BNLF2a could be a 
potential T cell target and thus could possibly be used in treatment of EBV infections and 
associated disease.   
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CHAPTER 6 
RECOGNITION OF EBV LYTIC CYCLE EPITOPES IN shRNA-
LENTIVIRUS TRANSDUCED LCLS LACKING THE EXPRESSION OF 
BNLF2A, BILF1 OR BGLF5 
 
 
In order to assess the roles BNLF2a, BILF1 and BGLF5 play in interfering with presentation 
of IE, E and L lytic epitopes, we selected lytic B95.8 LCLs and silenced the expression of 
BNLF2a, BILF1 or BGLF5 using shRNA-lentiviruses, as described in chapter 5. These LCLs, 
alongside their shNon-target- and BZLF1 counterparts, were then used as targets for CD8+ T 
cells specific for IE, E or L lytic epitopes. In order to minimise any experimental variation, we 
aimed to simultaneously measure the recognition of these transduced LCLs, by CD8
+
 T cells 
restricted through the same HLA-molecule, showing specificity towards epitopes derived 
from each phase of lytic cycle (IE, E and L).  
 
6.1. Experimental approach 
 
The approach adopted for this chapter was to select a range of lab donor B95.8-LCLs (Table 
6.1) which possessed the relevant HLA alleles and were no less than 1% lytic (according to 
intracellular BZLF1 staining). These were transduced with shNon-target-, shBNLF2a-, 
shBILF1- or shBGLF5-lentiviruses, in order to knockdown the expression of the appropriate 
EBV immune evasion genes. Following expansion of these transduced LCLs, the level of 
transduction was measured using flow cytometry to detect the level of CFP- (shBNLF2a and 
shNon-target), YFP- (shBILF1), or FP635- (shBGLF5) tag expression, as described in chapter 
5. Transformed LCLs which were more than 80% transduced were used immediately in T cell 
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recognition assays or; those which were less than 80% positive were enriched using MoFlo 
fluorescence activated cell sorting, and subsequently used in T cell recognition assays. To 
account for any differences in lytic cycle between target LCLs, the level of mRNA expression 
of each T cell target antigen, was also measured using qRT-PCR, as described in chapter 4. T 
cell recognition data was then normalised against the mRNA expression level of the target 
antigen. This allowed us to investigate the increase in T cell recognition of IE, E and L 
epitopes in the absence of BNLF2a, BILF1 or BGLF5 expression, when compared to shNon-
target-LCLs. The T cell cloning experiments described in chapter 3 provided the reagents to 
enable simultaneous assessment of recognition of both HLA-A2 and HLA-B7 restricted 
epitopes derived from IE, E and L phases of lytic cycle (Table 6.2). 
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Table 6.1 HLA types of donors used to generate shNon-target-, shBNLF2a-, shBILF1-, 
shBGLF5- and BZLF1-LCLs 
 
 
Donor HLA-A HLA-B HLA-C 
1 2 24 27 35 2 4 
3 2 3 7 27 1 7 
4 1 2 39 40 3 12 
5 2 ND 58 55 3 7 
6 2 ND 47 60 ND ND 
7 2 68 35 49 4 7 
8 2 29 7 44 7 16 
 
*ND HLA allele not determined 
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Table 6.2 Peptide epitope specificities of CD8+ T cell clones used in recognition assays 
 
 
 
 
 
  
Phase of 
expression 
EBV protein Peptide epitope  HLA 
restriction 
No. of clones 
Immediate 
early 
BZLF1 DPYQVPFVQAF B7 1 
BRLF1 YVLDHLIVV A2 3  
Early BMLF1 GLCTLVAML A2 3  
BMRF1 TLDYKPLSV A2 1  
BNLF2b RPGRPLAGFYA B7 1 
Late BALF4 FLDKGTYTL A2 2  
BNRF1 WQWEHIPPA A2 1 
 YPRNPTWQGNI B7 1 
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6.2. Recognition of HLA-A2 presented IE-, E- and L- lytic epitopes on LCLs lacking 
BNLF2a expression 
 
In this section a selection of HLA-A2 positive lab donor shBNLF2a-LCLs (Table 6.1) were 
used to assess the ability of a panel of HLA-A2 restricted T cells to recognise IE (BRLF1), E 
(BMLF1, BMRF1) and L (BALF4, BNRF1) lytic epitopes, in the absence of BNLF2a.  
HLA-A2 positive donor 3 shBNLF2a-LCLs were first used to study the recognition of the 
HLA-A2 restricted IE-YVL (BRLF1), E-GLC (BMLF1) and L-FLD (BALF4) epitopes. 
Figure 6.1 shows a full set of representative data for one CD8
+
 T cell clone per epitope. 
Figure 6.1a shows the raw level of recognition (IFN- release) by each T cell clone, including 
peptide pulsed BZLF1-LCLs to show maximal recognition, and BZLF1-LCL recognition 
as a negative control. In this example, shBNLF2a-LCLs were more highly recognised than 
shNon-target-LCLs, by YVL-, GLC- and FLD- specific T cells. These shBNLF2a-LCLs were 
expressing marginally higher levels of BRLF1-, BMLF1- and BALF4-transcripts, compared 
to that of shNon-target LCLs, as shown in Figure 6.1b. After normalising the level of T cell 
recognition on the level of antigen expression (Fig 6.1c), there was a clear increase in 
recognition of LCLs lacking BNLF2a by each T cell. Notably, the level of increased 
recognition differed between each epitope; recognition of the IE-YVL epitope was increased 
13-fold, E- GLC epitope recognition was increased 9-fold, whereas the increase in recognition 
of L-FLD epitope was less dramatic (2-fold increase).  
To confirm that this finding was not donor specific, the same experiment was carried out 
using different donor target LCLs (donor 4) and a different set of CD8
+
 T cell clones with the 
same specificities as those used in Figure 6.1. As shown in Figure 6.2a, shBNLF2a-LCLs 
were again better recognised by YVL-, GLC-, and FLD-epitope specific T cells (Fig 6.2a). In 
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this example however, shBNLF2a-LCLs were expressing substantially less lytic cycle antigen 
than the shNon-target control LCLs (Fig 6.2b). Although such differences were potentially 
detrimental to the interpretation of data, after normalisation of T cell recognition against 
measured transcript levels for the respective target antigens, the overall pattern of recognition 
of shBNLF2a-LCLs (Fig 6.2c) was remarkably similar to that seen in Figure 6.1c. Again, the 
recognition of YVL- and GLC-epitopes was dramatically increased in the absence of BNLF2a 
(30- and 24-fold respectively), whereas the increase in recognition of the FLD-epitope was 
less dramatic.  
In order to confirm this pattern remained consistent between different donors and other HLA-
A2 restricted T cell specificities, this work then was performed using three further sets of 
donor LCLs. Using donor 5 shBNLF2a-LCLs as targets for the same panel of HLA-A2 
restricted clones used in Figure 6.1, the same pattern of increased recognition following 
normalisation, was seen (Fig 6.3c). This was then extended to use donor 5 and 6 LCLs as 
targets for a slightly different panel of T cells which recognised IE-YVL (BRLF1), E-TLD 
(BMRF1) and L-WQW (BNRF1). As shown in Figure 6.4c and 6.5c, the pattern of increased 
recognition of epitopes derived from antigens which are expressed at the three different stages 
of lytic cycle remains consistent (IE>E>>L). It should be noted that due to BNRF1 expression 
in BZLF1-LCLs, as described in chapter 3, it was not possible to use these LCLs as negative 
controls for WQW specific T cells, for this reason, HLA mismatched LCLs were instead used. 
Finally, a more extensive panel was used to test the recognition of IE-YVL (BRLF1), E-GLC 
(BMLF1), E-TLD (BMRF1) and L-FLD (BALF4) when presented by donor 7 shBNLF2a-
LCLs (Fig 6.6). As shown in Figure 6.6c, the pattern described above remained consistent. 
Indeed, the most dramatic increase in recognition was of IE-YVL and E-GLC/E-TLD 
epitopes with a less dramatic increase in L-FLD epitope recognition. Therefore, despite 
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varying levels of lytic antigen expression, the pattern of increased recognition of different 
lytic cycle antigens (IE>E>>L) was consistent. All presented data, and that data to follow was 
repeated one or two further times, using different clones of the same specificity, if possible. 
Although this could not always be carried out simultaneously, due to limited cell numbers, the 
patterns shown in Figures 6.1-6.6 remained consistent, where the most dramatic increase in 
recognition was of IE- and especially E-epitopes, while the increase in L-epitope recognition 
was marginal, all data obtained during the course of this work is summarised Table 6.3. The 
difference in the magnitude of increase in recognition between donors is likely due to 
experimental variation of donor LCLs and T cells. However, the fact that the observed pattern 
remained consisted confirmed that the above experimental approach was valid and reliable for 
this work. For this reason, only normalised data will be shown for the rest of this chapter.  
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Figure 6.1 Recognition of donor 3 shBNLF2a-LCLs. 
A) Recognition of donor 3 LCLs by a IE-YVL, E-GLC and L-FLD specific CD8
+
 T cell clones. 
Recognition is shown as IFN- (pg/ml) release by T cell. Maximal recognition is shown as recognition 
of peptide sensitised BZLF1 LCLS. (B) Level of IE-BRLF1 (YVL), E-BMLF1 (GLC) and L-BALF4 
(FLD) mRNA transcript in target LCLs used in A. (C) Relative recognition of shBNLF2a-LCLs 
relative to shNon-target-LCLs, after normalisation of IFN- release against transcript level. 
Immediate early-BRLF1 
YVL c113 
Early-BMLF1 
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Figure 6.2 Recognition of donor 4 shBNLF2a-LCLs by HLA-A2 restricted T cell clones.  
A) Recognition of donor 4 LCLs by IE-YVL, E-GLC and L-FLD specific CD8
+
 T cell clones. 
Recognition is shown as IFN- (pg/ml) release. Maximal recognition is measured using peptide pulsed 
BZLF1-LCLs. (B) Level IE-BRLF1 (YVL), E-BMLF1 (GLC) and L-BALF4 (FLD) mRNA 
transcript in target LCLs used in A. C) Relative recognition of shBNLF2a-LCLs relative to shNon-
target-LCLs, after normalisation of IFN- release using transcript level. 
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Figure 6.3. Recognition of donor 5 shBNLF2a-LCLs by HLA-A2 restricted T cell clones. 
A) Recognition of donor 3 LCLs by an IE-YVL, E-GLC and L-FLD specific CD8+ T cell clones. 
Recognition is shown as IFN-g (pg/ml). B) Level of mRNA transcript of IE-BRLF1 (YVL), E-BMLF1 
(GLC) and L-BALF4 (FLD) in target LCLs used in A. C) Relative recognition of shBNLF2a-LCLs 
relative to shNon-target-LCLs, after normalisation of IFN-g release using transcript level. 
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Figure 6.4. Recognition of donor 5 shBNLF2a-LCLs by HLA-A2 restricted T cell clones. 
A) Recognition of donor 3 LCLs by an IE-YVL, E-TLD and L-WQW specific CD8+ T cell clones. 
Recognition is shown as IFN-g (pg/ml) release by T cell. B) Level of mRNA transcript of IE-BRLF1 
(YVL), E-BMRF1 (TLD) and L-BNRF1 (WQW) in target LCLs used in A. C) Relative recognition of 
shBNLF2a-LCLs relative to shNon-target-LCLs, after normalisation of IFN-g release using transcript 
level. 
B C 
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Figure 6.5. Recognition of donor 6 shBNLF2a-LCLs by HLA-A2 restricted CD8+ T cells  
A) Recognition of donor 3 LCLs by an IE-YVL, E-TLD and L-WQW specific CD8+T cell clones. 
Recognition is shown as IFN-g (pg/ml) release by T cell. (B) Level of mRNA transcript of IE-BRLF1 
(YVL), E-BMRF1 (TLD) and L-BNRF1 (WQW) in target LCLs used in A. (C) Relative recognition 
of shBNLF2a-LCLs relative to shNon-target-LCLs, after normalisation of IFN-g release using 
transcript level. 
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Figure 6.6. Recognition of donor 7 shBNLF2a-LCLs by HLA-A2 restricted CD8+ T cell 
clones. 
A) Recognition of donor 7 LCLs by an IE-YVL, E-GLC, E-TLD and L-FLD specific CD8+T cell 
clones. Recognition is shown as IFN-g (pg/ml) release by T cell. (B) Level of mRNA transcript of IE-
BRLF1 (YVL), E-BMRF1 (TLD) and L-BNRF1 (WQW) in target LCLs used in A. (C) Relative 
recognition of shBNLF2a-LCLs relative to shNon-target-LCLs, after normalisation of IFN-g release 
using transcript level. 
mRNA transcript level 
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6.2.1. Recognition of HLA-B7 presented immediate early, early and late lytic antigens in 
the absence of BNLF2a expression 
 
Next, the possibility that the inhibition of antigen processing by BNLF2a may be confined to 
HLA-A2 molecules was addressed. Although this was unlikely as BNLF2a acts upon the TAP 
transporter, and thus is unlikely to target certain HLA molecules, it was still interesting to 
determine if the above pattern remained consistent when investigating the effects of BNLF2a 
knockdown on the recognition of epitopes presented by HLA-B7 molecules. To do this, a 
panel of HLA-B7 restricted CD8
+
 T cell clones (Table 6.2) which recognise the IE-DPY 
(BZLF1), the E-RPG (BNLF2b) and the L-YPR (BNRF1) epitopes were used as effector cells 
against a selection of HLA-B7 positive shBILF1-LCLs.  
Using donor 3 and 8 shBNLF2a-LCLs, as shown in Figure 6.7, the pattern of increased 
recognition in the absence of BNLF2a was similar to that seen when using HLA-A2 restricted 
effector T cells. Again, recognition of the IE (DPY) and E (RGP) epitopes was increased 
more dramatically than that of a L (YPR) epitope.  
In summary, using a panel of HLA-A2 restricted T cells against 5 different sets of donor 
LCLs and a panel of HLA-B7 restricted T cells against 2 different sets of donor LCLs, as well 
as experiments carried out using partial panels of T cells, antigen presentation was found to be 
increased in the absence of BNLF2a for IE, E and L antigens. The extent of this increase 
differed, whereby more dramatic increases were seen for IE epitopes, less dramatic for E 
antigens and less again for L epitopes, as summarised in Table 6.3 is in agreement with data 
presented in chapter 4, and together these data suggest that at the IE and E phase of lytic 
cycle, BNLF2a plays a strong role in interfering with antigen presentation, and at the L phase, 
BNLF2a is likely playing a lesser role. This finding implies that at the L stages of lytic cycle, 
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when EBV has been found to be highly protected against CD8
+
 T cell recognition, other 
immune evasion mechanisms must be active and functional.  
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Figure 6.7 Normalised relative recognition of donor 3 and 8 shBNLF2a-LCLs by a panel 
of HLA-B7 restricted CD8+ T cell clones specific for the IE-, E- and L-lytic epitopes.  
(A) Relative recognition of donor 3 HLA-B7 positive shBNLF2a-LCLs, compared to shNon-target 
LCLs, by HLA-B7 restricted T cells specific for the IE-DPY (BZLF1), E- RPG (BNLF2b) and L-YPR 
(BNRF1) epitopes. (B) Relative recognition of donor 8 HLA-B7 positive shBNLF2a-LCLs compared 
to shNon-target LCLs, by HLA-B7 restricted T cells specific for the IE-DPY (BZLF1), E- RPG 
(BNLF2b) and L-YPR (BNRF1) epitopes.  
  
Donor 3  
A B 
Donor 8  
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Table 6.3 Summary of fold increase in CD8
+
 T cell recognition of IE-, E-, and L-antigens when 
presented by shBNLF2a-LCLs compared to shNon-target-LCLs 
 
 
    Fold increase 
Phase of 
expression 
EBV 
protein 
Epitope HLA 
restriction 
No. of 
expts* 
Range Median 
Immediate 
early 
BRLF1 YVL A2 11 6.5-30.7 17 
 BZLF1 DPY B7 4 7-14 8.3 
 
Early BMLF1 
 
GLC A2 10 7-24 11.5 
 BMRF1 
 
TLD A2 5 7.5-12 9 
 BNLF2b 
 
 
RPG B7 4 4.1-7 5.5 
 
Late BALF4 
 
FLD A2 11 2-5 2.3 
 BNRF1 WQW A2 4 2.3-3 2.5 
 YPR B7 4 2-3.5 2.5 
 
*More than one effector clone was used where possible (see Table 6.2). In total 7 different 
donor LCLs were used. 
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6.3. Recognition of HLA-A2 presented IE, E and L lytic epitopes presented by LCLs 
lacking BILF1 expression 
 
Next, the effect of BILF1 on antigen presentation during lytic cycle was investigated using 
similar experiments to above. To this end, a selection of lab donor shBILF1-LCLs (Table 6.1) 
were used as targets for the panels of HLA-A2 restricted CD8
+
 T cell clones outlined in Table 
6.2. 
This was first carried using donor 1 and 3 HLA-A2 positive shBILF1-LCLs as targets for two 
different sets of HLA-A2 restricted T cells specific for IE-YVL (BRLF1), E-GLC (BMLF1) 
and L-FLD (BALF4) epitopes. A representative example of these results, for one clone per 
epitope, is shown in Figure 6.7a and b. In these particular examples, the recognition of E-GLC 
and L-FLD epitopes was clearly increased in the absence of BILF1, compared to recognition 
of shNon-target counterparts, where clearly the increase of L-FLD recognition was more 
dramatic. In contrast, the increase in recognition of the IE-YVL epitope was minimal.  
This was then repeated using donor 5, 6 and 7 shBILF1-LCLs as targets for a more extensive 
panel of HLA-A2 restricted T cells which recognised IE-YVL, E-GLC or E-TLD, and L-FLD 
and/or L-WQW epitopes. In each representative example, the lack of BILF1 expression 
resulted in an increase in recognition of the E-epitopes TLD (Fig 6.8 d,f) and GLC (Fig 
6.8c,e), and a more striking increase in recognition of L-FLD (Fig 6.8c,e,f) and L-WQW (Fig 
6.8d,e) epitopes. In all examples, there was a minimal increase in recognition of the IE-YVL 
epitope. Clearly, the pattern of increased recognition of different lytic cycle epitopes in the 
absence of BILF1 is in contrast to that of BNLF2a. The pattern of increased recognition of 
epitopes when BILF1 was not expressed shows increased recognition of E epitopes, a more 
exaggerated increase in recognition of L epitopes, and minimal increases in recognition of IE 
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epitopes (IE<E<<L). This pattern remained consistent upon repeating the examples shown 
and when using shBILF1-LCLs as targets for partial panels of HLA-A2 restricted T cells, as 
summarised in Table 6.7. 
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Figure 6.8. Normalised relative recognition of shBILF1-LCLs, by a panel of HLA-A2 
restricted CD8+ T cells. 
 (A,B) Relative recognition of donor 3 and 2 shBILF1-LCLs by IE-YVL (BRLF1), E-GLC (BMLF1) 
and L-FLD (BALF4) specific T cells. (C) Relative recognition of donor 7 shBILF1-LCLs by IE-YVL 
(BRLF1), E-TLD (BMRF1) and L-FLD (BALF4) specific T cells. (D) Relative recognition of donor 6 
shBILF1-LCLs by a panel IE-YVL (BRLF1), E-GLC (BMLF1), L-FLD (BALF4) and the L-WQW 
(BNRF1) specific T cells. (E,F) Relative recognition of donor 5 shBILF1 LCLs IE-YVL (BRLF1), E-
GLC (BMLF1) and L-FLD (BALF4) (C) and, in a separate experiment, IE-YVL (BRLF1), E-TLD 
(BMRF1) and LWQW (BNRF1) epitopes.  
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6.3.1. Recognition of HLA-B7 presented IE, E and L lytic epitopes in shBILF1-LCLs 
 
As it is perhaps more likely that BILF1 could target specific HLA molecules, given that it 
interacts directly with MHC class I molecules, recognition of IE, E and L epitopes presented 
by HLA-B7 molecules was investigated. To do this, HLA-B7 positive shBILF1-LCLs were 
used as targets for a panel of HLA-B7 restricted T cells. These T cells recognised the IE-DPY 
(BZLF1), the E-RPG (BNLF2b) and the L-YPR (BNRF1) epitopes. Representative examples 
of these results, from two donors, for one T cell clone per epitope, are shown in Figure 6.9. 
Using donor 3 shBILF1 LCLs (Fig 6.9a), that was also used in Figure 6.8b, and donor 8 
shBILF1-LCLs (Fig 6.9b); there was an increase in recognition of E-RPG epitope, and a more 
exaggerated increase in recognition of L-YPR epitope. In a similar pattern to that described 
for the effect of BILF1 knockdown on recognition by HLA-A2 restricted T cells, the increase 
in recognition of IE-DPY epitope was minimal. This pattern is similar to that observed for 
HLA-A2 epitope recognition. These data show that the effect of BILF1 on antigen 
presentation is not confined to HLA-A2 restricted epitopes.  
As described previously, although the individual examples of results shown in Figures 6.8 and 
6.9 were carried out using one set of donor shBILF1-LCLs as targets for the panel of T cells 
indicated, this was not always possible when trying to repeat these experiments. This was due 
to limiting cell numbers and as a result of this, partial panels of HLA-A2 or HLA-B7 
restricted T cells had to be used when using complete T cell panels was not feasible. A 
summary Table of all completed experiments and the fold increase in recognition seen for all 
HLA-A2 and HLA-B7 T cells is shown in Table 6.4. Taken together, these data suggest that 
BILF1 plays a strong role in interfering with the presentation of antigens during the E and L 
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phases of lytic cycle, with its strongest effect being at the L-phase, while its effect at the IE-
phase is relatively weak.  
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Figure 6.9 Relative recognition of donor 3 and 8 shBILF1-LCLs by a panel of HLA-B7 
restricted CD8+ T cell clones.  
(A) Relative recognition of donor 3 shBILF1-LCLs, compared to shNon-target LCLs, by HLA-B7 
restricted T cells specific for the IE-DPY (BZLF1), E- RPG (BNLF2b) and L-YPR (BNRF1) epitopes. 
(B) Relative recognition of donor 8 HLA-B7 positive shBILF1-LCLs compared to shNon-target 
LCLs, by HLA-B7 restricted T cells specific for the IE-DPY (BZLF1), E- RPG (BNLF2b) and L-YPR 
(BNRF1) epitopes.  
  
Donor 3 Donor 8  A B 
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Table 6.4 Summary of fold increase in CD8+ T cell recognition of IE-, E-, and L-epitopes when 
presented by shBILF1-LCLs compared to shNon-target-LCLs 
 
     Fold increase 
Phase of 
expression 
EBV 
protein 
Epitope HLA 
restriction 
No. of 
expts* 
Range Median 
 
Immediate 
early 
BRLF1 
 
YVL A2 10 No increase-2.5 
 
1.9 
BZLF1 
 
DPY B7 4 1.2-1.8 1.7 
 
 
Early 
BMLF1 
 
GLC A2 8 7-11 9.1 
BMRF1 
 
TLD A2 5 3.2-10 6 
BNLF2b 
 
RPG B7 4 4.5-7 6 
 
 
 
Late 
BALF4 
 
FLD A2 8 10-25 13.5 
BNRF1 WQW A2 4 5.7-16 12.2 
YPR B7 4 9-23 11.3 
 
*More than one effector clone was used where possible (see table 6.2). In total 6 different 
donor LCLs were used. 
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6.4. Recognition of shBGLF5 LCLs by HLA-A2 and HLA-B7 restricted T cells 
specific for IE, E and L lytic epitopes 
 
Next the role that BGLF5 plays in interfering with antigen presentation during the three 
different phases of lytic cycle was investigated. These sets of experiments were more 
problematic due to the nature of shBGLF5-LCLs. These LCLs did not survive for longer than 
three weeks following transduction, thus the ability to simultaneously examine the recognition 
of shBGLF5-LCLs by our panels of HLA-A2 or HLA-B7 T cells was rarely possible. This 
meant that most experiments were carried using a partial panel of HLA-A2 or B7 restricted T 
cells (summarised in Table 6.5). Despite this, it was possible to assess the recognition of two 
sets of donor shBGLF5-LCLs using a panel of HLA-A2 T cells specific for; IE-YVL; E-GLC; 
and L-FLD or L-WQW epitopes. As shown in Figure 6.10a and b, there was minimal 
increased recognition of IE-, E- and L-epitopes in LCLs lacking BGLF5 expression, 
compared to their shNon-target LCL counterparts.  Although there appeared to be a more 
dramatic increase in recognition of the L-WQW epitope (Fig 6.10b), this pattern was not 
consistent when repeated. Although, as mentioned, using complete panels of HLA-A2 
restricted T cells was not always possible, numerous experiments were carried out using 
partial panels of HLA-A2 restricted T cells and, as shown in Table 6.5, this pattern of minimal 
effect of increased recognition in the absence of BGLF5 expression was reproducible. 
To determine if the observed minimal effect of BGLF5 knockdown on T cell recognition was 
a HLA-A2 phenomenon, the effect that knocking down BGLF5 had on recognition by HLA-
B7 T cells was investigated. Unfortunately, due to the technical difficulties described above, 
only one complete set was generated using donor 3 shBGLF5 LCLs (Fig 6.10c). In this 
example, the increase in recognition of IE-DPY, E-RPG and L-YPR epitopes was not more 
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than 2.5-fold above shNon-target LCLs. This pattern is almost identical to that seen for the 
HLA-A2 restricted T cell recognition of shBGLF5-LCLs (Fig 10a,b). Following repeats of 
these experiments, it was clear that the lack of BGLF5 expression consistently showed 
minimal effects on increasing recognition of IE- E- and L- epitopes, as summarised in Table 
6.5 
Overall, these findings suggest that BGLF5 plays a minimal role in interfering with antigen 
presentation at all three stages of EBVs lytic cycle. In some cases there was no effect of 
BGLF5 knockdown on increasing epitope recognition and in other others, there was a 
minimal increase in recognition. However, this should be taken with the caveat that these 
assays were complicated by the fact that shBGLF5-LCLs were more difficult to work with 
than shBNLF2a- and shBILF1-LCLs. It is also important to note that the lack of phenotypic 
effect of BGLF5 knockdown could be due to the activity of any residual BGLF5 expression in 
the low number of LCLs entering lytic cycle. However, the above data is consistent with data 
accumulated using BGLF5 knockout LCLs, as described in chapter 4, thus the above 
phenotypic effects of BGLF5 knockdown on T cell recognition are likely a true reflection of 
the effect of BGLF5 knockdown.  
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Figure 6.10. Normalised relative recognition of donor 5, 6 and 3 shBGLF5-LCLs by 
HLA-A2 and HLA-B7 restricted CD8+ T cell clones.  
(A) Relative recognition of donor 5 shBGLF5-LCLs, compared to shNon-target-LCLs, by a panel of 
HLA-A2 restricted CD8+ T cells specific for IE-YVL (BRLF1), E-GLC (BMLF1) and L-FLD 
(BALF4) epitopes. (B) Relative recognition of donor 6 shBGLF5-LCLs, compared to shNon-target-
LCLs, by a panel of HLA-A2 restricted CD8
+
 T cells specific for IE-YVL (BRLF1), E-GLC (BMLF1) 
and L-WQW (BNRF1) epitopes. (C) Relative recognition of donor 3 HLA-B7 positive shBGLF5-
LCLs, compared to shNon-target LCLs, by HLA-B7 restricted T cells specific for the IE-DPY 
(BZLF1), E- RPG (BNLF2b) and L-YPR (BNRF1) epitopes.  
  
Donor 5  Donor 6  
A B 
Donor 3  C 
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Table 6.5 Summary of fold increase in CD8+ T cell recognition of IE-, E-, and L-epitopes when 
presented by shBGLF5-LCLs compared to shNon-target-LCLs 
     Fold increase 
Phase of 
expression 
EBV 
protein 
Epitope HLA 
restriction 
No. of 
expts* 
Range Median 
 
Immediate 
early 
BRLF1 YVL A2 10 No Increase-2.5 1.3 
 
 
BZLF1 DPY B7 2 1.1-1.4 1.2 
 
 
Early 
BMLF1 
 
GLC A2 8 No Increase-4 1.6 
BMRF1 
 
TLD A2 3 1.4-1.7 1.5 
BNLF2b RPG B7 2 1.9-2.2 2 
 
 
Late 
BALF4 
 
FLD A2 4 1.5-3 1.8 
BNRF1 WQW A2 3 1.9-4.3 2.6 
YPR B7 3 1.5-1.9 1.9 
 
 
*More than one effector clone was used where possible (see Table 6.2). In total 6 different 
donor LCLs were used. 
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6.5. Assessing the effect of BNLF2a, BILF1 and BGLF5, in parallel, on recognition 
of HLA-A2 presented IE- E- and L-epitopes 
 
The data shown in the preceding sections (6.2-6.4) provide a clear indication of the relative 
effects of each candidate immune evasion gene on recognition of epitopes at different stages 
of lytic cycle. However, as the effects of BNLF2a, BILF1 and BGLF5 were examined in 
separate experiments, the magnitude of the effects relative to one other cannot be ascertained 
with confidence. To this end, whilst technically challenging, the following set of experiments 
were performed in order to investigate in a single experiment the relative effects of BNLF2a, 
BILF1 and BGLF5 on recognition of IE, E and L lytic epitopes. 
This was done by generating donor 5 shBNLF2a-, shBILF1- and shBGLF5- and shNon-
target- LCLs, and measuring the relative recognition of these LCLs, in parallel, by a panel of 
HLA-A2 restricted CD8
+
 T cells. In the representative example shown in Figure 6.11, those 
clones used recognised the IE-YVL (BRLF1), E-GLC (BMLF1) and L-FLD (BALF4) 
epitopes. After normalisation on the expression of BRLF1, BMLF1 and BALF4, the patterns 
of increased recognition remained similar to the previous findings. LCLs lacking BNLF2a 
were better recognised by IE- and E-specific T cells (15- and 10-fold respectively), whereas 
the increased recognition in L-epitopes was minimal. In contrast, those LCLs lacking BILF1 
expression were better recognised by E- and L-epitope specific T cells (6- and 12-fold 
respectively), where the most dramatic effect is seen in the recognition of L-FLD and finally, 
LCLs lacking in BGLF5 expression showed a small level of increased recognition of E- and 
L-epitopes. Unfortunately, the level of BRLF1 expression by shBGLF5-LCLs was 
insufficient for T cell recognition, thus, a result could not be determined here.  
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Relatively speaking, this result suggests that at the IE phase of lytic cycle, BNLF2a plays the 
most dominant role in interfering with antigen presentation, while BILF1 plays a small role. 
At the E phase of lytic cycle, both BILF1 and BNLF2a appear to play strong roles, where 
BNLF2a is possibly more dominant and finally at L phase lytic cycle; BILF1 plays a more 
dominant role, while BNLF2a contributes a small effect. In contrast, BGLF5 appears to 
contribute little or no effect at any phase of lytic cycle. However, it should be noted that this 
could not be repeated in other donors, due to the unreliability of transduced shBGLF5 
transduced LCLS, where some were no longer lytic, or did not expand to a high enough 
number for use. Nevertheless, these data are consistent with the conclusion that BNLF2a and 
BILF1 are the predominant effectors of immune evasion and that BNLF2a plays a decreasing 
role as lytic cycle progresses, while BILF1 plays an increasing role. 
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Figure 6.11 Direct comparisons of the relative effects of BILF1, BNLF2a and BGLF5 on 
recognition of IE-, E-, and L-epitopes by HLA-A2 restricted T cells specific for IE-YVL 
(BRLF1), E-GLC (BMLF1) and L-FLD (BALF4).  
Recognition of epitopes presented by each LCL was measured simultaneously. T cell recognition 
(IFN-g release) was then normalised on the expression of each appropriate mRNA transcript. Data is 
shown as recognition of knockdown LCLs relative to shNon-target LCLs.  
*ND-Expression levels of target antigen were not sufficient in shBGLF5-LCLs. No result was seen. 
  
Donor 5  
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6.6. Correlation of epitope recognition with lytic cycle expression 
 
The above results are perhaps surprising since it has previously been reported that BNLF2a is 
expressed as an E lytic gene, therefore the strong effect it has on IE-epitope presentation is 
unexpected. In order to determine if we could explain the patterns of effect that BNLF2a, 
BILF1 and BGLF5 have on antigen presentation during lytic cycle, we next measured the 
kinetics of expression of these genes in cells undergoing synchronous lytic cycle. To do this, 
an EBV-infected cell line known as Akata was used. Akata cells can be efficiently and 
synchronously induced into lytic cycle by ligation of surface IgG (Takada and Ono 1989). 
Following induction, gene expression was measured at successive time points.   
The expression kinetics of the IE gene BZLF1, E gene BMRF1 and L gene BALF4 were 
measured, alongside that of BNLF2a, BILF1 and BGLF5. RNA samples were harvested at 
time points 0-48 hours post induction. cDNA was then generated and qRT-PCR analysis was 
used to assess the relative levels of transcription of each gene at each time point. Figure 6.12 
shows a representative example of hours post induction plotted against the level of transcript 
expressed as a percentage of their maximum, the timing of each phase of lytic cycle is also 
indicated.  
As shown in Figure 6.12b, the expression of BNLF2a was first detected at 2 hours post-
induction. This is almost the same time at which BZLF1 is first detected (Fig 6.12a). BNLF2a 
expression then steadily increases and peaks at the E time point of 12 hours, decreasing 
thereafter. Thus, although BNLF2a is considered an E expressed lytic gene, it is clearly 
expressed, to up to 73% of its maximum level of expression, during IE-phase lytic cycle. It is 
therefore unsurprising that it is most effective at interfering with antigen presentation during 
IE and E phase lytic cycle, when its expression is at its highest. Notably, the expression of 
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BNLF2a transcript remains high, at 73% during L-stage lytic cycle, yet does not have a strong 
effect on antigen presentation at this phase. This is due to a rapid decrease in protein 
expression after 12 hours post transduction. In fact, BNLF2a protein expression is almost 
undetectable by 24-48 hours post induction (data not shown), indicating that this level of 
transcript is not directly proportional to the level of protein expression, explaining why 
despite high levels of transcript, there is little phenotypic effect of BNLF2a.  
The pattern of BILF1 transcript expression is slightly different, in that the initial expression of 
BILF1 is detected later than BNLF2a, at around 4-hours post-induction (Fig 6.12b), which is 
in the E phase of lytic cycle, as indicated by the expression of BMRF1 (Fig 6.12b). BILF1 
expression then rapidly increases and peaks at 8 hours, declining thereafter. This would 
explain why BILF1 has a subtle effect on the presentation of IE-lytic epitopes and a stronger 
affect on E-lytic epitope presentation. Interestingly, the expression of BILF1 transcript 
declines to 77% by 24 hours, and continues to decrease beyond this time. Given that lytic 
cycle can last for up to 4 days, this is perhaps surprising, since it is at the L-phase of lytic 
cycle when BILF1 appears to exert its strongest effect. Presumably, this level of transcript 
translates into relatively high levels of protein, which is active and functional during the late 
phase of lytic cycle. Unfortunately, the lack of available anti-BILF1 antibody means this 
cannot be confirmed. However, the obvious phenotypic effect that knocking down BILF1 has 
on presentation of L-lytic epitopes means that it can be confidently assumed that this is the 
case. 
The kinetics of BGLF5 expression is perhaps more surprising. BGLF5 transcript can be 
detected at the same time as BILF1, after which it increases, peaking during L phase lytic 
cycle, at 24 hours. Thus, it would be expected that its immune evasion function would be 
active during the E-phase of lytic cycle and more so at the L phase. However, the data 
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presented in the above sections suggest this is not the case. This could perhaps be because the 
effect of BGLF5 on antigen presentation, in the context of whole virus infection is minimal 
throughout lytic cycle. 
Taken together these data suggest that the roles that BNLF2a and BILF1 play in interfering 
with antigen presentation are perhaps a consequence of their timings of expression. However, 
the minimal effect of BGLF5 throughout lytic cycle cannot be explained in this way, this is 
perhaps a consequence of a weak immune evasion function of BGLF5, compared to BILF1 
and BNLF2a. It would be an advantage to assess the kinetics of BNLF2a, BILF1 and BGLF5 
protein expression; however, due to the lack of suitable BILF1 antibody this is not possible.  
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Figure 6. 12 Expression kinetics of EBV lytic cycle. 
EBV infected cells (AKATA) were induced into lytic cycle. RNA was harvested at the indicated time 
points and cDNA was then synthesised followed by qRT-PCR analysis to detect the expression of (A) 
IE-BZLF1, E-BMRF1 and L-BALF4 genes and (B) BNLF2a, BILF1 and BGLF5 genes. Samples were 
tested in duplicate and normalised to cellular GAPDH. Data is expressed as the relative number of 
transcripts as percentage of the maximum for each gene.  
A) 
B) 
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6.7. Assessment of co-operation or redundancy of BNLF2a and BILF1 using dual 
knockdown of BILF1 and BNLF2a-LCLs  
 
Finally, to ascertain if there was any co-operation or redundancy between BNLF2a and BILF1 
at the IE- and L- phases of lytic cycle, double knockdown-LCLs were used as targets for IE- 
and L-antigen specific T cells. To do this, donor LCLs in which both BNLF2a and BILF1 had 
been silenced using shRNA-lentiviruses, were generated. The recognition of these double 
knockdown LCLs by IE- or L-epitope specific HLA-A2 restricted T cells was then assessed, 
alongside the recognition of their shBNLF2a-, shBILF1- and shNon-target-LCL counterparts.  
In order to treat all cells in the same way, LCLs were transduced with two lentiviruses; 
shBNLF2a and shNon-target; shBILF1 and shNon-target; shNon-target and shNon-target or; 
shBNLF2a and shBILF1. It was determined that the best way to generate these double 
knockdown LCLs was to transduce with one virus, sort the cells on the basis of their 
expressed fluorescence tags, and then transduce with the second appropriate virus. This 
strategy was technically challenging and was only successful using two sets of donor LCLs.  
Using donor 7 and 8 LCLs, we first investigated the recognition of the HLA-A2 restricted IE-
YVL (BRLF1) epitope. As shown in Figure 6.13, using two different IE-YVL epitope specific 
T cells, the recognition of shBILF1- and shBNLF2a-LCLs fits the pattern discussed 
previously, where there was slight increase in recognition of shBILF1-LCLs, by both clones, 
and a more substantial increase in the recognition of YVL presented by shBNLF2a-LCLs (Fig 
6.13a,b). Interestingly, there was a more dramatic increase in recognition of YVL presented 
by LCLs lacking in both BILF1 and BNLF2a. This suggests that BNLF2a and BILF1 
synergise in their interfering with antigen presentation during the IE phase of lytic cycle, since 
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the increased recognition of the double knockdown is more dramatic than the sum of the two 
single knockdowns.  
These same donor LCLs were then used in a separate experiment in order to assess the level 
of co-operation or redundancy between BILF1 and BNLF2a during L phase lytic cycle. In the 
representative examples shown in Figure 6.13c and d, the pattern of recognition of single 
knockdown shBILF1- and shBNLF2a-LCLs was again as expected, where L-FLD is better 
recognised when presented by shBILF1-LCLs, compared to shBNLF2a-LCLs.  As noted 
previously, as with the recognition by IE- specific effectors, the simultaneous knockdown of 
both BILF1 and BNLF2a resulted in a more dramatic increase in recognition of the L-FLD 
(Fig 6.13c and d) epitope. This suggests that at L-phase lytic cycle BILF1 and BNLF2a may 
co-operate or indeed synergise, albeit to a lesser extent than at the IE phase.  
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Figure 6.13 Relative recognition of LCLs lacking in both BNLF2a and BILF1 expression 
by an IE-YVL (BRLF1) and a L-FLD (BALF4) specific, HLA-A2 restricted CD8+ T cell 
clones.  
A,B) Recognition of IE-YVL presented by donor 8 and 7 LCLs was measured simultaneously. T cell 
recognition (IFN-g release) was then normalised on the expression of BRLF1 mRNA transcript. Data 
is shown as recognition of knockdown LCLs relative to shNon-target LCLs.(C,D) Recognition of L-
FLD presented by each donor 8 and 7 LCLs was measured simultaneously. T cell recognition (IFN-g 
release) was then normalised on the expression of BRLF1 mRNA transcript. Data is shown as 
recognition of knockdown LCLs relative to shNon-target LCLs.  
A 
Donor 8  
Donor 7  
Donor 8  
Donor 7  
B 
C D 
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6.8. Discussion 
 
Experimental approach 
This chapter utilised shBNLF2a-, shBILF1 and shBGLF5-LCLs, generated in chapter 5, to 
assess the roles that the immune evasion proteins BNLF2a, BILF1 and BGLF5 play in 
interfering with antigen presentation to CD8
+
 T cells during EBV lytic cycle. These LCLs, 
which were spontaneously reactivating in to lytic cycle, were used as target populations, 
alongside their shNon-target-LCLs counterparts, in CD8
+
 T cell recognition experiments. In 
the first instance this was carried out in separate experiments using single knockdown LCLs, 
to compare the effect that knockdown had on epitope recognition. Following this, single 
knockdown LCLs were used in parallel, in the same experiment, to allow for a direct 
comparison of the effects of these immune evasion mechanisms on lytic epitope presentation. 
Finally, to investigate the possible co-operation or redundancy between BILF1 and BNLF2a, 
dual knockdown LCLs were generated. In order to minimise any experimental variation, the 
ability of IE-, E- and L-epitope specific T cells to recognise target LCLs was done in parallel, 
where possible. 
Although the above experimental approach was valid, since results were consistent and any 
differences in lytic antigen expression by LCLs did not affect the observed pattern, it did pose 
technical challenges that limited the number of complete experiments that could be 
performed. Most often this was due to the fact that transduced LCLs could not be cultured for 
long periods of time, meaning that T cell assays had to be performed shortly after 
transduction, which meant that cell numbers became the limiting factor. 
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Immediate early and early epitopes are better presented by LCLs which lack BNLF2a 
expression 
The data accumulated within the first section of this chapter (section 6.2) show that there is a 
clear increase in CD8
+
 T cell recognition of IE and E lytic epitopes when presented by LCLs 
lacking BNLF2a (shBNLF2a-LCLs), compared to their shNon-target-LCL counterparts. This 
implies that BNLF2a functions to protect these epitopes from presentation to CD8
+
 T cells. 
This increase in recognition remained consistent across a range of epitopes and HLA class I 
alleles, although the magnitude of increase for each epitope differed between donors. 
The increased recognition of the IE epitopes YVL (BRLF1) and DPY (BZLF1) was 
consistently more dramatic than the increase seen for E- and L-epitopes, in the same 
experiment (with the exception of one donor). However, IE-YVL recognition was increased 
6.5-30.7 fold, in the absence of BNLF2a (Table 6.3), while the increased recognition in DPY 
ranged from 7-14 fold. This difference in magnitude may be due to the fact that BZLF1, from 
which the DPY epitope originates, is expressed earlier than BRLF1 and thus even earlier than 
BNLF2a, therefore the ability of BNLF2a to interfere with DPY epitope presentation may be 
diminished. However, this cannot be drawn as a firm conclusion due to variations in the 
magnitude of increasing recognition between donors (discussed below). 
Recognition of E epitopes in the absence of BNLF2a was also substantially increased across a 
range of donors, using both HLA-A2 and HLA-B7 restricted T cells. The epitopes 
investigated here included GLC (BMLF1) and TLD (BMRF1), both restricted through HLA-
A2 and RPG (BNLF2b), restricted through HLA-B7. In these experiments, the recognition of 
GLC and TLD was seen to be highly increased (7-24 fold and 7.5-12 fold respectively) in the 
absence of BNLF2a. Although these magnitudes vary, the increase in E-epitope recognition, 
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within the same donor, was consistently less than the increase seen in IE-epitope recognition, 
with the exception of one example (Fig 6.3B). However, the range of increase in recognition 
of RPG (BNLF2) was smaller (4.1-7 fold). This is likely due to a problem with the 
experimental approach taken, BNLF2b expression is driven from the same transcript as 
BNLF2a, and although the shRNA used in this work was specific for BNLF2a transcript, it 
became apparent that the expression of BNLF2b was also decreased in shBNLF2a-LCLs, 
albeit to a lesser extent than BNLF2a. Therefore, it is likely that we are underestimating the 
effect of BNLF2a on interfering with the presentation of BNLF2b-RPG epitope. Ideally a 
different method of gene silencing or deletion would be used, however, due to time 
constraints, this was not feasible.  
Recognition of late epitopes, which included the HLA-A2 presented FLD (BALF4) and 
WQW (BNRF1) epitopes and the HLA-B7 presented YRP (BNRF1) epitope, were 
consistently marginally increased in the absence of BNLF2a (2-5 fold increases).   
The differences in magnitude of recognition between donors is likely due to differences in 
epitope display levels by different donor LCLs and differences between T cell clone avidity 
on different days. Although it should be noted, that the avidity of the different T cell clones 
used tended to be similar and since in each case, increased recognition was compared to 
control transduced cell, any differences in T cell affinity was somewhat controlled for. The 
apparent differences in donor LCL epitope presentation and T cell avidity is the reason we 
attempted to carry out T cell recognition of epitopes expressed at the different phases 
simultaneously, although this was not always possible.  
Finally, the peptide sequence may play a role in the sensitivity of epitopes to BNLF2a action. 
A panel of EBV specific epitopes have been identified as TAP-dependant or TAP-
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independent, according to their level of hydrophobicity (Lautscham et al., 2001; Lautscham et 
al., 2003; Lautscham et al., 2003). This was assessed using a TAP negative cell line (T2-cells) 
and thus it cannot be ruled out that the TAP-independent epitopes may preferentially use TAP 
under normal conditions and are only TAP-independent in the absence of TAP. YVL and 
GLC are hydrophobic and have been identified as TAP-independent and therefore would be 
expected to be less affected by the action of BNLF2a (Table 6.6). However, given those 
results outlined in the present study, these epitopes were dramatically affected by the 
knockdown of BNLF2a. Also, TLD has been identified as a TAP-dependant epitope, thus we 
would expect this to be highly affected by the knockdown of BNLF2a, however the range in 
fold increase in recognition of TLD was similar to that observed for GLC. Therefore it is not 
possible to predict the effect BNLF2a will have on epitopes according to their TAP 
dependence.  
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Table 6.6. TAP dependency and hydrophobicity of peptide-epitopes used. 
Antigen Peptide HLA 
restriction 
Hydrophobicity 
(%)*  
TAP 
dependency 
Reference 
BRLF1 YVLDHLIVV 
 
A2 78  Independent Lautscham et al. 
2001 
BMLF1 GLCTLVAML 
 
A2 78  
 
Independent Lautscham et al. 
2001 
BMRF1 TLDYKPLSV 
 
A2 44 
 
Dependent Lautscham et al. 
2001 
BALF4 FLDKGTYTL 
 
A2 44 
 
Unknown N/A 
BNRF1 WQWEHIPPA 
 
A2 44  
 
Unknown N/A 
BZLF1 DPYQVPFVQAF 
 
B7 55   
 
Unknown N/A 
BNLF2b RPGRPLAGFYA 
 
B7 45  
 
Unknown N/A 
BNRF1 YPRNPTWQGNI 
 
B7 27 
 
Unknown N/A 
*Hydrophobicity was calculated using software available at http://lifetein.com/peptide-
analysis-tool.html.  
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Although the magnitude of increased recognition varied between donors, the pattern of 
BNLF2a knockdown effect on recognition remained consistent. In all cases, with the 
exception of one, the recognition of IE-epitopes was most dramatically increased; E-epitope 
recognition was substantially increased, albeit to a lesser extent than IE and; increases in L-
epitope recognition was minimal in all cases.  
This finding is perhaps surprising since BNLF2a is designated as an early expressed lytic 
gene. To address this, the kinetics of lytic gene expression was assessed using EBV infected 
cells which could be induced into synchronous lytic cycle. This revealed that although 
BNLF2a is classified as an E lytic cycle gene is initially expressed during the IE phase of lytic 
cycle, which is perhaps the reason it has a strong effect on antigen presentation at the IE phase 
of lytic cycle. In addition, although the transcript levels of BNLF2a remain relatively high 
during late phase lytic cycle, the protein expression of BNLF2a after 24-hours post induction 
is dramatically decreased, which explains why it has only a marginal effect on L epitope 
presentation.  
 
Early and late epitopes are better presented by LCLs lacking in BILF1 expression  
In the next section we set out to assess the role BILF1 plays in interfering with antigen 
presentation during lytic cycle. Using the same experimental approach as above, the pattern in 
increased recognition in the absence of BILF1 was different to that of BNLF2a. In all 
examples shown, there was a minimal increase in recognition of IE-epitopes presented by 
LCLs lacking BILF1 compared to their shNon-target-LCL counterparts (0-2.5 fold increase), 
a more notable increase in recognition of E-epitopes (3.2-11 fold) and a more dramatic 
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increase in recognition of L-epitopes (5.7-25). This pattern remained consistent using both 
HLA-A2 and HLA-B7 panels of T cells and across a selection of donor LCLs.  
Again, there were differences in the magnitudes of increases between different donor LCLs, 
for those reasons described earlier. Within the HLA-B7 assays which were performed, the 
increase in recognition of the E-RPG (BNRF1) epitope, compared to that of the L-YPR 
(BNRF1) was a more dramatic difference, perhaps due to the fact that BNLF2b is expressed 
very early in E lytic cycle and thus before BILF1.  
More recently it was reported that BILF1 does not target HLA-C molecules for degradation. It 
is now known that the specific residues which enable BILF1 to bind to HLA molecules are 
not expressed in the tail of HLA-C molecules. Unfortunately, during this study the assessment 
of HLA-C restricted T cell recognition was not included.   
The above findings suggest that BILF1 plays a more dominant role in interfering with antigen 
presentation during L phase lytic cycle and contributes a strong effect during the E phase, 
having little or no effect at the immediate early stage. Since BILF1 is expressed later than 
BNLF2a and presumably remains relatively high during L lytic cycle, is perhaps the fact that 
BILF1 has a stronger effect later in lytic cycle. It would be an advantage to measure the level 
of BILF1 protein at L stage lytic cycle in order to confirm this observation. 
 
BGLF5 appears to have little or no effect on interfering with antigen presentation 
during lytic cycle 
In the present study the effect of BGLF5 on interfering with antigen presentation during IE-, 
E- and L-phase lytic cycle appeared to be minimal. Using numerous donors and both HLA-A2 
and HLA-B7 restricted T cells the increase in recognition ranged from no increase to 2.5 for 
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IE-epitopes, no increase-4 for E-epitopes and 1.5-4.3 for L-epitopes. This would suggest that 
BGLF5 plays a minimal role towards interfering with antigen presentation throughout lytic 
cycle. 
However, it should be noted that the number of donors in which complete panels of T cells 
which recognised IE-, E- and L- epitopes could be performed at the same time was minimal. 
This was due to the shBGLF5-LCLs showing little or no cell expansion following 
transduction, or cells were no longer lytic and thus could not be used. Despite this, in all cases 
there was minimal increased recognition, across a range of donors and T cells and no pattern 
of increased recognition was observed. It should be noted that it cannot be ruled out that any 
residual BGLF5 expression may account for the lack of effect seen following BGLF5 
knockdown, although, this is unlikely considering the consistent results seen in Table 6.5. 
This lack of BGLF5 effect is surprising in one respect since BGLF5 is expressed at the same 
time as BILF1 and to a high level; however, when considering the function of BGLF5 this 
finding is perhaps unsurprising. BGLF5 has a global host protein shut off function and has 
been observed to down regulate other host proteins, including TLR-9. This implies that 
BGLF5 has a less targeted approach to interfering with antigen presentation, and thus it is 
perhaps unsurprising that its effect is less dramatic and consistent.  
It is also important to consider the possibility that the knockdown of BGLF5 may also result 
in the knockdown of BGLF4 expression, since these two genes are expressed from the same 
transcript. BGLF4 is a protein kinase which has been shown to antagonise the host shutoff 
function of BGLF5 (Feederle et al., 2009). These two enzymes have been shown to act 
together to modulate viral gene expression and virus protein production. If only BGLF5 was 
knocked down in our shBGLF5-LCLs, then we may expect to see an increase in the 
expression of some viral genes including BFLF2 and BFRF1, the expression of which is 
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stimulated or upregulated by BGLF4. However, studies performed using ΔBGLF5-LCLs 
(discussed previously) show that a lack of BGLF5 expression does not prevent LCLs 
progressing through lytic cycle, although there is a lower level of viral production. 
Alternatively, if both BGLF4 and BGLF5 were knocked down in our experimental system, 
there would be a more exaggerated decrease in the level of viral production and perhaps a 
different pattern of gene expression during lytic cycle. In addition, BGLF4 has recently been 
shown to downregulate MHC class I surface expression (personal communication, Dr J. Zuo), 
therefore a more exaggerated level of T cell evasion may be expected. Although this is an 
interesting consideration, this project utilises both BGLF5-knockdown and -knockout LCLs 
as targets for T cells and the data obtained using these different targets LCLs are similar, the 
issue of BGLF4 knockdown is perhaps not overly important. 
 
Simultaneous assessment of the role of BILF1, BNLF2a and BGLF5 at all phases of lytic 
cycle 
To allow for the direct comparison of the relative contribution that BILF1, BNLF2a and 
BGLF5 make towards interfering with antigen presentation during lytic cycle, simultaneous 
assessment of the recognition of LCLs lacking in the expression of these individual genes, by 
a panel of HLA-A2 restricted T cells was performed. This confirmed the above conclusions, 
where LCLs lacking in BNLF2a expression showed a dramatic increase in recognition of IE-
YVL epitope, compared to LCLs lacking BILF1 and BGLF5. LCLs lacking in BILF1 and 
those lacking BNLF2a resulted in an increase in recognition of E-GLC epitope, with 
shBNLF2a-LCLs showing a higher increase and finally LCLs lacking in BILF1 expression 
resulted in a dramatic increase in recognition of L-FLD epitope compared to cells lacking in 
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BNLF2a and BGLf5 expression. Although this was only assessed using one set of donor 
LCLs, due to the experimental problems which were encountered when attempting to generate 
a panel of knockdown LCLs which remained lytic and expanded to a an appropriate number, 
the above mentioned results confirmed what was expected.  
Taken together, the above results suggest that at the IE-phase of lytic cycle BNLF2a plays the 
more dominant role in interfering with antigen presentation, at the E-phase of lytic cycle, 
BNLF2a and BILF1 both contribute, with BNLF2a perhaps playing more of a role, and at the 
late stage it is the function of BILF1 which is more dominant. This can be explained by 
considering the kinetics of expression of these genes. BNLF2a is expressed very early in lytic 
cycle, peaks at 12 hours and is decreasing during late phase lytic cycle. Conversely, the 
expression of BILF1 is minimal in the immediate early phase of lytic cycle, peaks during the 
early phase and remains relatively high at the late phase.  
 
Dual knockdown of BNLF2a and BILF1indicate a co-operative function during the IE- 
and L- phases of lytic cycle 
The data generated in the final section of this chapter suggests that there is a level of synergy 
between BILF1 and BNLF2a almost certainly at the IE- phase of lytic cycle. This is evident 
when considering the level of increase when both BILF1 and BNLF2a are not expressed; the 
level of increase seen is more dramatic than that of shBNLF2a-LCLs. At the L stage of lytic 
cycle this level of synergy is perhaps less dramatic and could be considered as cooperation of 
the two, rather than synergy. Regardless, there is most certainly a more dramatic increase in 
recognition of the L-FLD epitope when both BILF1 and BNLF2a are not expressed. Although 
this was only completed using two donors and two epitopes, it suggests that there is a level of 
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synergy between these genes during the IE- and L-stages of lytic cycle, and most certainly no 
implied redundancy.   
To confirm this finding, it would be necessary to assess the increase in recognition of IE-, E- 
and L-epitopes across a selection of donors and HLA-restrictions and extend this further to 
confirm the minimal role of BGLF5 by generating a triple knockdown target LCL. However, 
due to time constraints, this was not possible. Since it is the transduction of two lentiviruses 
which appeared to be the problem, it could be an advantage to generate one lentivirus which 
expresses shRNAs to target both BNLF2a and BILF1 or all three genes. However, this has not 
been attempted using LCLs and there are reported problems with this approach due to the use 
of two identical promoters to drive the expression of the separate shRNAs.    
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CHAPTER 7 
 
FINAL DISCUSSION 
 
Like other persistent viruses, EBV has evolved to encode a plethora of immune evasion 
mechanisms. The work outlined in this thesis focuses on three of these; BNLF2a, BILF1 and 
BGLF5, that when ectopically expressed in model systems are able to interfere with different 
stages of the MHC class I antigen presentation pathway. The overall aim of this research 
project was to investigate the functional effect of these individual immune evasion proteins on 
peptide presentation to CD8
+
 T cells during virus lytic cycle and, ultimately to determine the 
relative contribution each makes towards interfering with antigen presentation at the three 
different phases of lytic cycle (IE, E and L).  
In 2007, BNLF2a was identified as able to interfere with the function of the TAP transporter 
and reduce peptide presentation to CD8
+
 T cells (Hislop et al., 2007; Croft et al., 2009). 
Shortly after this BILF1 and BGLF5 were identified as able to decrease the levels of cell 
surface expression of MHC class I molecules, upon ectopic expression. BILF1 was 
subsequently shown to target newly assembled MHC class I molecules for lysosomal 
degradation and also target MHC class I molecules which make it to the cell surface, for 
degradation (Zuo et al., 2009; Zuo et al., 2011). The mechanism by which BGLF5 was able to 
exert this effect was via its host-shutoff function which increases the turnover of cellular 
mRNA and thus non-specifically reduces the level of newly synthesised MHC class I 
molecules available for peptide loading and presentation of CD8
+
 T cells (Rowe et al., 2007).  
Whilst at the start of this thesis some details were known of the molecular mechanisms of 
these potential modulators of antigen presentation, there was a largely unresolved question of 
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their relative contributions to immune evasion during lytic cycle. In 2009 Croft et al carried 
out a study to examine the effects of BNLF2a on antigen presentation during IE- E- and L- 
phases of lytic cycle. This study utilised recombinant EBV viruses and successfully showed 
that in the absence of BNLF2a expression, recognition of IE- epitopes was increased and, 
more strikingly, recognition of E- epitopes was dramatically increased. This same study 
indicated that BNLF2a did not play a role in interfering with antigen pretention during L- 
stage lytic cycle, since cells transformed with EBV lacking BNLF2a were no better 
recognised by CD8
+
 T cells specific for L-epitopes than their wild-type counterparts (Croft et 
al., 2009). This then posed the question as to what exactly is protecting EBV infected cells 
from recognition by L- epitope specific CD8
+
 T cells, since it is known that these T cells, 
despite being avid and functional, show much reduced recognition of target cells. This 
phenomenon is not explained by level of L antigen expression but is thought to be a direct 
result of a decrease in efficiency of antigen-epitope presentation in wild-type LCLs as lytic 
cycle progresses (Pudney et al., 2005). Perhaps this diminished efficiency in epitope 
presentation is due to the action of BILF1 and BGLF5? T cell studies investigating the 
functions of these immune evasion proteins side by side, in the context of whole virus life 
cycle are lacking. Therefore the work outlined in this research project was carried out to study 
the function of BNLF2a, BILF1 and BGLF5 using lytic LCLs; the most informative results 
were obtained in which the expression of BNLF2a, BILF1 and BGLF5 had been silenced 
using shRNAs. These target LCLs served a means of testing the relative contribution of 
BNLF2a, BILF1 and BGLF5 to T cell recognition of IE-, E- and L- derived lytic cycle 
epitopes. 
Data presented in this thesis show that the relative contribution of BNLF2a, BILF1 and 
BGLF5 towards interfering with antigen presentation differs between the three different 
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phases of lytic cycle. In LCLs lacking the expression of BNLF2a there was a dramatic 
increase in presentation of IE-epitopes and a less dramatic increase in presentation of E-
epitopes presented to CD8+ T cells. In contrast to the study by Croft et al., this study also 
found a marked increase in L- epitope presentation, albeit less dramatic than the increase in 
IE- and E-epitope presentation (Croft et al., 2009). This minor discrepancy is most likely due 
to the wider range of potent L epitope-specific CD8
+
 T cell clones and target cell lines used in 
this thesis compared to the rather limited T cell/target combination used in the original study. 
However, the general take-home message is essentially unaltered in that both sets of data 
suggest that the role BNLF2a plays in interfering with antigen presentation diminishes as lytic 
cycle progresses (IE>E>>L). Indeed, by studying the kinetics of BNLF2a expression, in 
relation to the expression of other lytic genes, is was revealed that BNLF2a transcript was 
detectable and increased dramatically during the IE stage of lytic cycle, peaking at the E 
stages, which offers an explanation as to why BNLF2a appears to confer such a dramatic 
effect on the presentation of epitopes at these phases of lytic cycle. Although BNLF2a 
transcripts show only a modest decrease at the L stage of lytic cycle, we know that this does 
not correlate with the levels of protein expression, which is actually dramatically decreased by 
L phase lytic cycle, possibly accounting for why there appears to be less of a dramatic effect 
of BNLF2a on epitope presentation at this stage of lytic cycle.  
A major novel finding of the work outlined in this thesis is the effect of BILF1 on antigen 
presentation during lytic cycle. This protein appears to exert its strongest effects when 
BNLF2a is beginning to show weaker effects. Indeed, in the absence of BILF1 there is a 
dramatic enhancement of presentation of L epitopes to CD8
+
 T cells with a less dramatic 
effect seen at the E and an even weaker effect seen on IE (IE<<E<L). Thus, it appears that 
BILF1 plays the most important role at interfering with antigen presentation during the L 
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stage of lytic cycle. Again, when studying the kinetics of BILF1 expression it is clear that 
BILF1 is expressed later than BNLF2a and, given the phenotypic effects shown in these data; 
it would be reasonable to assume that the level of transcript of BILF1 is also correlated to 
relatively high levels of protein expression. Unfortunately, without an anti-BILF1 antibody, 
this is hard to confirm. It could be that BILF1 protein is expressed at higher levels at the L 
stages, perhaps accumulating in order to have the dramatic effect it does at the this stage. The 
small effect BILF1 has on IE epitope presentation compared to L stages is perhaps 
unsurprising considering that IE gene expression peaks before the expression of BILF1 is seen 
and these genes are expressed to a much lower level when BILF1 is highly expressed, thus the 
window in which BILF1 is available to interfere with the presentation of these epitopes is 
minimal. It should be noted that although BZLF1 protein remains expressed throughout lytic 
cycle, transcription declines, and since newly translated products (DRiPs) provide the 
peptides for antigen presentation, stable BZLF1 protein probably serves as a minimal source 
of peptides for presentation.  
Quite surprisingly, this thesis revealed that the effect of BGLF5 on antigen presentation is 
weak throughout lytic cycle, despite its expression and host shut-off function throughout the E 
and especially L stages. One interesting possibility is that the non-specific down regulation of 
MHC class I by BGLF5 actually confers little protection from CD8
+
 T cell recognition. It is 
known that human cells express a huge excess of MHC class I at the cell surface, thus it may 
be that the small effect that BGLF5 has on the decrease of these molecules actually makes 
little difference to T cell recognition of EBV epitopes. It may be that the seemingly minimal 
role played by BGLF5 is actually more of a fine tuning role. 
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Most importantly, this thesis has shown a direct comparison of these immune evasion effects. 
Studying the simultaneous recognition of cells lacking in BNLF2a, BILF1 or BGLF5 
expression revealed the stage-specific, relative contribution of these proteins during lytic 
cycle. At the IE stage, BNLF2a is most important; at the E it is the role of BNLF2a and 
BILF1 and at the late stage BILF1 has the dominant effect, with a small contribution by 
BNLF2a. In addition to this, these data revealed, for the first time, the level of synergy or co-
operation between the two most potent immune evasion proteins, BNLF2a and BILF1 using 
double knockdown LCLs. Although experiments were limited due to technical difficulties, 
this work indicated that at the IE stages of lytic cycle, BNLF2a and BILF1 are highly 
synergistic and at the L stage their functions most certainly co-operate, if not synergise. This 
suggests that the concerted action of these two immune evasion proteins contributes to 
protecting EBV infected cells from recognition during the IE and L stages of lytic cycle.  
These findings raise some interesting points to consider. Firstly, these data pose the question 
as to why EBV would downregulate the expression of BNLF2a at the L stages of lytic cycle, 
when it is clearly such a potent immune evasion mechanism. This could perhaps be due to the 
action of BILF1 and other immune evasion mechanisms being sufficiently capable of 
protecting EBV infected cells from recognition at the L phase. Alternatively, the expression of 
too many immune evasion mechanisms contributing to the down regulation MHC class I 
levels could leave cells too vulnerable to NK cell destruction. The controlled expression of 
BNLF2a and BILF1 is perhaps an eloquent trait of EBV, in order to maximise protection from 
CD8
+
 T cell recognition, while avoiding NK cell induced destruction. Moreover, perhaps the 
action of BNLF2a on TAP is not efficient at the L stage of lytic cycle. At this stage, which 
can last for up to 4 days, the level of viral transcripts are relatively low, due at least in part to 
the RNase activity of BGLF5. Consequently, one might anticipate less accumulation of viral 
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DRiPs and therefore, it may be that it is more efficient to target MHC class I molecules 
themselves, rather than the TAP transporter. In support of this scenario, the blocking of 
BGLF5 expression might be expected to boost antigen presentation. However, this was not 
supported by the experimental data presented in this thesis.  
Another interesting point to consider is the fact that at the L stage of lytic cycle wild-type 
LCLs show less efficient antigen processing than at the IE stages, which results in decreased 
recognition of L-epitopes by CD8
+
 T cells, compared to IE-epitope recognition, as shown by 
Pudney et al and further confirmed during the course of this Research project (Pudney et al., 
2005). Thus, one might assume that the knockdown of BILF1 expression would result in a 
much more exaggerated increase in recognition by L-epitope specific CD8
+
 T cells than is 
seen for the increase in recognition of IE-epitopes presented by LCLs lacking in BNLF2a 
expression. However, this was not the case. In fact the increase in recognition of shBILF1-
LCLs by L-epitope specific T cells was often comparable to the increase in recognition of 
shBNLF2a-LCLs by IE-epitope specific LCLs. This may suggest that there potentially could 
be other immune evasion mechanisms in action at the L stage of lytic cycle. A study carried 
out by other members of the lab identified at least two other E and L expressed viral genes 
which are capable of down-regulating MHC class I levels, when ectopically expressed (Dr 
Jianmin Zuo, personal communication). These new potential immune-evasion genes warrant 
further study to assess their mechanisms of action and whether either or both might 
preferentially modulate recognition by CD8
+
 T cells specific for L-epitopes. 
From these data a model is proposed whereby, upon EBV entry into lytic cycle, BNLF2a, the 
TAP inhibitor, is highly active at interfering with peptide transport into the ER and is able to 
protect these lytic cells from recognition by T cells, with the help of BILF1. Since BNLF2a 
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does not confer a complete block of TAP, perhaps BILF1, which is expressed slightly later 
than BNLF2a, plays the role of mopping up some of peptide loaded MHC class I molecules 
which are generated. During the E stage of lytic cycle the concerted action of BILF1 and 
BNLF2a are responsible for protecting cells from recognition and finally, at the L stages 
BILF1 is highly potent, acting in synergy with the less active BNLF2a immune evasion 
mechanism to confer blocking of peptide presentation, perhaps with the help of other, as of 
yet, unidentified immune evasion mechanisms. During this process, the diminished MHC 
class I synthesis imposed by BGLF5 appears to play little role in interfering with peptide 
presentation to T cells, despite its expression during the E and L phase. This supports the 
importance of investigating the effects of immune evasion mechanisms in the context of virus 
life cycle, rather than ectopic expression of these genes. The relative role of these immune 
evasion proteins during lytic cycle is shown in a schematic in Figure 7.1. 
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Figure 7.1. The relative roles of BNLF2a, BILF1 and BGLF5 in interfering with antigen 
presentation as lytic cycle progresses. 
Diagram showing the strength of each immune evasion gene function at all stages of lytic cycle. 
BNLF2a is more potent at the IE time point and its effect diminishes as lytic cycle progresses. The 
potency of BILF1 increases as lytic cycle progresses. BGLF5 plays a minimal role throughout.  
BNLF2a 
BILF1 
BGLF5 
IE E L 
Phase of lytic cycle 
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This thesis serves to highlight the importance of using functional T cell assays in order to 
investigate the effects of immune evasion mechanisms on the life cycle of EBV. If we 
consider only the level of MHC class I at the surface of infected cells, results may be 
misinterpreted. This is particularly evident in previously published experiments where the 
effects of ectopic expression of the viral genes was examined (Hislop et al., 2007; Rowe et 
al., 2007; Zuo et al., 2009), in which relatively small changes in surface MHC class I 
expression are often associated with substantial inhibition of T cell recognition. Furthermore, 
LCLs derived by infection with recombinant EBV lacking BNLF2a expression show the same 
level of MHC class I surface expression during late phase lytic cycle, despite this protein still 
having a marginal effect on the presentation of epitopes at this stage. This is especially 
apparent when considering the data seen from knocking down BGLF5. Whereas ectopic 
expression of this gene clearly confers a reduction in MHC class I molecules, this does not 
translate in to diminished recognition by T cells. Thus measurement of total surface MHC 
class I expression does not necessarily reveal important qualitative differences in the 
repertoire of peptides and thus T cell recognition. 
Another intriguing issue to consider is that BNLF2a, the TAP inhibitor, also appears to have 
dramatic effect on the presentation of epitopes defined as TAP-independent (Table 6.6). Thus, 
BNLF2a impairs presentation of the paradigmatic TAP-independent GLC epitope from the 
BMLF1 EBV protein as efficiently as it does presentation of the TAP-dependent TLD epitope 
from the BMRF1 protein. The critical experiment, which to our knowledge has not yet been 
reported, would be to determine whether BNLF2a is also active in the absence of TAP. In the 
first instance this could be done by ectopically expressing BNLF2a in the TAP negative cell 
line T2, alongside both TAP independent and TAP dependant antigen epitopes, to see if there 
is any difference in the effect of BNLF2a on the presentation of these peptides when TAP is 
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not expressed. Initial experiments performed suggest that the expression of BNLF2a from a 
vaccinia virus, in T2 cells, results in decreased recognition of both TAP independent (GLC) 
and TAP dependent (TLD) epitopes, despite the lack of TAP expression (personal 
communication, Dr V. Pudney). Thus it could be postulated that BNLF2a is able to target a 
yet unidentified TAP independent antigen processing pathway. However, this is complicated 
by the fact that T2-cells are latently infected with EBV (DeMars et al., 1984), therefore if the 
results presented in chapter 5 hold true for T2-cells, BNLF2a may be expressed in these cells 
which would influence the above experimental design. It could be that any endogenous 
BNLF2a expression is insufficient to inhibit TAP however, if there is some function from this 
expression it could reduce the sensitivity of the assay described or mask any effect of 
ectopically expressed BNLF2a. It would therefore be necessary to knockdown the expression 
of BNLF2a in T2-cells, if it is seen to be expressed, in order to determine if it is functional.   
In addition, since T2-cells are tightly latent it would be necessary to establish new lines to 
examine the role of BNLF2a, in the absence of TAP, in lytic cycle. To do this, LCLs could be 
generated from individuals who suffer from a rare disease where they do not express TAP, 
known as bare lymphocyte syndrome ((Teisserenc et al., 1997)), reviewed in (Gadola et al., 
2000)). If patients were obtained, LCLs would be generated using BNLF2a and wild-type 
EBV. Or use shRNA to knockdown BNLF2a in wild-type LCLs from these patients or 
alternatively, knockdown the expression of TAP1/2 in wild-type LCLs. BNLF2a could also 
be ectopically expressed in wild-type LCLs derived from these patients, to determine if there 
is an effect of BNLF2a in the absence of TAP. Subsequently, BNLF2a pull down assays, 
followed by mass spectrometry identification of associated proteins could be carried out in 
order to identify exactly what BNLF2a is interacting with, in the absence of TAP.  
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During the course of this work it came to light that some genes that are currently considered 
lytic genes, namely BNLF2a and BNRF1, are actually expressed in lytic-incompetent cells 
(BZLF1-LCLs). It is not entirely clear how BNLF2a is expressed during latency. One 
possibility is that BNLF2a transcripts are merely a read-through of the abundant LMP1 
transcripts (Fig 7.2), in which case it does not necessarily follow that BNLF2a will be 
efficiently translated. This issue could be clarified by performing rapid amplification of the 
cDNA ends (RACE) to determine the full length transcript of BNLF2a expressed during 
latency, and thus determine the promoter usage for its expression and by more rigorous 
quantification of BNLF2a protein expression in latency and lytic cycle. The implications for 
BNLF2a in this respect are interesting from an immune evasion point of view. It could be that 
BNLF2a expressed in these latent cells, albeit to a much lesser extent, may well be protecting 
latent cells from recognition by CD8
+
 T cells. It would be interesting to firstly, determine if 
the low level of BNLF2a which is expressed in these cells is conferring a level of antigen 
presentation inhibition. In addition, regardless of whether BNLF2a is expressed sufficiently to 
modulate antigen presentation in latency, it might be expressed sufficiently to provide targets 
of T cell recognition, which is shown in chapter 5 to be expressed to a high enough level to be 
recognised by BNLF2a specific T cells. This potential additional role of BNLF2a is even 
more impressive when considering the recent findings of Jochem et al.who published data 
showing that BNLF2a mRNA is contained within the EBV virion, and is subsequently 
translated immediately following infection and protects newly infected cells against 
recognition by T cells early in infection (Jochum et al., 2012; Jochum et al., 2012). These 
findings suggest that BNLF2a perhaps plays a more important role in the life cycle of EBV 
than originally thought.  
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Figure 7.2 Transcripts of LMP1 and BNLF2a.  
The expression of BNLF2a during lytic cycle utilises its own promoter. However, it is at located 
within the transcript of LMP1, thus its expression during latency could be due to read through of the 
LMP1 transcript. 
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The expression of BNRF1 in latency is interesting in the context of a recent study by Abbott 
et al. (unpublished), which included the work found in chapter 3 of this thesis. This study 
showed that BNRF1 is in fact a dominant target for CD8
+
 T cells in healthy EBV carriers, 
thus BNRF1 expression in latency may be the reason it is such a frequent CD8
+
 T cell target. 
If BNRF1 was also found to be expressed in other latent EBV infected cells, it could make for 
an attractive target for immunotherapy of EBV-associated disease. Moreover, these data bring 
to light the grey area which exists between latent and lytic cycle, suggesting that this may be 
more complicated than initially thought. 
The work in this thesis has extended the earlier ectopic expression models of EBV immune 
evasion to a more physiologically relevant examination of evasion genes in the context of 
EBV lytic cycle; whilst these in vitro data help to develop an understanding of the role of 
immune-modulation in EBV persistence, in vivo confirmatory data is currently lacking. It 
would be most interesting to investigate the direct role of BNLF2a, BILF1 and BGLF5 in 
vivo. Our group are currently collaborating with Professor Christian Munz using the 
humanised mouse model developed by his group and infecting these mice with recombinant 
EBV, lacking in the expression of BNLF2a, BILF1 and BGLF5, this work is on-going. 
Taking into account the findings in this study it may be expected that BNLF2a and BILF1 
virus infection would result in smaller tumour growth in these mice. It would be expected that 
there would be an increase in T cell responses, due to more efficient antigen processing and 
recognition by T cells and also a lower viral load, since presumably infected B-cells could be 
successfully recognised and eliminated by T cells. Alternatively, other animal models could 
be used such as rhesus macaque infection with the EBV-related lymphocryptovirus. To 
investigate the effects knocking down these genes has on disease progression and T cell 
responses. 
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